<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Subtitle 10 LABORATORIES | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.10/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.10/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|10|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|10" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="/us/md/exec/comar/10.10"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Subtitle 10 LABORATORIES | Library of Maryland Regulations"/>
    <meta property="og:image" content="/us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.10/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.10/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10" data-search-heading="">
                  <span title="Subtitle 10 LABORATORIES">Subtitle 10 LABORATORIES</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|10">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.10">Subtitle 10 LABORATORIES</h1>
                <h2 id="/us/md/exec/comar/10.10.01" data-order="|10|10|01|" data-ref-path="10|10|01" class="h__chapter">Chapter 01 General</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: July 1, 1969</p>
                  <p>Chapter revised effective March 2, 1977 (4:5 Md. R. 372)</p>
                  <p>Chapter revised effective February 10, 1986 (13:3 Md. R. 271)</p>
                  <p>Regulation .03N amended effective December 28, 1987 (14:26 Md. R. 2747)</p>
                  <p>Regulation .06 amended effective December 28, 1987 (14:26 Md. R. 2747)</p>
                  <p>——————</p>
                  <p>Chapter revised effective October 30, 1989 (16:21 Md. R. 2261)</p>
                  <p>Chapter revised effective October 29, 1990 (17:21 Md. R. 2529)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03" title=".03 Definitions.">Regulation .03</a> amended as an emergency provision effective April 1, 1994 (21:8 Md. R. 665); adopted permanently effective August 1, 1994 (21:15 Md. R. 1305)</p>
                  <p>Regulations .05, .10—.12, .15, and .18 amended and new Regulation .20 adopted as an emergency provision effective May 1, 1992 (19:10 Md. R. 926) Regulation .05A amended effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Regulation .10B amended effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Regulation .11 repealed and new Regulation .11 adopted effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Regulation .12 amended effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Regulation .14 repealed and new Regulation .14 adopted as an emergency provision effective April 1, 1994 (21:8 Md. R. 665); adopted permanently effective August 1, 1994 (21:15 Md. R. 1305)</p>
                  <p>Regulation .15 repealed and new Regulation .15 adopted effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Regulation .18C amended effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>——————</p>
                  <p>Regulation .20 adopted effective October 1, 1992 (19:15 Md. R. 1390)</p>
                  <p>Chapter, Medical Laboratories in Maryland, repealed and new chapter General, adopted effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.02" title=".02 Scope.">Regulation .02</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">Regulation .03B</a> amended effective February 18, 2002 (29:3 Md. R. 220); December 23, 2002 (29:25 Md. R. 1982); June 1, 2009 (36:11 Md. R. 787); January 13, 2011 (38:1 Md. R. 11); April 16, 2012 (39:7 Md. R. 492); April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.04#B" title="">Regulation .04B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <h3>Authority</h3>
                  <p><a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcj&amp;section=10-1001" title="">Courts and Judicial Proceedings Article, §10-1001</a>; Health-General Article, §§17-201, 17-202, 17-205, 17-214, and 17-501; <br/>Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.01.01" data-order="|10|10|01|.01|" data-ref-path="10|10|01|.01" class="h__section">.01 Purpose.</h3>
                <p>The people of Maryland are entitled to the highest level of competency, reliability, and accuracy that reasonably may be expected from a medical laboratory or crime laboratory. It is the intent of this subtitle to protect the public and individual health by requiring a medical laboratory or crime laboratory to employ qualified personnel and to operate under reliable procedures, effective quality control and quality assurance programs, and qualified supervision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.01.02" data-order="|10|10|01|.02|" data-ref-path="10|10|01|.02" class="h__section">.02 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#A">A.</span> This subtitle contains the standards and requirements that a medical laboratory shall meet to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#A(1)">(1)</span> Obtain and retain a license to offer to perform or perform tests on human specimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#A(2)">(2)</span> Certify chemists and analysts in crime laboratories to perform approved testing procedures for controlled dangerous substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B">B.</span> This subtitle does not apply to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B(1)">(1)</span> A research facility that tests human specimens and does not:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B(1)(a)">(a)</span> Report any patient-specific test results for use in connection with the diagnosis and control of human disease or the assessment of the health, nutritional, or medical condition or job-related alcohol and controlled dangerous substances evaluation of individual patients or clients, or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B(1)(b)">(b)</span> Provide test results to the patient, the patient's family, or a health care provider;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B(2)">(2)</span> A medical laboratory operated by the federal government, unless the laboratory or tissue bank is directed by a federal agency to meet the requirements of this subtitle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.02#B(3)">(3)</span> A crime laboratory operated by the federal government.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.01.03" data-order="|10|10|01|.03|" data-ref-path="10|10|01|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#A">A.</span> In this subtitle, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(1)">(1)</span> Accuracy or Accurate.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(1)(a)">(a)</span> "Accuracy" or "accurate" means the degree of agreement between the determination of a quantity and its true value.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(1)(b)">(b)</span> "Accuracy" or "accurate" includes the quality of a test result as it relates to the analytic phase of the testing process when the test result:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(1)(b)(i)">(i)</span> Conforms exactly to a standard; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(1)(b)(ii)">(ii)</span> Deviates only within established limits from a standard.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(2)">(2)</span> "Alternative sanction" means a directed plan of correction or a limitation placed on testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(3)">(3)</span> "Analyte" means a substance or constituent for which a laboratory conducts testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(4)">(4)</span> "Analytical system" means a test system's methods, procedures, instruments, equipment, kits, reagents, and supporting materials used to detect or measure an analyte or perform a test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(5)">(5)</span> Authorized Person.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(5)(a)">(a)</span> "Authorized person" means an individual allowed to request a laboratory test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(5)(b)">(b)</span> "Authorized person" is limited to those individuals identified under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(5-1)">(5-1)</span> “Buccal cavity” means the vestibule of the mouth, specifically the area lying between the teeth and cheeks.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(5-2)">(5-2)</span> “Buccal swab” means a specialized applicator with a sponge, cotton, or Dacron tip, used to collect epithelial cells for DNA testing by rubbing the applicator tip on the inside of the cheek in the buccal cavity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(6)">(6)</span> "Calibrator" means a material having a known value or concentration that is used to standardize an analytical system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(7)">(7)</span> "CDC" means the Centers for Disease Control and Prevention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(8)">(8)</span> "Certified analyst" means an individual who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(8)(a)">(a)</span> Meets the qualifications established under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.01#B" title="">COMAR 10.10.09.01B</a> and .02C; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(8)(b)">(b)</span> Is thereby permitted to identify marijuana or marijuana products, or both, using procedures approved under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">COMAR 10.10.09.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(9)">(9)</span> "Certified chemical analyst" means an individual who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(9)(a)">(a)</span> Meets the qualifications established under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.01#A" title="">COMAR 10.10.09.01A</a> and .02B; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(9)(b)">(b)</span> Is thereby permitted to identify marijuana or marijuana products, or both, cocaine base, cocaine hydrochloride, and heroin using procedures approved under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">COMAR 10.10.09.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(10)">(10)</span> "Certified chemist" means an individual who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(10)(a)">(a)</span> Meets the qualifications established under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.01#A" title="">COMAR 10.10.09.01A</a> and .02A; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(10)(b)">(b)</span> Is thereby permitted to identify any controlled dangerous substance using procedures approved under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">COMAR 10.10.09.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(11)">(11)</span> "CFR" means the Code of Federal Regulations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(12)">(12)</span> "CLIA" means the federal Clinical Laboratory Improvement Amendments of 1988 in Section 353 of the Public Health Service Act and any amendments to it (42 U.S.C. §263a).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(13)">(13)</span> "CMS" means the federal Centers for Medicare and Medicaid Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(14)">(14)</span> "Collection station" means a site other than a laboratory where specimens are gathered before being shipped elsewhere for laboratory testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(15)">(15)</span> "Complaint investigation" means an investigation of a laboratory, including an on-site survey, initiated in response to a complaint.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(16)">(16)</span> "Control sample" means a material, solution, or lyophilized preparation used in laboratory quality control, the concentration of which is within certain specified and known limits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(17)">(17)</span> "Controlled dangerous substance" means any drug, substance, or immediate precursor in Schedules I through V of <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gcr/gcr.pdf" title="">Criminal Law Article, Title 5, Subtitle 4, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(18)">(18)</span> "Deficiency" means a situation or finding of statutory or regulatory noncompliance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(19)">(19)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(20)">(20)</span> "Directed plan of correction" means a set of corrective actions stipulated by the Secretary that a laboratory shall implement to effect statutory or regulatory compliance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)">(21)</span> Discipline.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(a)">(a)</span> "Discipline" means a scientific field of study in which a laboratory is licensed to offer to perform or perform tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)">(b)</span> "Discipline" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(i)">(i)</span> Chemistry, including the subdisciplines of blood gas analysis, endocrinology, radioimmunoassay, routine chemistry, toxicology, and urinalysis;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(ii)">(ii)</span> Forensic toxicology, including job-related alcohol and controlled dangerous substances, limited to the detection of alcohol or a controlled dangerous substance for a non-therapeutic or non-diagnostic, job-related purpose.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(iii)">(iii)</span> Genetics, including the subdisciplines of biochemical genetics, cytogenetics, medical genetics, and molecular genetics;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(iv)">(iv)</span> Health awareness testing, which is limited to health awareness tests set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.01.03#B(27)" title="">§B(27) of this regulation</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(v)">(v)</span> Hematology, including the subdisciplines of coagulation testing, hemoglobinopathy screening, and routine hematology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(vi)">(vi)</span> Immunology, including the subdisciplines of serology, immunohematology, and histocompatibility;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(vii)">(vii)</span> Microbiology, including the subdisciplines of bacteriology, mycobacteriology, mycology, parasitology, and virology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(viii)">(viii)</span> Molecular biology, including nucleic acid probes; nucleic acid target, probe, and signal amplifications; recombinant nucleic acid techniques; and other techniques of applied molecular genetics other than cytogenetics used in connection with the diagnosis and control of human disease or the assessment of human health; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(21)(b)(ix)">(ix)</span> Pathology, including the subdisciplines of gynecologic cytology, dermatopathology, and histopathology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(22)">(22)</span> "Examinee" means an individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(22)(a)">(a)</span> Whose specimen is collected or tested by a laboratory; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(22)(b)">(b)</span> Who is subject to a proficiency test in gynecologic cytology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(23)">(23)</span> "Excepted laboratory" means a medical laboratory that offers to perform or performs tests limited to one or more excepted tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(24)">(24)</span> "Excepted test" means a medical laboratory test, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#B" title="">COMAR 10.10.03.02B</a>, that is authorized by the Secretary to be offered or performed by a laboratory operating under a letter of exception.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(25)">(25)</span> "Exfoliative" means falling off in scales or layers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(26)">(26)</span> General Supervisor.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(26)(a)">(a)</span> "General supervisor" means a technologist who possesses at least 4 years technical experience in a licensed medical laboratory other than an excepted laboratory.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(26)(b)">(b)</span> "General supervisor" includes an individual who qualified as a supervisory technologist under previous State regulations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(27)">(27)</span> "HDL-C" means high density lipoprotein cholesterol.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)">(28)</span> Health Awareness Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)(a)">(a)</span> “Health awareness test” means a test approved by the Secretary to be performed at a temporary or mobile laboratory, such as a health fair in a shopping mall.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)(b)">(b)</span> “Health awareness test” is limited to tests that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)(b)(i)">(i)</span> Are performed solely for the purposes of screening for certain medical conditions and are not to be used for diagnostic or management of healthcare conditions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)(b)(ii)">(ii)</span> Are performed on a CLIA waived testing device; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(28)(b)(iii)">(iii)</span> Measure glucose, lipids, or other clinical values which the Secretary has concluded are in the interest of public health to be measured at a health awareness event.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(29)">(29)</span> "Immediate jeopardy" means a deficiency that poses immediate danger to public health or safety and requires the Secretary to take immediate action to remove the jeopardy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(30)">(30)</span> "Immediate precursor" means a substance that the Department has found to be, and by regulation designates as being, the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled dangerous substance, the control of which is necessary to prevent, curtail, or limit that manufacture.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(31)">(31)</span> "Laboratory" means a medical laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(32)">(32)</span> "Letter of exception" means a license issued by the Secretary authorizing the operation of a laboratory to offer to perform or perform one or more excepted tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(33)">(33)</span> "Letter of exception—limited testing for rare diseases" means a license issued by the Secretary authorizing the operation of a laboratory to offer to perform or perform testing limited to one or more rare disease tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(34)">(34)</span> "License" means a permit, letter of exception, certificate, or other document issued by the Secretary granting approval or authority to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(34)(a)">(a)</span> Offer to perform or perform medical laboratory tests or examinations in this State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(34)(b)">(b)</span> Offer to perform or perform medical laboratory tests or examinations on specimens acquired from health care providers in this State at a medical laboratory located outside this State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(34)(c)">(c)</span> Represent or service in this State a medical laboratory regardless of the laboratory's location.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(35)">(35)</span> "Licensed laboratory" means a laboratory operating under a license issued by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(36)">(36)</span> "Licensee" means a person who holds a license under this chapter to operate a laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(37)">(37)</span> "Limited public health testing" means testing limited to a combination of 15 or fewer excepted tests performed by a nonprofit organization or a State, county, or local health department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(38)">(38)</span> "Marginal proficiency testing performance" means failure to attain the minimum satisfactory score for two of three consecutive proficiency testing events.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)">(39)</span> Medical Laboratory.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(a)">(a)</span> "Medical laboratory" means a facility, entity, or site that offers to perform or performs tests in connection with:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(a)(i)">(i)</span> The diagnosis and control of human disease;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(a)(ii)">(ii)</span> The assessment of human health, nutrition, or medical conditions; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(a)(iii)">(iii)</span> Job-related testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)">(b)</span> "Medical laboratory" includes but is not limited to a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(i)">(i)</span> Physician office laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(ii)">(ii)</span> Point-of-care laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(iii)">(iii)</span> Laboratory owned or operated by the State, a county, or a municipal health department;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(iv)">(iv)</span> Not-for-profit laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(v)">(v)</span> Hospital laboratory; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(39)(b)(vi)">(vi)</span> Commercial laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)">(40)</span> Method Verification.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)(a)">(a)</span> "Method verification" means evaluation of an analytical system by assessment of each analytical system component, including instrument, test strip, cartridge, card, and kit reagent.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)(b)">(b)</span> "Method verification" includes but is not limited to the determination of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)(b)(i)">(i)</span> An analytical system's reportable range;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)(b)(ii)">(ii)</span> Accuracy; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(40)(b)(iii)">(iii)</span> Within-run and run-to-run precision.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(41)">(41)</span> "Mobile laboratory" means a laboratory located in a moveable vehicle, such as a truck, trailer, van, or ambulance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(42)">(42)</span> "Multi-site permit" means a permit available to the State, a county, or a municipal health department authorizing the operation of limited public health testing at more than one mobile or permanent laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(43)">(43)</span> "Office of Health Care Quality (OHCQ)" means the Office of Health Care Quality of the Maryland Department of Health, formerly the Licensing and Certification Administration (LCA).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(44)">(44)</span> "Operator of an analytical system" means an individual who applies a test specimen or control sample to an analytical system and performs the necessary operative steps to isolate or identify an infectious agent or measure an analyte.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(45)">(45)</span> "Owner" means a person who possesses a financial interest in a laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(46)">(46)</span> "Patient of the practice" means an individual who accepts referral to or is seen or otherwise examined by a member or members of a practice of medicine.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(47)">(47)</span> Permit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(47)(a)">(a)</span> "Permit" means a license issued by the Secretary authorizing a person to operate a medical laboratory conducting one or more tests that are not excepted tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(47)(b)">(b)</span> "Permit" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(47)(b)(i)">(i)</span> Provisional permit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(47)(b)(ii)">(ii)</span> Temporary permit.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(48)">(48)</span> "Permitted laboratory" means a licensed laboratory operating under a permit.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(49)">(49)</span> "Phlebotomist" means an individual who procures a blood specimen by venipuncture, arterial puncture, or capillary sampling.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(50)">(50)</span> "Physician" means a doctor of medicine or a doctor of osteopathy licensed by the Maryland State Board of Physicians and a doctor of podiatric medicine licensed by the Maryland State Board of Podiatric Medical Examiners.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(51)">(51)</span> "Physician of a practice" means a physician employed, salaried, or otherwise engaged to operate or function as a member in a medical practice, even if the physician does not have an ownership interest in the practice or the practice's laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(52)">(52)</span> "Physician office laboratory (POL)" means a medical laboratory operated by a single practice of medicine, individually or collectively by one or more physicians, that is used solely as an adjunct to the care of patients of the practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(53)">(53)</span> "Point-of-care laboratory (POCL)" means a laboratory operated as part of, or in association with, a medical care facility, such as a hospital, nursing home, community health center, health maintenance organization, county or municipal health department, or a pharmacy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(54)">(54)</span> "Practice" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(54)(a)">(a)</span> An individual physician licensed to practice medicine in the State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(54)(b)">(b)</span> A medical partnership, professional association, professional service corporation, or medical corporation of two or more physicians licensed to practice medicine in the State and sharing facilities, personnel, income, or business expenses.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(55)">(55)</span> "Precision" means the agreement of results among themselves when a specimen or sample is tested multiple times.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(56)">(56)</span> "Pre-field evaluation" means the assessment of an analytical system before it may be used in a mobile or temporary laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(57)">(57)</span> "Primary standard" means a comprehensive general standard or set of standards that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(57)(a)">(a)</span> A laboratory must meet to obtain or retain a license to operate; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(57)(b)">(b)</span> An individual must meet in order to examine gynecologic cytology specimens.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(58)">(58)</span> "Principal sanction" means the denial, suspension, or revocation of a license.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(59)">(59)</span> "Proficiency testing (PT)" means evaluation of an individual's ability to perform laboratory procedures or tests within the PT program's defined limits of accuracy through analysis of unknown samples distributed at periodic intervals by an external source.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(60)">(60)</span> "Public health laboratory" means a public, nonprofit laboratory solely owned and operated by or for the State, a county, or a municipal health department located in the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)">(61)</span> Quality Assurance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(a)">(a)</span> "Quality assurance" means a system of established written policies and procedures designed to monitor, review, evaluate, and improve the ongoing and overall quality of the preanalytic, analytic, and postanalytic aspects of laboratory testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)">(b)</span> "Quality assurance" includes but is not limited to practices involving:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(i)">(i)</span> Patient preparation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(ii)">(ii)</span> Specimen collection, labeling, processing, and transport;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(iii)">(iii)</span> Quality control strategies, practices, and results;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(iv)">(iv)</span> Record keeping;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(v)">(v)</span> Personnel training and competency;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(vi)">(vi)</span> Continuing education;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(vii)">(vii)</span> Proficiency testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(viii)">(viii)</span> Remedial and corrective actions; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(61)(b)(ix)">(ix)</span> Analytical system evaluation, validation, and verification.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)">(62)</span> Quality Control.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(a)">(a)</span> "Quality control" means established written policies and procedures designed to ensure reliable laboratory testing by monitoring, reviewing, and evaluating the analytic aspects of laboratory testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(b)">(b)</span> "Quality control" includes but is not limited to policies and procedures that detect, monitor, review, and evaluate the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(b)(i)">(i)</span> Accuracy and precision of the analytic phase of a testing process;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(b)(ii)">(ii)</span> Changes in the chemical, electronic, optical, or mechanical components of an analytical system;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(b)(iii)">(iii)</span> Deterioration of reagents, materials, or supplies used in a testing process; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(62)(b)(iv)">(iv)</span> Personnel practices during a testing process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(63)">(63)</span> "Quality control test" means an examination performed on an external test sample that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(63)(a)">(a)</span> Is not part of the analytical system;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(63)(b)">(b)</span> Contains a known quantity of the analyte being tested;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(63)(c)">(c)</span> Is similar in its physical characteristics and constituents to patient specimens tested by the system; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(63)(d)">(d)</span> Reacts with all system components in the same way as a patient specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)">(64)</span> "Rare disease" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(a)">(a)</span> A disabling, chronically debilitating, or life-threatening disease or condition that has fewer than 200,000 affected individuals in the United States, which is equivalent to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(a)(i)">(i)</span> A prevalence of fewer than one individual per 2,000 individuals in the population; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(a)(ii)">(ii)</span> An incidence of fewer than one affected individual per 10,000 individuals in the population;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(b)">(b)</span> A disabling or life-threatening disease or condition that is listed as a rare disease by the National Institutes of Health Office of Rare Diseases; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(c)">(c)</span> A disabling or life-threatening disease or condition in which more than 200,000 individuals are affected if:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(c)(i)">(i)</span> A subpopulation of the disease or condition is equal to the prevalence standard for a rare disease in <a class="internal-link " href="/us/md/exec/comar/10.10.01.03#B(64)(a)" title="">§B(64)(a) of this regulation</a>; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(64)(c)(ii)">(ii)</span> The incidence of the disease or condition is fewer than five affected individuals per 10,000 in a defined community.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)">(65)</span> Rare Disease Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(a)">(a)</span> "Rare disease test" means a test that is:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(a)(i)">(i)</span> Performed on a specimen obtained from an individual in order to determine or evaluate whether the individual has a rare disease or condition;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(a)(ii)">(ii)</span> Based on a single method using one sample of a specimen to produce the test result; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(a)(iii)">(iii)</span> Not routinely offered or performed by a medical laboratory permitted by the Department.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)">(b)</span> "Rare disease test" includes a test with multiple clinical or health evaluation uses such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)(i)">(i)</span> Newborn screening;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)(ii)">(ii)</span> Carrier screening;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)(iii)">(iii)</span> Predictive testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)(iv)">(iv)</span> Disease diagnosis; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(65)(b)(v)">(v)</span> Disease prognosis.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(66)">(66)</span> "Reliable" means that the quality of a test result meets the quality standards for the preanalytic, analytic, and postanalytic phases of the testing process as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(67)">(67)</span> "Remeasurement" means repeating the measurement of an analyte.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(68)">(68)</span> "Sample" means a substance, constituent, or material intended for use in quality control, proficiency testing, or another aspect of a laboratory's quality assurance program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(69)">(69)</span> Sanction.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(69)(a)">(a)</span> "Sanction" means an action that the Secretary may take to effect statutory or regulatory compliance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(69)(b)">(b)</span> "Sanction" includes a principal sanction and an alternative sanction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(70)">(70)</span> Secretary.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(70)(a)">(a)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(70)(b)">(b)</span> "Secretary" includes the Office of Health Care Quality as a designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)">(71)</span> "Single-use test device for forensic testing" means the reagent-containing unit of a test system that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)(a)">(a)</span> Is in the form of a sealed container or cartridge possessing a validity check;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)(b)">(b)</span> Possesses a nonresealable closure or an evidentiary tape to ensure detection of tampering;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)(c)">(c)</span> Is self-contained and individually packaged;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)(d)">(d)</span> Is discarded after each test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(71)(e)">(e)</span> Does not allow any test component or constituent of a test system to interact from test to test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(72)">(72)</span> "Single-use test device for nonforensic testing" means the reagent-containing unit of a test system in the form of a cartridge, test pack, or other container that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(72)(a)">(a)</span> Includes a validity check;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(72)(b)">(b)</span> Is self-contained and individually packaged;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(72)(c)">(c)</span> Is discarded after each test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(72)(d)">(d)</span> Does not allow any test component or constituent of a test system to interact from test to test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(73)">(73)</span> "SOPM" means a standard operating procedure manual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(74)">(74)</span> "Specialty" means a scientific field of study within a laboratory subdiscipline, such as compatibility testing within the subdiscipline of immunohematology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(75)">(75)</span> "Specimen" means material collected from the human body and intended for laboratory testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(76)">(76)</span> "Standard" means one or more specific technical, procedural, fiscal, or other requirements that a laboratory or individual must meet to comply with this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(77)">(77)</span> "Subdiscipline" means a scientific field of study within a laboratory discipline, such as bacteriology within the discipline of microbiology and dermatopathology within the discipline of pathology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)">(78)</span> Survey.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(a)">(a)</span> "Survey" means an on-site visit to a laboratory by one or more employees of the OHCQ to carry out or oversee the regulation of medical laboratories.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(b)">(b)</span> "Survey" includes but is not limited to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(b)(i)">(i)</span> Inspection;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(b)(ii)">(ii)</span> Follow-up inspection;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(b)(iii)">(iii)</span> Complaint investigation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(78)(b)(iv)">(iv)</span> On-site monitoring.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(79)">(79)</span> System Check.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(79)(a)">(a)</span> "System check" means a device that verifies all or part of the chemical, electronic, optical, or mechanical components or constituents of a test system to determine if the test system is functioning properly.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(79)(b)">(b)</span> "System check" includes chemical, electronic, optical, or mechanical devices, such as a card, tube, or strip that simulates a properly functioning single-use test device.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(79)(c)">(c)</span> "System check" does not include a quality control test sample or patient specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(80)">(80)</span> "Technical supervisor" means an individual who is qualified to direct medical laboratory testing in at least one laboratory discipline.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(81)">(81)</span> "Technician" means an individual who has at least 1 year of experience in a licensed medical laboratory, other than an excepted laboratory, and who has earned:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(81)(a)">(a)</span> An associate degree in a laboratory science or medical laboratory technology from an accredited college or university; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(81)(b)">(b)</span> 60 semester hours of academic credit, including 24 semester credit hours of science that include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(81)(b)(i)">(i)</span> 6 semester hours of chemistry, and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(81)(b)(ii)">(ii)</span> 6 semester hours of biology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(82)">(82)</span> "Technologist" means an individual who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(82)(a)">(a)</span> Possesses a bachelor's degree in a chemical, physical, biological, or clinical laboratory science or in medical technology from an accredited college or university and has at least 1 year of full-time laboratory experience in the discipline in which the individual performs tests;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(82)(b)">(b)</span> Received a passing score in the United States Department of Health and Human Services proficiency examination for clinical laboratory technologists; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(82)(c)">(c)</span> Meets the technologist qualifications set forth in 42 CFR §493.1491, which is incorporated by reference in <a class="internal-link " href="/us/md/exec/comar/10.10.01.04" title=".04 Incorporation by Reference.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(83)">(83)</span> "Temporary laboratory" means a medical laboratory located at a temporary testing site, such as a health fair or shopping mall, for fewer than 30 days in 12 consecutive months.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(84)">(84)</span> "Test" means a medical laboratory examination, analysis, procedure, or preanalytic, analytic, or postanalytic phase of a testing process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(85)">(85)</span> "Testing event" means an occasion when a health awareness test is offered or performed on a specified date at a temporary laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(86)">(86)</span> "Testing personnel" means an individual or individuals employed or otherwise engaged by a laboratory to perform medical laboratory tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(87)">(87)</span> "Total number of tests" means all tests performed by a laboratory in all disciplines in the previous calendar year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(88)">(88)</span> "Unsatisfactory proficiency testing performance" means failure to attain the minimum satisfactory score for three of four consecutive proficiency testing events.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.03#B(89)">(89)</span> "Validity check" means a procedural, testing process, or analytical verification of proper performance of one or more analytical steps performed by the test system operator, built into a single-use test device, and carried out by a single-use test device to detect environmental damage or interfering substances that may have affected the device or the results of the testing process.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.01.04" data-order="|10|10|01|.04|" data-ref-path="10|10|01|.04" class="h__section">.04 Incorporation by Reference.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#A">A.</span> In this subtitle, the following documents are incorporated by reference.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B">B.</span> Documents Incorporated.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(1)">(1)</span> 29 CFR §1910.1030, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(2)">(2)</span> 29 CFR §1910.1450, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(3)">(3)</span> 42 CFR §§493.801—493.959, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(4)">(4)</span> 42 CFR §§493.1100—493.1299, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(5)">(5)</span> 42 CFR §§493.1405—493.1495, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(6)">(6)</span> 49 CFR §40.87, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.01.04#B(7)">(7)</span> Forensic Chemists and Analysts Training and Procedure Manual (Maryland Department of Health, 1992).</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.02" data-order="|10|10|02|" data-ref-path="10|10|02" class="h__chapter">Chapter 02 Medical Laboratories — General</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.01" title=".01 Responsibilities of the Department.">Regulation .01</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.01#E" title="">Regulation .01E</a> adopted effective January 21, 2002 (29:1 Md. R. 23)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.01#E" title="">Regulation .01E</a> amended effective April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.01#F" title="">Regulation .01F</a> adopted effective August 29, 2005 (32:17 Md. R. 1438)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.01#F" title="">Regulation .01F</a> amended effective April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.02" title=".02 Accredited Laboratory and Accrediting Organization.">Regulation .02</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.02#C" title="">Regulation .02C</a> amended effective July 24, 2000 (27:14 Md. R. 1340)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.03" title=".03 Surveys.">Regulation .03</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, Annotated Code of Maryland<br/>Regulations	Sections</p>
                </section>
                <p>.01	17-202, 17-207, 17-208, 17-217, 17-504, 17-507</p>
                <p>.02	17-202, 17-504</p>
                <p>.03	17-202, 17-504</p>
                <h3 id="/us/md/exec/comar/10.10.02.01" data-order="|10|10|02|.01|" data-ref-path="10|10|02|.01" class="h__section">.01 Responsibilities of the Department.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#A">A.</span> The OHCQ. The OHCQ shall conduct surveys, as set forth in this subtitle, of laboratories that obtain or retain a license.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#B">B.</span> Surveys. The OHCQ shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#B(1)">(1)</span> Conduct or oversee an announced or unannounced survey of a laboratory at any time during its hours of operation to assess compliance with applicable sections of Health-General Article, Title 17, Subtitles 2 and 5, Annotated Code of Maryland, and this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#B(2)">(2)</span> Examine, as part of a survey, a laboratory's facilities, equipment, quality assurance records and procedures, operating procedures, personnel and personnel records, proficiency testing, patient reports, and other records and files pertinent and subject to this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C">C.</span> Issuance of Licensing Documents. The OHCQ shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(1)">(1)</span> License a person to operate a laboratory by issuing a letter of exception or permit when the laboratory is in compliance with the applicable standards set forth in this subtitle;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(2)">(2)</span> Issue a license that includes the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(2)(a)">(a)</span> Name of the laboratory;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(2)(b)">(b)</span> Name of the licensee or laboratory director;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(2)(c)">(c)</span> Name of the laboratory owner; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(2)(d)">(d)</span> Expiration date of the license; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(3)">(3)</span> Issue a license that designates:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(3)(a)">(a)</span> The classes of services, that is, disciplines, provided;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(3)(b)">(b)</span> The tests or examinations offered; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#C(3)(c)">(c)</span> Both §C(3)(a) and (b) of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D">D.</span> Administration and Information Management. The OHCQ shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(1)">(1)</span> Maintain a list of licensed laboratories;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(2)">(2)</span> Document information regarding denial, suspension, or revocation of a license and submit this documentation to the Secretary;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(3)">(3)</span> Monitor the proficiency testing performance of a laboratory required to participate in proficiency testing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(4)">(4)</span> Conduct a cytology proficiency testing program for each cytotechnologist and pathologist who performs gynecological examinations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(5)">(5)</span> Set and collect fees as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04" title="Chapter 04 Medical Laboratories">COMAR 10.10.04</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#D(6)">(6)</span> Impose alternative sanctions and initiate actions leading to imposition of principal sanctions against a laboratory under the appropriate provisions of this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E">E.</span> Recommending Excepted Test Status.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(1)">(1)</span> The Secretary shall maintain a Laboratory Advisory Committee to advise the Secretary on matters relating to medical laboratories as set forth in Health-General Article, Title 17, Subtitle 2, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(2)">(2)</span> The Laboratory Advisory Committee's responsibilities shall include making a recommendation to the Secretary in favor of or against granting a test excepted status.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)">(3)</span> The Laboratory Advisory Committee shall consider a test for excepted test status and make a recommendation to the Secretary if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(a)">(a)</span> The Laboratory Advisory Committee is requested in writing by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(a)(i)">(i)</span> The Secretary;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(a)(ii)">(ii)</span> A Maryland chapter of a specialty medical society; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(a)(iii)">(iii)</span> The Medical and Chirurgical Faculty of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(b)">(b)</span> The test on which the request is based is waived under CLIA, by the CDC, or by the federal Food and Drug Administration;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(c)">(c)</span> The test employs a directly collected specimen not subjected to post-collection manipulation or processing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(3)(d)">(d)</span> The test is a manual test or is a test system employing a single use test device for nonforensic testing that tests for one or more analytes in a single specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)">(4)</span> The Laboratory Advisory Committee shall make a recommendation to the Secretary concerning excepted test status based on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(a)">(a)</span> Immediate patient need for the test in order to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(a)(i)">(i)</span> Provide rapid patient follow-up;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(a)(ii)">(ii)</span> Order additional tests; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(a)(iii)">(iii)</span> Make an immediate diagnostic or therapeutic decision;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(b)">(b)</span> Whether the test is core to a physician's practice, based on:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(b)(i)">(i)</span> Physician specialty;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(b)(ii)">(ii)</span> Usefulness of the test in the specialty; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(b)(iii)">(iii)</span> Who actually performs the test;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(c)">(c)</span> Access, applicability, and ease of performance by personnel in a POL and POC setting;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(d)">(d)</span> Whether all analytes testable on a multi-test, single-use test device are recommended for excepted status;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(e)">(e)</span> Consideration of the known benefits and risks of the test or test system, especially those involving an infectious disease; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(f)">(f)</span> The potential harm to a patient if the test:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(f)(i)">(i)</span> Is performed incorrectly; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(4)(f)(ii)">(ii)</span> Produces a false positive or false negative test result.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#E(5)">(5)</span> In recommending a test for excepted status, the Laboratory Advisory Committee may specify certain conditions to be met based on factors set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.02.01#E(4)" title="">§E(4) of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F">F.</span> Authorizing Excepted Test Status.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(1)">(1)</span> The Secretary may authorize a test for excepted status if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(1)(a)">(a)</span> The test is recommended for excepted test status by the Laboratory Advisory Committee; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(1)(b)">(b)</span> The Secretary:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(1)(b)(i)">(i)</span> Determines that the test meets the criteria of §E(3)(b)—(d) of this regulation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(1)(b)(ii)">(ii)</span> Bases the authorization for excepted status on the factors set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.02.01#E(4)" title="">§E(4) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.01#F(2)">(2)</span> In authorizing a test for excepted status, the Secretary may specify certain requirements to be met based on factors set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.02.01#E(4)" title="">§E(4) of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.02.02" data-order="|10|10|02|.02|" data-ref-path="10|10|02|.02" class="h__section">.02 Accredited Laboratory and Accrediting Organization.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#A">A.</span> Accredited Laboratory — Determination. The Secretary shall accept as meeting the survey requirements of this chapter a laboratory accredited by an organization approved by the Secretary, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.02.02#C" title="">§C of this regulation</a>, if the OHCQ determines that the standards of the laboratory's accrediting organization are equivalent to those under this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#B">B.</span> Accredited Laboratory — Requirements. In addition to meeting the requirements for its certificate of accreditation, as set forth by its accrediting organization, an accredited laboratory shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#B(1)">(1)</span> Obtain and maintain a valid license issued by the Secretary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#B(2)">(2)</span> Be subject to survey by the OHCQ for the purpose of investigating complaints or validating findings of the laboratory's accrediting organization.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C">C.</span> Accrediting Organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(1)">(1)</span> A private, nonprofit laboratory accrediting organization may inspect and accredit laboratories in the State for the purpose of Maryland State licensure only after applying for and receiving approval of the OHCQ.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)">(2)</span> The OHCQ shall base approval of a laboratory accrediting organization on a review of that organization, when the review includes but is not limited to an evaluation of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(a)">(a)</span> Documentation of current accrediting status issued by CMS and of compliance with CMS reporting requirements;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(b)">(b)</span> Accreditation policies and standards;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(c)">(c)</span> Copies of survey forms and guidelines;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(d)">(d)</span> Surveying and deficiency writing policies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(e)">(e)</span> Surveyor qualifications;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(f)">(f)</span> Complaint investigation policies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(g)">(g)</span> Proficiency test monitoring policies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)">(h)</span> Procedures the accrediting organization will follow when notifying the OHCQ that the organization:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)(i)">(i)</span> Is denying, withdrawing, suspending, or revoking a laboratory's accreditation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)(ii)">(ii)</span> Finds serious patient jeopardy or identifies a hazard to public safety;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)(iii)">(iii)</span> Accredits a new laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)(iv)">(iv)</span> Imposes an adverse or corrective action on a laboratory; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(h)(v)">(v)</span> Is initiating a complaint investigation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(2)(i)">(i)</span> The accrediting organization's compliance with the requirements of <a class="internal-link " href="/us/md/exec/comar/10.10.02.02#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)">(3)</span> In addition to requirements set forth elsewhere in this regulation, an accrediting organization shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)">(a)</span> Provide to the OHCQ:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)(i)">(i)</span> Annually, an updated list containing the names, addresses, and accreditation expiration dates of all accredited laboratories in the State;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)(ii)">(ii)</span> Within 30 days after conducting a survey, a certified written or electronic copy of each survey report covering each laboratory applying for or maintaining accreditation in the State;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)(iii)">(iii)</span> Written notice of any proposed change to requirements for laboratory accreditation, at least 30 days before the effective date of the change;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)(iv)">(iv)</span> Within 30 days after a laboratory's certificate of accreditation expires, written or electronic notice when the laboratory does not renew its certificate; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(a)(v)">(v)</span> Within 24 hours after taking an action, telephonic or electronic notice whenever an accredited laboratory's certificate of accreditation is limited, suspended, revoked, or surrendered;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)">(b)</span> Evaluate compliance, when applicable, with State regulations pertaining to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(i)">(i)</span> Cholesterol testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(ii)">(ii)</span> Gynecological cytology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(iii)">(iii)</span> Dermatopathology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(iv)">(iv)</span> Forensic toxicology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(v)">(v)</span> Laboratory reporting of test results covering contagious disease, blood lead, cancer, and other tests as required by law or regulation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(vi)">(vi)</span> Proficiency testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(vii)">(vii)</span> Special medical waste disposal; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(b)(viii)">(viii)</span> Testing performed at a temporary or mobile laboratory;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(c)">(c)</span> Evaluate compliance with State regulations by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(c)(i)">(i)</span> Employing a checklist provided by the Department;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(c)(ii)">(ii)</span> Incorporating an evaluation of compliance with State regulatory requirements into its own survey process; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(c)(iii)">(iii)</span> Demonstrating that its existing survey process adequately evaluates compliance with State regulations; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(d)">(d)</span> On request, provide to OHCQ a copy of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(d)(i)">(i)</span> A complaint investigation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(d)(ii)">(ii)</span> Surveyor qualifications;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(d)(iii)">(iii)</span> A change in a laboratory's disciplines, subdisciplines, or specialties; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.02.02#C(3)(d)(iv)">(iv)</span> Other information the Secretary may require relating to approval of a laboratory accrediting organization.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.02.03" data-order="|10|10|02|.03|" data-ref-path="10|10|02|.03" class="h__section">.03 Surveys.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A">A.</span> General.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(1)">(1)</span> A licensee shall allow an on-site survey by the OHCQ or, when applicable, by the laboratory's approved accrediting organization, at any time during the laboratory's normal hours of operation, to evaluate the laboratory's compliance with the applicable requirements, conditions, and standards of this subtitle.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)">(2)</span> A survey may include but is not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(a)">(a)</span> Observation and examination of laboratory facilities;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(b)">(b)</span> Equipment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(c)">(c)</span> Quality assurance and quality control program records;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(d)">(d)</span> Operating procedures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(e)">(e)</span> Personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(f)">(f)</span> Personnel records;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(g)">(g)</span> Proficiency testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(h)">(h)</span> Patient reports; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(2)(i)">(i)</span> Other records and files pertinent to this subtitle.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#A(3)">(3)</span> Laboratory employees shall make data and records accessible within a reasonable time during the on-site survey.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#B">B.</span> Excepted Laboratory. A licensee operating a laboratory under a letter of exception, other than a mobile or temporary laboratory, is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#B(1)">(1)</span> Not subject to routine, on-site surveys;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#B(2)">(2)</span> Subject to surveys resulting from complaints or periodic validations, or both, conducted by the Secretary or CMS, or both, to determine regulatory compliance; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#B(3)">(3)</span> Required to make available, pursuant to a survey, records the Secretary may reasonably require to determine regulatory compliance.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C">C.</span> Permitted Laboratory. A licensee operating a laboratory under a permit shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(1)">(1)</span> Be subject to routine surveys conducted by OHCQ;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(2)">(2)</span> Undergo a routine annual survey for 2 consecutive years after the laboratory:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(2)(a)">(a)</span> Begins operating;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(2)(b)">(b)</span> Undergoes a change in ownership;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(2)(c)">(c)</span> Fails to complete or submit to the Department an acceptable quality assurance self-assessment on forms provided by the OHCQ; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(2)(d)">(d)</span> Has imposed on it a principal or alternative sanction; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(3)">(3)</span> Undergo a routine biennial survey when the laboratory:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(3)(a)">(a)</span> Does not fall under one of the categories set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.02.03#C(2)" title="">§C(2) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#C(3)(b)">(b)</span> Completes and submits to the OHCQ an acceptable quality assurance self-assessment on forms provided by the OHCQ on the years when the OHCQ does not conduct an on-site survey, except as provided in <a class="internal-link " href="/us/md/exec/comar/10.10.02.03#D" title="">§D of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#D">D.</span> Accredited Laboratory. An accredited laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#D(1)">(1)</span> Undergoing routine on-site surveys conducted by an accrediting organization approved by the Secretary, except as provided in §D(2) and (3) of this regulation, is not subject to routine surveys conducted by the OHCQ;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#D(2)">(2)</span> Is subject to surveys conducted by the OHCQ to investigate a complaint or to determine regulatory compliance; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#D(3)">(3)</span> Holding a permit in the discipline of forensic toxicology, subdiscipline of job-related testing, is subject to routine surveys of the laboratory's alcohol and controlled dangerous substances testing areas conducted by the OHCQ.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#E">E.</span> Temporary or Mobile Laboratory. The OHCQ may survey each testing event site when a temporary or mobile laboratory licensee offers to perform or performs testing services.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.02.03#F">F.</span> Excepted Laboratory — Limited Testing for Rare Diseases. A licensee operating a laboratory under a letter of exception — limited testing for rare diseases is subject to the survey requirements stated in <a class="internal-link " href="/us/md/exec/comar/10.10.02.03#B" title="">§B of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.03" data-order="|10|10|03|" data-ref-path="10|10|03" class="h__chapter">Chapter 03 Medical Laboratories — Licenses</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.01" title=".01 General.">Regulation .01</a> amended effective July 24, 2000 (27:14 Md. R. 1340); July 23, 2001 (28:14 Md. R. 1321)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.01#A" title="">Regulation .01A</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.01#E" title="">Regulation .01E</a> adopted effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02" title=".02 Letters of Exception.">Regulation .02</a> amended effective July 24, 2000 (27:14 Md. R. 1340); June 1, 2009 (36:11 Md. R. 787); April 13, 2015 (42:7 Md. R. 568)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#A" title="">Regulation .02A</a> amended effective July 22, 2002 (29:14 Md. R. 1074); April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#B" title="">Regulation .02B</a> amended as an emergency provision effective November 1, 2004 (31:25 Md. R. 1789); amended permanently effective January 6, 2005 (31:26 Md. R. 1863)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#B" title="">Regulation .02B</a> amended effective August 29, 2005 (32:17 Md. R. 1438); February 22, 2010 (37:4 Md. R. 341); April 16, 2012 (39:7 Md. R. 492); November 12, 2012 (39:22 Md. R. 1428); April 1, 2013 (40:6 Md. R. 473); March 13, 2017 (44:5 Md. R. 292)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#C" title="">Regulation .02C</a> amended effective November 12, 2012 (39:22 Md. R. 1428)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.03#C" title="">Regulation .03C</a> amended effective June 1, 2009 (36:11 Md. R. 787); August 29, 2016 (43:17 Md. R. 953)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.04" title=".04 Letter of Exception and Permit — Administrative Procedures.">Regulation .04</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.04#B" title="">Regulation .04B</a>, E amended effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.05" title=".05 Letter of Exception — Limited Testing for Rare Diseases.">Regulation .05</a> adopted effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.06" title=".06 Letter of Exception — Limited Testing for Rare Diseases; Standards and Requirements.">Regulation .06</a> adopted effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.06#A" title="">Regulation .06A</a> amended effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <h3>Authority</h3>
                  <p><a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gen&amp;section=6-303" title="">Environment Article, §6-303</a>; Health-General Article, §§2-104(b), 17-202, 17-205—17-210, 17-212, 17-502, 17-503, 17-505, <br/>17-508, and 17-510; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.03.01" data-order="|10|10|03|.01|" data-ref-path="10|10|03|.01" class="h__section">.01 General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A">A.</span> Requirement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(1)">(1)</span> General. A person shall possess a license before:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(1)(a)">(a)</span> Offering to perform or performing a medical laboratory test or examination in this State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(1)(b)">(b)</span> Offering to perform or performing a medical laboratory test or examination on a specimen acquired from a health care provider in this State at a laboratory located outside this State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(1)(c)">(c)</span> Representing or servicing in this State a laboratory regardless of the laboratory's location.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(2)">(2)</span> Prohibited Tests. The Secretary may impose principal and alternative sanctions as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.01#A" title="">COMAR 10.10.08.01A</a> if a person offers to perform or performs a test or part of a test, including the use of a reagent, supply, procedure, technique, kit, or equipment, that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(2)(a)">(a)</span> Does not produce accurate or reliable results as evidenced by documented, independent scientific testing and evaluation; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(2)(b)">(b)</span> Lacks proof of efficacy substantiated by an independently conducted and documented scientifically based clinical trial.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(3)">(3)</span> Cholesterol Testing Plan for Health Departments.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(3)(a)">(a)</span> A local or county health department intending to perform cholesterol testing outside a permanently located laboratory may submit to the Secretary a cholesterol testing plan instead of applying for a cholesterol testing permit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(3)(b)">(b)</span> If the submitted plan meets applicable standards under this chapter, the Secretary may waive the permit requirement for a cholesterol testing permit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#A(3)(c)">(c)</span> If the plan does not meet the applicable standards of this chapter, the local or county health department shall apply for a permit as set forth in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#B">B.</span> Limitation. A person may not operate a laboratory in a discipline other than what is listed on the license.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#C">C.</span> Eligibility. A person meeting the requirements and standards of this chapter may apply for one or more of the following licenses:</p>
                <div class="table_wrap">
                  <table class="layout-table">
                    <tbody>
                      <tr>
                        <td>License:</td>
                        <td>Laboratory that may apply for the license:</td>
                      </tr>
                      <tr>
                        <td>Letter of exception</td>
                        <td>POL<br/>POCL</td>
                      </tr>
                      <tr>
                        <td>Permit (single-site)</td>
                        <td>POL<br/>POCL<br/>State, county, or municipal hospital<br/>commercial</td>
                      </tr>
                      <tr>
                        <td>Permit (multi-site)</td>
                        <td>State, county, or municipal hospital<br/>private nonprofit<br/>mobile</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D">D.</span> Issuance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(1)">(1)</span> Provisional Permit.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(1)(a)">(a)</span> The Secretary may issue a provisional permit before or after conducting an initial survey and pending determination of compliance with the standards in this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(1)(b)">(b)</span> A provisional permit is valid for not more than 180 days and may not be renewed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(2)">(2)</span> Letter of Exception and Permit. The Secretary may issue a letter of exception or permit that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(2)(a)">(a)</span> Is valid for not more than 2 years from the date of issue; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(2)(b)">(b)</span> Shall be renewed before its date of expiration if a person intends to operate the laboratory in the succeeding permit period.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)">(3)</span> Single-Site and Multi-Site Licenses.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)(a)">(a)</span> Except as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.03.01#D(3)(b)" title="">§D(3)(b) of this regulation</a>, a person shall obtain a separate, single-site license for each location at which a laboratory performs a test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)(b)">(b)</span> The Secretary may issue a multi-site license to a person operating:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)(b)(i)">(i)</span> A mobile laboratory using the address of its home base or main administrative office in the State;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)(b)(ii)">(ii)</span> A nonprofit laboratory or public health laboratory performing limited public health testing; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#D(3)(b)(iii)">(iii)</span> Hospital laboratories located at the same street address or within contiguous buildings and under common direction.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.01#E">E.</span> In order to maintain a State license issued by the Department pursuant to this subtitle, a licensee shall be in compliance with all applicable federal, State, and local laboratory requirements.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.03.02" data-order="|10|10|03|.02|" data-ref-path="10|10|03|.02" class="h__section">.02 Letters of Exception.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A">A.</span> Eligibility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(1)">(1)</span> An individual directing a POL or POCL who offers to perform or performs tests limited to one or more excepted tests may obtain a letter of exception instead of a permit to offer to perform or perform those tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)">(2)</span> An individual eligible for a letter of exception shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(a)">(a)</span> Be qualified as a laboratory director as set forth in 42 CFR §493.1405, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(a)(i)">(i)</span> Being a doctor of medicine or doctor of osteopathy licensed in the State and having laboratory training or experience appropriate for the testing performed; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(a)(ii)">(ii)</span> Holding an earned doctoral, master's, or bachelor's degree in a chemical, physical, biological, or clinical laboratory science or medical technology from an accredited institution;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)">(b)</span> Provide evidence of training in the performance and interpretation of excepted tests and be licensed in the State as a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(i)">(i)</span> Nurse midwife;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(ii)">(ii)</span> Nurse practitioner;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(iii)">(iii)</span> Physician assistant;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(iv)">(iv)</span> Chiropractor;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(v)">(v)</span> Podiatrist;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(vi)">(vi)</span> Dentist; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(b)(vii)">(vii)</span> Pharmacist; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(c)">(c)</span> Be clinical staff who:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(c)(i)">(i)</span> Meets the qualifications set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.01.06#D" title="">COMAR 10.47.01.06D</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(c)(ii)">(ii)</span> Is employed by a substance abuse treatment program that is certified or accredited in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.04.03" title=".03 Certification Required.">COMAR 10.47.04.03</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(2)(c)(iii)">(iii)</span> Is authorized to order tests to detect the presence of controlled dangerous substances on patients enrolled in the substance abuse treatment program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#A(3)">(3)</span> A person operating a temporary medical laboratory to perform health awareness tests, regardless of testing site location, is not eligible for a letter of exception.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B">B.</span> Excepted Tests. A POL or POCL operating under a letter of exception may perform one or more of the following excepted tests or types of tests:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(1)">(1)</span> Whole blood glucose by glucose monitoring devices cleared by the FDA for home use or a CLIA waived analyzer;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(2)">(2)</span> Dermatophyte screen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(3)">(3)</span> Dipstick glucose;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)">(4)</span> Dipstick urinalysis using reagent test pads affixed to plastic strips that detect one or a combination of any of the following urine characteristics or constituents:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(a)">(a)</span> Glucose;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(b)">(b)</span> Bilirubin;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(c)">(c)</span> Ketones detected in the form of acetoacetic acid;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(d)">(d)</span> Specific gravity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(e)">(e)</span> Red blood cells or hemoglobin;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(f)">(f)</span> pH;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(g)">(g)</span> Protein;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(h)">(h)</span> Urobilinogen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(i)">(i)</span> Nitrites; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(4)(j)">(j)</span> Leukocytes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(5)">(5)</span> Gram stain;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(6)">(6)</span> Group A streptococcal screen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(7)">(7)</span> Hematocrit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(8)">(8)</span> Hemoglobin;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(9)">(9)</span> Infectious mononucleosis slide or card test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(10)">(10)</span> Microscopic urinalysis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(11)">(11)</span> Occult blood;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(12)">(12)</span> Pinworms;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(13)">(13)</span> Potassium hydroxide skin preparations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(14)">(14)</span> Rheumatoid factor slide agglutination test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(15)">(15)</span> Sickle-cell screen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(16)">(16)</span> H. pylori test with a single-use test device for nonforensic testing, using a whole-blood specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(17)">(17)</span> Fructosamine test with a single-use test device for nonforensic testing, using a whole-blood specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(18)">(18)</span> Heterophile antibodies test with a single-use test device for nonforensic testing, using a whole-blood specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(19)">(19)</span> Urine bacteria colony count;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(20)">(20)</span> Urine pregnancy test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(21)">(21)</span> Wet mounts;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(22)">(22)</span> Influenza antigen test using a direct nasal or throat swab specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(23)">(23)</span> Hemoglobin A1c test using a whole blood specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(24)">(24)</span> Qualitative test for bladder cancer markers in voided urine including a test to detect:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(24)(a)">(a)</span> Human complement factor H-related protein; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(24)(b)">(b)</span> Nuclear mitotic apparatus protein (NMP);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(25)">(25)</span> Brain natriuretic peptide (BNP) test using a whole blood specimen to detect:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(25)(a)">(a)</span> Heart disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(25)(b)">(b)</span> The response of treatment for heart failure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(26)">(26)</span> Fern test for qualitative detection of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(26)(a)">(a)</span> Amniotic fluid crystallization; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(26)(b)">(b)</span> Estrogenic activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(27)">(27)</span> Qualitative semen analysis, limited to detecting:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(27)(a)">(a)</span> The presence or absence of sperm; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(27)(b)">(b)</span> Sperm motility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(28)">(28)</span> Nitrazine vaginal pH test using phenaphthazine reagent paper strips;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(29)">(29)</span> Qualitative immunochromatographic test to detect the presence of adenovirus antigens directly from eye fluid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(30)">(30)</span> Microalbumin-creatinine urinalysis test utilizing an instrument based dip-and-read reagent test strip for determining urine albumin and creatinine levels, including the urinary albumin-to-creatinine ratio (UACR) in a random urine specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(31)">(31)</span> Screening tests for urine or saliva performed on FDA-cleared for home use or FDA approved single-use test devices for the presence of alcohol and drugs of abuse solely for the purpose of directing patient counseling;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(32)">(32)</span> Qualitative enzyme activity test using a chromogenic substrate of bacterial sialidase for use in the detection of bacterial vaginosis directly from vaginal fluid specimens;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(33)">(33)</span> Qualitative immunochromatographic test to detect the presence of Trichomonas vaginalis antigens directly from a vaginal swab;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(34)">(34)</span> CLIA-waived Prothrombin Time/International Normalized Ratio (PT/INR) with the additional requirements that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(34)(a)">(a)</span> The licensee shall enroll into a Proficiency Testing program offered by an entity that has been approved by the Centers for Medicare and Medicaid Services (CMS) to ensure validation of all measurement capabilities for the instrument used to perform the test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(34)(b)">(b)</span> When the numerical score is less than 80 percent, the licensee shall submit the official proficiency test results to the Office of Health Care Quality for review and monitoring with evidence of documented remedial actions taken;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(35)">(35)</span> CLIA waived blood lipid analysis for cholesterol, HDL, LDL, and triglycerides;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)">(36)</span> Whole blood lead testing on a CLIA waived analyzer with the additional requirements:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(a)">(a)</span> The licensee shall enroll into a Proficiency Testing program offered by an entity that has been approved by the Centers for Medicare and Medicaid Services to ensure validation of all measurement capabilities for the instrument used to perform the test;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(b)">(b)</span> When the numerical score is less than 80 percent, the licensee shall submit the official proficiency test result to the Office of Health Care Quality for review and monitoring with evidence of documented remedial actions taken;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(c)">(c)</span> All staff involved in testing shall undergo training on the testing device and testing techniques with annual competencies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(d)">(d)</span> Records of training and competencies for staff shall be:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(d)(i)">(i)</span> Maintained by the laboratory; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(d)(ii)">(ii)</span> Made available for review by the Department; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(36)(e)">(e)</span> Reporting requirements stated in <a class="internal-link " href="/us/md/exec/comar/10.10.03.02#C" title="">§C of this regulation</a> shall be followed; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(37)">(37)</span> CLIA Waived Urine Drug Screens with the following additional requirements:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(37)(a)">(a)</span> The licensee shall enroll into a proficiency testing program offered by an entity that has been approved by the Centers for Medicare and Medicaid Services; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#B(37)(b)">(b)</span> When the numerical score is less than 80 percent, the licensee shall submit the official proficiency test result to the Office of Health Care Quality for review and monitoring with evidence of documented remedial actions taken.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C">C.</span> Reporting Requirements for Whole Blood Lead Testing on a CLIA Waived Analyzer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(1)">(1)</span> The blood tests for lead shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(1)(a)">(a)</span> Be reported under this regulation in the format approved by the Maryland Department of the Environment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(1)(b)">(b)</span> Include the information required by this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)">(2)</span> The blood tests for lead to be reported shall include the following information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)">(a)</span> Demographic information including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(i)">(i)</span> Name, including first, last, middle initial;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(ii)">(ii)</span> Date of birth, sex, and race;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(iii)">(iii)</span> Complete home address at the time the blood specimen was drawn including house or apartment number, street, city, county or town, zip code, and state;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(iv)">(iv)</span> Telephone number; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(v)">(v)</span> Parent or guardian name;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(a)(vi)">(vi)</span> Residential status, for example, whether parent or guardian owns their home or rents;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(b)">(b)</span> Type of specimen, either venous or capillary, and date the specimen was drawn;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(c)">(c)</span> Clinic or practice name, address, and telephone number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(d)">(d)</span> Draw site name and address, if different from clinic or practice;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(e)">(e)</span> Blood lead level in micrograms per deciliter; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#C(2)(f)">(f)</span> Any additional information as may be required by the Maryland Department of the Environment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D">D.</span> Regulatory Requirements. An individual required to obtain a license to operate a laboratory who chooses to operate under a letter of exception shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(1)">(1)</span> Obtain, complete, and file an application as prescribed in <a class="internal-link " href="/us/md/exec/comar/10.10.03.04" title=".04 Letter of Exception and Permit — Administrative Procedures.">Regulation .04 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)">(2)</span> Comply with good laboratory practices that include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(a)">(a)</span> Following the manufacturer's instructions for instrument or test system operation and test performance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(b)">(b)</span> Having a procedure manual describing the processes for performing tests and reporting patient test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(c)">(c)</span> Performing and documenting quality control procedures using applicable levels of control materials each day of testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(d)">(d)</span> Performing and documenting that remedial action has been taken when problems or errors are identified;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(e)">(e)</span> Documenting lot numbers of all quality control reagents used; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.02#D(2)(f)">(f)</span> Performing and documenting test system function for instruments with internal quality controls on each day of testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.03.03" data-order="|10|10|03|.03|" data-ref-path="10|10|03|.03" class="h__section">.03 Permits.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#A">A.</span> Requirement. A person operating a medical laboratory that performs one or more tests other than excepted tests shall obtain and renew a laboratory permit as required in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#B">B.</span> Tests Other than Excepted Tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#B(1)">(1)</span> A test other than an excepted test is one not listed in <a class="internal-link " href="/us/md/exec/comar/10.10.03.02#B" title="">Regulation .02B of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#B(2)">(2)</span> A person holding a permit may perform both excepted tests and tests other than excepted tests.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C">C.</span> Regulatory Requirements. A person operating a medical laboratory under a permit shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C(1)">(1)</span> Obtain, complete, and submit permit applications as prescribed in this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04" title="Chapter 04 Medical Laboratories">COMAR 10.10.04</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C(2)">(2)</span> Comply with the survey requirements set forth in this subtitle;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C(3)">(3)</span> Comply with the applicable quality assurance and quality control requirements required in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C(4)">(4)</span> Comply with the applicable proficiency testing requirements required in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.03#C(5)">(5)</span> Comply with the applicable personnel requirements required in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.15#B" title="">COMAR 10.10.06.15B</a> and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07" title="Chapter 07 Medical Laboratories — Personnel">10.10.07</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.03.04" data-order="|10|10|03|.04|" data-ref-path="10|10|03|.04" class="h__section">.04 Letter of Exception and Permit — Administrative Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A">A.</span> Application — Filing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(1)">(1)</span> Except for a laboratory eligible for a multi-site license as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.03.01#D(3)(b)" title="">Regulation .01D(3)(b) of this chapter</a>, a person shall apply for a license for each laboratory location.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(2)">(2)</span> A person holding a license to operate a laboratory in the discipline of chemistry or health awareness testing is not required to obtain a separate cholesterol testing permit to conduct cholesterol testing at a temporary laboratory site if the licensee complies with the requirements applicable to a temporary laboratory as set forth in this subtitle.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(3)">(3)</span> A person shall complete and file an application for a license using forms provided by the OHCQ.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(4)">(4)</span> A person shall complete on the application a description of laboratory services, which includes but is not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(4)(a)">(a)</span> Types of tests performed or to be performed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(4)(b)">(b)</span> Total number of tests performed or to be performed annually, excluding tests for quality control and proficiency testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(4)(c)">(c)</span> Qualifications of personnel who direct, supervise, and perform laboratory testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(5)">(5)</span> The laboratory director shall sign the application forms attesting that the information provided is accurate and that the laboratory is or will be operated in accordance with the requirements and standards required in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#A(6)">(6)</span> A person shall submit with the application the nonrefundable partial licensing fee set forth in COMAR 10.10.04.02C.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B">B.</span> Application — Evaluation and Billing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B(1)">(1)</span> The OHCQ shall review and evaluate an application in accordance with the standards and requirements of this subtitle to determine if an application is complete.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B(2)">(2)</span> The OHCQ shall review and evaluate an application in accordance with the standards and requirements of this subtitle to determine if the laboratory is eligible for a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B(2)(a)">(a)</span> Letter of exception;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B(2)(b)">(b)</span> Letter of exception — limited testing for rare diseases; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#B(2)(c)">(c)</span> Permit.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#C">C.</span> Application — Denial of License. If the OHCQ determines that a laboratory is not in compliance with the requirements of this chapter and therefore cannot be issued a license, the OHCQ shall provide to the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#C(1)">(1)</span> A written statement of the grounds on which the denial is based; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#C(2)">(2)</span> The opportunity to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#C(2)(a)">(a)</span> Amend and resubmit the application; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#C(2)(b)">(b)</span> Request, in writing, an opportunity for a hearing as provided in the Administrative Procedure Act, State Government Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-201" title="">10-201</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-226" title="">10-226</a>, and Health-General Article, §§17-210 and 17-509, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#D">D.</span> Notification Requirements. A licensee shall notify the OHCQ within 30 days of a change in laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#D(1)">(1)</span> Ownership;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#D(2)">(2)</span> Name;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#D(3)">(3)</span> Location; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#D(4)">(4)</span> Director.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#E">E.</span> Amending a Permit. Except as prescribed in <a class="internal-link " href="/us/md/exec/comar/10.10.03.04#D" title="">§D of this regulation</a>, a licensee holding an unexpired permit who wishes to amend it shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#E(1)">(1)</span> Submit a written request for amendment to the Secretary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#E(2)">(2)</span> Obtain written approval from the OHCQ before implementing the amendment.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#F">F.</span> Expiration and Renewal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#F(1)">(1)</span> A letter of exception or permit expires on the date shown on the license.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#F(2)">(2)</span> The OHCQ shall mail a renewal application to a laboratory not less than 30 days before the expiration date shown on the license.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#F(3)">(3)</span> A licensee shall file an application to renew a license using forms provided by the OHCQ and following the same procedures prescribed in §§A and B of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#F(4)">(4)</span> A licensee who fails to submit a completed renewal application before the expiration date may not operate the laboratory after its letter of exception or permit has expired.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.04#G">G.</span> Non-Transferability. A license is not transferable between laboratories, directors, or locations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.03.05" data-order="|10|10|03|.05|" data-ref-path="10|10|03|.05" class="h__section">.05 Letter of Exception — Limited Testing for Rare Diseases.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#A">A.</span> The Secretary may waive the permit requirements under this subtitle for a laboratory that offers to perform or performs a rare disease test if the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#A(1)">(1)</span> Meets the requirements of Regulations .05 and .06 of this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#A(2)">(2)</span> Obtains and maintains a letter of exception — limited testing for rare diseases.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B">B.</span> Eligibility. A person operating a medical laboratory may be eligible for a letter of exception — limited testing for rare diseases if the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(1)">(1)</span> Is operated as:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(1)(a)">(a)</span> A not-for-profit entity; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(1)(b)">(b)</span> Part of an accredited educational institution;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(2)">(2)</span> Performs not more than a total of 50 tests per year for a specific rare disease on specimens from Maryland patients;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(3)">(3)</span> Offers to perform or performs only rare disease tests as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(4)">(4)</span> Possesses a valid CLIA certificate for the complexity of the testing performed;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(5)">(5)</span> Does not possess a Maryland permit for offering to perform or performing medical laboratory testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#B(6)">(6)</span> Meets the requirements for a laboratory to operate under a letter of exception — limited testing for rare diseases.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.05#C">C.</span> Research Laboratory. A research laboratory may obtain a letter of exception — limited testing for rare diseases if the laboratory meets the eligibility requirements of <a class="internal-link " href="/us/md/exec/comar/10.10.03.05#B" title="">§B of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.03.06" data-order="|10|10|03|.06|" data-ref-path="10|10|03|.06" class="h__section">.06 Letter of Exception — Limited Testing for Rare Diseases; Standards and Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A">A.</span> Application Requirements and Testing Approval. A person required to obtain a license to operate a laboratory that chooses to operate under a letter of exception — limited testing for rare diseases shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)">(1)</span> Submit:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(a)">(a)</span> A completed:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(a)(i)">(i)</span> Application as prescribed in <a class="internal-link " href="/us/md/exec/comar/10.10.03.04" title=".04 Letter of Exception and Permit — Administrative Procedures.">Regulation .04 of this chapter</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(a)(ii)">(ii)</span> Report or questionnaire as required by the Secretary to determine regulatory compliance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(b)">(b)</span> A copy of the laboratory's:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(b)(i)">(i)</span> Current CLIA certificate issued by CMS; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(b)(ii)">(ii)</span> Most recent CLIA survey report;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)">(c)</span> Documentation of the rare disease testing offered or performed, including but not limited to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(i)">(i)</span> The test procedure, including instructions for quality control and quality assurance;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(ii)">(ii)</span> A description of the disease or condition;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(iii)">(iii)</span> An explanation of the clinical validity of the test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(iv)">(iv)</span> The performance characteristics of the test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(v)">(v)</span> The expected turnaround time for patient test results; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(1)(c)(vi)">(vi)</span> Additional information necessary for determining eligibility and compliance with this subtitle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(2)">(2)</span> Agree to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(2)(a)">(a)</span> Make records and reports available to the Department as the Secretary may require;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(2)(b)">(b)</span> Notify the Department when a change to a licensee's rare disease testing procedure occurs for the purpose of the Department's determining whether the change is in compliance with this subtitle;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(2)(c)">(c)</span> Perform not more than 50 rare disease tests each year on specimens from Maryland patients; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#A(2)(d)">(d)</span> Submit to the Department statistics that detail the number and types of rare disease tests performed each year on specimens from Maryland patients.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B">B.</span> Standards. A person that wishes to obtain and maintain a letter of exception — limited testing for rare diseases shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)">(1)</span> Comply with good laboratory practices that include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)(a)">(a)</span> Following the manufacturer's instructions for instrument or test system operation and test performance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)(b)">(b)</span> Having and following a written procedure manual describing the processes for performing tests and reporting patient test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)(c)">(c)</span> Performing applicable instrument calibration procedures at least once every 6 months;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)(d)">(d)</span> Performing and documenting quality control procedures using applicable levels of control materials each day of testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(1)(e)">(e)</span> Performing and documenting that remedial action has been taken when problems or errors are identified; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)">(2)</span> Meet the requirements and standards in this subtitle applicable to a permitted laboratory including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)(a)">(a)</span> Proficiency testing under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)(b)">(b)</span> Quality assurance under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)(c)">(c)</span> Personnel under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07" title="Chapter 07 Medical Laboratories — Personnel">COMAR 10.10.07</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)(d)">(d)</span> Sanctions under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">COMAR 10.10.08</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#B(2)(e)">(e)</span> CLIA regulations incorporated by reference at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.04#B(3)" title="">COMAR 10.10.01.04B(3)</a> — (5).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#C">C.</span> If the submitted application and explanatory documentation do not meet the requirements of this regulation or if the information submitted for the plan is insufficient to make a determination of compliance with this subtitle, a person may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#C(1)">(1)</span> Submit amendments to the application and explanatory documentation; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#C(2)">(2)</span> Apply for a permit in accordance with this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#D">D.</span> The OHCQ may conduct on-site surveys of a laboratory operating under a letter of exception — limited testing for rare diseases to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#D(1)">(1)</span> Investigate a complaint; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#D(2)">(2)</span> Determine compliance with this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.03.06#E">E.</span> If a licensee wishes to perform more than 50 rare disease tests per year, the licensee shall submit an application for and obtain a permit as required under this subtitle.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.04" data-order="|10|10|04|" data-ref-path="10|10|04" class="h__chapter">Chapter 04 Medical Laboratories</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 19, 1990 (17:3 Md. R. 297)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01" title=".01 General.">Regulation .01</a> amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .03B amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .05 amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .06 amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .07 amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .08E amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .09 amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>Regulation .12B and C amended effective December 9, 1991 (18:24 Md. R. 2644)</p>
                  <p>——————</p>
                  <p>——————</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01" title=".01 General.">.01</a>—.12 repealed and new Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01" title=".01 General.">.01</a>—.19 adopted effective February 26, 1996 (23:4 Md. R. 273)</p>
                  <p>Chapter, Cholesterol Testing, repealed and new chapter, Medical Laboratories — Fees, adopted effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01" title=".01 General.">Regulation .01</a> amended effective July 24, 2000 (27:14 Md. R. 1340); June 1, 2009 (36:11 Md. R. 787)</p>
                  <p>——————</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.02" title=".02 Licensing — Letter of Exception.">Regulation .02</a> amended effective July 23, 2001 (28:14 Md. R. 1321); June 1, 2009 (36:11 Md. R. 787); August 19, 2013 (40:16 Md. R. 1344); December 21, 2015 (42:25 Md. R. 1543)</p>
                  <p>Regulation .03A amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p>Chapter, Medical Laboratories — Fees renamed Medical Laboratories effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01#E" title="">Regulation .01E</a> amended effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.02" title=".02 Licensing — Letter of Exception.">Regulation .02</a> amended effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <p>Regulation .03 repealed effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202, 17-204, 17-205, 17-207, 17-209, 17-502, 17-503, and 17-506, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.04.01" data-order="|10|10|04|.01|" data-ref-path="10|10|04|.01" class="h__section">.01 General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#A">A.</span> Requirement. A person required to obtain and maintain a license as set forth under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03" title="Chapter 03 Medical Laboratories — Licenses">COMAR 10.10.03</a> shall pay the appropriate fees as set forth in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#B">B.</span> A person shall submit a licensing fee in the form of a check or money order made payable to the Maryland Department of Health.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#C">C.</span> Fees. Fees include but are not limited to the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#C(1)">(1)</span> Amend an unexpired permit — $50;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#C(2)">(2)</span> Replace a lost permit — $30;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#C(3)">(3)</span> Provide a copy of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>—.10.10.09, "Medical Laboratories" — as provided under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.01.08" title="Chapter 08 Procedures for Access to Records">COMAR 10.01.08</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#C(4)">(4)</span> For the Department to conduct out-of-State, on-site surveys of a laboratory seeking or maintaining a license to test specimens of a type and in a scientific field of study for which there is no national certification, for example, the subdiscipline of job-related testing of hair for drugs of abuse — full cost to the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#D">D.</span> Public Health Laboratory. A public health laboratory, as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03" title=".03 Definitions.">COMAR 10.10.01.03</a>, is exempt from paying fees under this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#E">E.</span> Fee Waiver. The Secretary may waive all licensing fees for a:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#E(1)">(1)</span> Municipal or county health department; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#E(2)">(2)</span> Governmental agency that receives funding to operate from the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#F">F.</span> Payment of Prorated Fees. A licensee issued a letter of exception or a permit at a time other than at the beginning of a regulatory cycle shall pay a letter of exception or permit fee based on the total number of full plus partial months remaining in a regulatory cycle on the date a permit or letter of exception is issued.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#G">G.</span> Refunds and Credits. The Secretary may not issue a refund or credit or return any licensing application fees to a laboratory that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#G(1)">(1)</span> Withdraws a licensing application;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#G(2)">(2)</span> Replaces a permit with a letter of exception; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#G(3)">(3)</span> Voluntarily or involuntarily ceases to operate or reduces or limits a testing service before a license expires.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.01#H">H.</span> Failure to Pay Fees. The Secretary may not issue a new license or issue a renewed license until all outstanding fees are paid.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.04.02" data-order="|10|10|04|.02|" data-ref-path="10|10|04|.02" class="h__section">.02 Licensing — Letter of Exception.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.02#A">A.</span> Letter of Exception. A person applying for a letter of exception for a POL or POCL shall submit an initial application and biennially after that with each renewal application.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.04.02#B">B.</span> Letter of Exception — Limited Testing for Rare Diseases. A person applying for a letter of exception-limited testing for rare diseases for a laboratory shall submit an initial application and biennially after that with each renewal application.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.05" data-order="|10|10|05|" data-ref-path="10|10|05" class="h__chapter">Chapter 05 Medical Laboratories — Proficiency Testing</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: October 5, 1998 (25:20 Md. R. 1529)</p>
                  <p>——————</p>
                  <p>Chapter, Job-Related Alcohol and Controlled Dangerous Substances Testing, repealed and new chapter, Medical Laboratories—Proficiency Testing, adopted effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.01" title=".01 Participation and Evaluation.">Regulation .01</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.02#B" title="">Regulation .02B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.04" title=".04 Cytology — Departmental Requirements.">Regulation .04</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.04#D" title="">Regulation .04D</a> amended effective November 29, 2010 (37:24 Md. R. 1658)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.05#B" title="">Regulation .05B</a>, C amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.05#C" title="">Regulation .05C</a> amended effective November 29, 2010 (37:24 Md. R. 1658)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202 and 17-211, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.05.01" data-order="|10|10|05|.01|" data-ref-path="10|10|05|.01" class="h__section">.01 Participation and Evaluation.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A">A.</span> Participation. A licensee operating under a permit shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(1)">(1)</span> Enrolls in and participates satisfactorily in a PT program that meets the criteria set forth in this chapter for each of the tests that the laboratory offers to perform or performs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(2)">(2)</span> Tests PT samples in the same manner and number of times that it routinely tests patient specimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(3)">(3)</span> Complies with the applicable standards contained in 42 CFR §§493.801—493.807.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#B">B.</span> Evaluation — General. When a PT program does not evaluate a participating laboratory's PT results or the evaluated PT results are inconsistent with satisfactory performance, the participating laboratory and the OHCQ shall evaluate the PT results by comparing them to the all-method-results mean, all-instrument-results mean, or the all-participant-results mean found in the PT program's summaries of PT results.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C">C.</span> Evaluation — Departmental.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)">(1)</span> Administrative Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(a)">(a)</span> Submission of Results. The OHCQ shall monitor for regulatory purposes only official results sent directly from the PT program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(b)">(b)</span> Multiple Programs. If a licensee enrolls in more than one PT program and duplicate testing and reporting occurs, the licensee shall notify the OHCQ which PT program is to be scored for regulatory purposes.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)">(c)</span> Sample Testing. A licensee shall operate under the following PT procedures:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(i)">(i)</span> PT samples shall be tested each time a shipment is received and for only those procedures offered or allowed under a laboratory's license;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(ii)">(ii)</span> If a test is no longer offered or performed, the licensee shall inform the OHCQ in writing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(iii)">(iii)</span> PT samples shall be tested only in the laboratory for which they are intended;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(iv)">(iv)</span> PT samples shall be handled, processed, and tested in the same manner as patient specimens; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(v)">(v)</span> Repeat testing may not be performed on PT samples unless it is the laboratory's policy to test patients in duplicate or if abnormal test results are routinely repeated to verify accuracy.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)">(d)</span> Testing and Reporting Deadlines.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)(i)">(i)</span> A licensee shall test PT samples and report PT results within the time limits set by the PT program.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)(ii)">(ii)</span> PT results submitted late by a licensee are deemed unsatisfactory by the PT program and the OHCQ.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(e)">(e)</span> PT Program Evaluation Errors. A licensee is responsible for seeing that an evaluation error on the PT report is corrected by the PT program and that the program sends a corrected PT report to the OHCQ.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)">(f)</span> Performance Records. A laboratory's marginal or unsatisfactory PT performance may not be changed to reflect satisfactory performance when:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(i)">(i)</span> PT results are not submitted;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(ii)">(ii)</span> PT results are submitted after the due date; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(iii)">(iii)</span> Transcription errors involving PT results went unnoticed until the evaluated results were scored.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)">(2)</span> Evaluation Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)">(a)</span> Grading Criteria.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)(i)">(i)</span> The PT program shall score test results in terms of correlation with reference or referee laboratory test results, target values, or statistical methods based on means and standard deviations.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)(ii)">(ii)</span> The OHCQ shall determine a laboratory's PT performance based on a PT program's numerical score for each specialty, subspecialty, constituent, analyte, and culture type.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)">(b)</span> Scores. Numerical PT scores required for satisfactory performance in each subdiscipline, specialty or subspecialty are as follows:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(i)">(i)</span> AFP for NTD, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(ii)">(ii)</span> Antibodies for HIV, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(iii)">(iii)</span> Bacteriology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(iv)">(iv)</span> Blood gases, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(v)">(v)</span> Blood lead, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(vi)">(vi)</span> Chemistry, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(vii)">(vii)</span> Coagulation, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(viii)">(viii)</span> Cytogenetics, as set by PT program;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(ix)">(ix)</span> Drugs of abuse, forensic, equal to or greater than 90 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(x)">(x)</span> Drugs of abuse, clinical or diagnostic, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xi)">(xi)</span> Hematology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xii)">(xii)</span> Immunohematology, ABO and Rh typing, antibody screen, 100 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xiii)">(xiii)</span> Immunohematology, antibody identification, equal to or greater than 90 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xiv)">(xiv)</span> Mycology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xv)">(xv)</span> Mycobacteriology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xvi)">(xvi)</span> Immunology, nonsyphilis serology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xvii)">(xvii)</span> Parasitology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xviii)">(xviii)</span> Syphilis serology, equal to or greater than 80 percent; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xix)">(xix)</span> Urinalysis, equal to or greater than 80 percent.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(c)">(c)</span> Scoring Criteria. A percent score is derived by dividing the number of satisfactory PT results by the total number of PT results for each subdiscipline, specialty, subspecialty, or individual constituent or analyte within a subspecialty.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(d)">(d)</span> PT Failure. PT scores lower than the percent scores listed in <a class="internal-link " href="/us/md/exec/comar/10.10.05.01#C(2)(b)" title="">§C(2)(b) of this regulation</a> are failing scores.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(e)">(e)</span> Evaluated PT Results. PT results evaluated in determining PT performance include PT results not evaluated by the PT program, code 10 results, for example, 10E, 10G, 10T, and codes of tests not performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)">(3)</span> Initial or Single PT Failure.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)(a)">(a)</span> Licensee Action. A licensee shall investigate a single or initial PT failure and document the corrective action taken.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)(b)">(b)</span> Departmental Procedures. The OHCQ shall document an initial or single PT failure and may request a licensee to submit a plan of correction and supporting documentation related to the failure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)">(4)</span> Marginal PT Performance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(a)">(a)</span> Test Scores. PT performance is marginal when a laboratory exhibits failing PT scores in two of three consecutive testing events in a subdiscipline, specialty, subspecialty, or individual constituent or analyte, for example, Na, RBC, cholesterol.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)">(b)</span> Departmental Procedures. The OHCQ shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(i)">(i)</span> Document the marginal PT;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(ii)">(ii)</span> Send written notice of the marginal PT to the licensee; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(iii)">(iii)</span> Request the licensee to submit a written plan of correction.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(c)">(c)</span> Laboratory Actions. A licensee shall submit to the OHCQ a written plan of correction that describes the investigation and steps taken to improve the applicable test performance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)">(5)</span> Unsatisfactory PT Performance. PT performance is unsatisfactory when a laboratory exhibits:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(a)">(a)</span> Failing PT scores in three of four consecutive testing events in a subdiscipline, specialty, or individual constituent or analyte, for example, Na, RBC, cholesterol;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(b)">(b)</span> Failing PT scores in two of three consecutive testing events in a subdiscipline, specialty, subspecialty, or individual constituent or analyte, for example, Na, RBC, cholesterol, and the next PT report for the test states "test not performed"; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(c)">(c)</span> An average PT score for a test over the last four consecutive testing events that falls below the minimum percent score set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.01#C(2)(b)" title="">§C(2)(b) of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.05.02" data-order="|10|10|05|.02|" data-ref-path="10|10|05|.02" class="h__section">.02 Discipline, Specialty, and Subspecialty.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A">A.</span> Primary Standard. A licensee operating under a permit shall ensure that the laboratory participates successfully in PT, when applicable, for each test or analyte in each of the following disciplines, subdisciplines, and specialties:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)">(1)</span> Microbiology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(a)">(a)</span> Bacteriology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(b)">(b)</span> Mycobacteriology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(c)">(c)</span> Mycology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(d)">(d)</span> Parasitology; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(e)">(e)</span> Virology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)">(2)</span> Immunology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(a)">(a)</span> General immunology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(b)">(b)</span> General serology; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(c)">(c)</span> Syphilis serology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)">(3)</span> Chemistry, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(a)">(a)</span> Blood gas analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(b)">(b)</span> Endocrinology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(c)">(c)</span> Routine chemistry; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(d)">(d)</span> Toxicology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)">(4)</span> Genetics, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(a)">(a)</span> Biochemical genetics;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(b)">(b)</span> Cytogenetics; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(c)">(c)</span> Molecular genetics;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)">(5)</span> Hematology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)(a)">(a)</span> Coagulation testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)(b)">(b)</span> Routine hematology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(6)">(6)</span> Pathology, including the subdiscipline of gynecologic cytology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)">(7)</span> Immunohematology, including the specialties of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(a)">(a)</span> ABO group and D(Rho) typing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(b)">(b)</span> Unexpected antibody detection, that is, antibody screen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(c)">(c)</span> Antibody identification; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(d)">(d)</span> Compatibility testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(8)">(8)</span> Forensic toxicology limited to job-related alcohol and controlled dangerous substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B">B.</span> Discipline Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(1)">(1)</span> General. A licensee operating under a permit shall ensure that the laboratory meets the applicable PT standards set forth in this chapter and in 42 CFR §§493.821 — 493.865.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)">(2)</span> Gynecologic Cytology. A licensee operating under a permit to perform gynecologic cytology shall ensure that the laboratory enrolls and maintains successful participation in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)(a)">(a)</span> A cytology PT program operated by the Secretary if the laboratory is located inside this State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)(b)">(b)</span> A cytology PT program approved by CMS if the laboratory is located outside this State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)">(3)</span> Job-Related Testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(a)">(a)</span> A licensee operating under a permit to perform job-related testing for alcohol or controlled dangerous substances shall ensure that the laboratory enrolls and continues to participate satisfactorily, when applicable, in one or more of the programs listed in §B(3)(b)—(e) of this regulation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)">(b)</span> Screening Tests. A licensee operating under a permit to perform screening tests for job-related alcohol and controlled dangerous substances shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(i)">(i)</span> The American Association of Bioanalysts (AAB) Urine Toxicology Screening survey;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(ii)">(ii)</span> The American Association for Clinical Chemistry/College of American Pathologists (AACC/CAP) Forensic Urine Drug Testing Screening survey; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(iii)">(iii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)">(c)</span> Confirmation Tests. A licensee operating under a permit to perform confirmation tests for job-related alcohol and controlled dangerous substances shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(i)">(i)</span> The AACC/CAP Forensic Urine Drug Testing Confirmatory survey;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(ii)">(ii)</span> The federal Substance Abuse and Mental Health Services Administration's Federal Workplace Drug Testing Program; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(iii)">(iii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)">(d)</span> Blood Alcohol Tests. A licensee operating under a permit to perform tests for alcohol in blood shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)(i)">(i)</span> The AACC/CAP survey for whole blood alcohol or serum alcohol, or both; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)(ii)">(ii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)">(e)</span> Hair Analysis. A licensee operating under a permit to perform tests for a controlled dangerous substance in hair shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)(i)">(i)</span> The State of Florida's P.T. program for drug testing in hair; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)(ii)">(ii)</span> Another program that possesses standards set by the Secretary or that are equivalent to the State of Florida's PT program for drug testing in hair and is approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.05.03" data-order="|10|10|05|.03|" data-ref-path="10|10|05|.03" class="h__section">.03 Program Approval.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#A">A.</span> Approval Required. A private, nonprofit, or commercial organization or government agency may not provide a PT program in this State without first obtaining program approval from CMS or the OHCQ.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#B">B.</span> Approval Granted Automatically. Except in the discipline of job-related alcohol and controlled dangerous substances, or other disciplines, subdisciplines, or specialties not covered by federal PT requirements, a PT program is approved when it is based on written evidence issued by CMS showing the program meets CMS's criteria for approval of PT programs as set forth in 42 CFR §§493.901—493.959.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C">C.</span> Approval Granted by the Secretary. The OHCQ may approve a PT program for a laboratory discipline, subdiscipline, or specialty not approved by CMS, if the program:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C(1)">(1)</span> Provides reliable, documented evidence that the program is technically and administratively able to meet the applicable requirements of this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C(2)">(2)</span> Uniformly and routinely prepares and submits directly to the OHCQ evaluations of all PT results from all laboratories enrolled in the program and holding a Maryland permit.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.05.04" data-order="|10|10|05|.04|" data-ref-path="10|10|05|.04" class="h__section">.04 Cytology — Departmental Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#A">A.</span> The Secretary may not issue a license to operate a laboratory that examines gynecologic cytology specimens if the laboratory does not enroll and participate satisfactorily in a cytology PT program operated or approved by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#B">B.</span> The OHCQ shall conduct annual PT for each pathologist and cytotechnologist who examines gynecological cytology slides acquired in the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#C">C.</span> The OHCQ or an agent of the Department shall hand carry test materials for first-event testing in a PT cycle to a laboratory and shall conduct and supervise all testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D">D.</span> The OHCQ shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(1)">(1)</span> Conduct announced and unannounced on-site testing for individuals during an annual PT cycle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)">(2)</span> Schedule and conduct a retesting event for an individual who has failed the annual PT testing event not more than 45 days after receipt of the notification of the PT testing event failure by the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)(a)">(a)</span> Individual who failed the annual PT testing event; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)(b)">(b)</span> Laboratory director of the individual who failed the annual PT testing event.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#E">E.</span> The OHCQ may conduct unannounced PT at any time during normal laboratory working hours when the testing is conducted as part of routine PT, a complaint investigation, a follow-up certification, or a regulatory compliance survey.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#F">F.</span> The OHCQ shall conduct announced retesting within an annual PT cycle at a site selected by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#G">G.</span> The OHCQ shall schedule an individual who misses a laboratory's annual PT event to make up the missed test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#H">H.</span> The OHCQ shall evaluate an individual's PT performance as set forth in 42 CFR §493.945.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.05.05" data-order="|10|10|05|.05|" data-ref-path="10|10|05|.05" class="h__section">.05 Cytology — Laboratory and Individual Standards.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#A">A.</span> Primary Standard. A pathologist or cytotechnologist who examines gynecological cytology specimens from individuals in this State shall participate satisfactorily in an annual cytology PT program approved by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B">B.</span> Laboratory Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(1)">(1)</span> A licensee operating under a permit to examine gynecologic cytology specimens shall ensure that each pathologist and cytotechnologist who examines gynecologic cytology specimens participates in a cytology PT program conducted by the Department or approved by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(2)">(2)</span> An in-State laboratory shall participate in the Department's PT program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(3)">(3)</span> An out-of-State laboratory shall participate in either the Department's PT program or another equivalently rigorous cytology PT program approved by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)">(4)</span> A licensee employing an individual who has failed a second testing event in an annual PT cycle shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)(a)">(a)</span> Prohibit the individual from examining gynecologic specimens and provide or secure remedial training and education in gynecologic cytology for the individual, which training and education includes examination by the individual of gynecologic specimens in the individual's area of failure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)(b)">(b)</span> Document the individual's completion of education and training using a form provided by the OHCQ.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)">(5)</span> A licensee employing an individual who has failed a first or subsequent PT event and who does not obtain mandated retesting or retraining, or both, shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)(a)">(a)</span> Immediately remove that individual from a position of examining gynecologic cytology specimens for the purpose of reporting diagnostic test results to a health care provider; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)(b)">(b)</span> Provide written notice to the OHCQ within 30 days after being informed of the individual's last test failure that the individual is no longer examining gynecologic cytology specimens for the purpose of reporting diagnostic test results to a health care provider.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C">C.</span> Individual Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(1)">(1)</span> A cytotechnologist or pathologist who examines gynecological cytology specimens shall participate in an annual PT event that involves the examination of a 10-slide or 20-slide test set as set forth in 42 CFR §493.945.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(2)">(2)</span> An individual passes a testing event and performs satisfactorily in PT when the individual scores at least 90 percent on a 10-slide or 20-slide test set.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)">(3)</span> An individual fails a testing event and performs unsatisfactorily in PT if the individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)(a)">(a)</span> Scores less than 90 percent on a 10-slide or 20-slide test set; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)(b)">(b)</span> Fails to take a scheduled retest without prior Department approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)">(4)</span> An individual who fails the annual testing event shall take a second test with another 10-slide test set:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)(a)">(a)</span> Within 45 days after receiving notice of a test failure; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)(b)">(b)</span> At a later date with prior Department approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)">(5)</span> An individual who fails a second test shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(a)">(a)</span> Cease examining gynecologic specimens immediately upon being notified of the second failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(b)">(b)</span> Complete at least 40 hours of remedial training and education in gynecologic cytology that includes examining gynecological specimens in the area of failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)">(c)</span> Complete the required training and education in a laboratory that operates under a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)(i)">(i)</span> State permit for in-State laboratories; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)(ii)">(ii)</span> Certificate issued by CMS in the subdiscipline of gynecologic cytology for out-of-State laboratories;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(d)">(d)</span> Document the required remedial training and education when completed, using a form provided by the OHCQ, and submit the completed form to the OHCQ;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(e)">(e)</span> Schedule and take a third test with a 20-slide test set within 30 days of completing the required remedial training and education; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(f)">(f)</span> Begin examining gynecologic cytology specimens only after the OHCQ informs the individual that the individual obtained a passing score on the third test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)">(6)</span> An individual who fails a third or subsequent test shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(a)">(a)</span> Complete at least 35 hours of documented, formally structured, continuing education in diagnostic cytopathology that focuses on the examination of gynecologic preparations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(b)">(b)</span> Document the education when completed, using a form provided by the OHCQ, and submit the completed form to the OHCQ;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(c)">(c)</span> Schedule and take a subsequent test with a 20-slide test set within 30 days of completing the required continuing education; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(d)">(d)</span> Begin examining gynecologic cytology specimens only after the OHCQ informs the individual that the individual obtained a passing score on the test required under <a class="internal-link " href="/us/md/exec/comar/10.10.05.05#C(6)(c)" title="">§C(6)(c) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)">(7)</span> An individual who fails a first or subsequent testing event in an annual PT cycle and who chooses not to complete mandatory retesting or remedial training, or both, shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)(a)">(a)</span> Immediately cease examining gynecologic cytology specimens and notify the OHCQ of this in writing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)(b)">(b)</span> Reenter the PT process at the point where the individual previously chose to withdraw from the testing process, if the individual decides at a later date to satisfy PT requirements.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.06" data-order="|10|10|06|" data-ref-path="10|10|06" class="h__chapter">Chapter 06 Medical Laboratories — Quality Assurance</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: November 18, 1985 (12:23 Md. R. 2217)</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.01" title=".01 General.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.06" title=".06 Quality Control — Single-Use Test Devices.">.06</a>, Physicians' Group Practice Laboratories in Maryland, repealed effective August 6, 1990 (17:15 Md. R. 1859)</p>
                  <p>——————</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.01" title=".01 General.">.01</a>—.28, Physician Office and Other Point-of-Care Laboratories, adopted effective August 6, 1990 (17:15 Md. R. 1859)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03#B" title="">Regulation .03B</a> amended effective September 16, 1991 (18:18 Md. R. 2005)</p>
                  <p>Regulation .08C amended effective September 16, 1991 (18:18 Md. R. 2005)</p>
                  <p>Regulation .09B amended effective September 16, 1991 (18:18 Md. R. 2005)</p>
                  <p>——————</p>
                  <p>Regulation .25 amended effective September 16, 1991 (18:18 Md. R. 2005)</p>
                  <p>Chapter, Physician Office and Other Point-of-Care Laboratories, repealed and new chapter, Medical Laboratories—Quality Assurance, adopted effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.01" title=".01 General.">Regulation .01</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02#A" title="">Regulation .02A</a> amended effective July 22, 2002 (29:14 Md. R. 1074); April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02#B" title="">Regulation .02B</a> amended effective April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02#C" title="">Regulation .02C</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03" title=".03 Patient Test Management.">Regulation .03</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03#B" title="">Regulation .03B</a> amended effective July 24, 2000 (27:14 Md. R. 1340); January 13, 2011 (38:1 Md. R. 11)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.04#B" title="">Regulation .04B</a> adopted effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.04#B" title="">Regulation .04B</a> amended effective April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.05" title=".05 Quality Control — General.">Regulation .05</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.05" title=".05 Quality Control — General.">Regulation .05</a>-1 adopted effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.07#B" title="">Regulation .07B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.08" title=".08 Quality Control — Job-Related Alcohol and Drug Testing.">Regulation .08</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.08#B" title="">Regulation .08B</a> amended effective July 24, 2000 (27:14 Md. R. 1340)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.09" title=".09 Repealed.">Regulation .09</a> repealed effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.10" title=".10 Quality Control — Cytology.">Regulation .10</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.10#B" title="">Regulation .10B</a> amended effective July 24, 2000 (27:14 Md. R. 1340)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.12" title=".12 Quality Control — Temporary and Mobile Laboratories: General.">Regulation .12</a> amended effective July 22, 2002 (29:14 Md. R. 1074); April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.12#B" title="">Regulation .12B</a> amended effective April 16, 2012 (39:7 Md. R. 492)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.14#B" title="">Regulation .14B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.15" title=".15 Quality Control — Temporary and Mobile Laboratories: Cholesterol and Health Awareness.">Regulation .15</a> amended effective June 1, 2009 (36:11 Md. R. 787); April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.15#B" title="">Regulation .15B</a> amended effective July 24, 2000 (27:14 Md. R. 1340)</p>
                  <p>Regulation .16 repealed effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p>Regulation .16A amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202, 17-202.1, 17-214, and 17-504, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.06.01" data-order="|10|10|06|.01|" data-ref-path="10|10|06|.01" class="h__section">.01 General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A">A.</span> Primary Standards. To obtain or maintain a permit to operate a laboratory, a person or licensee shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(1)">(1)</span> Establishes and follows written policies and procedures for a comprehensive quality assurance program designed to monitor and evaluate the ongoing and overall quality and safety of the total, that is, preanalytic, analytic, and postanalytic phases of the testing process;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)">(2)</span> Maintains a quality assurance program that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(a)">(a)</span> Continually evaluates the effectiveness of the laboratory's policies and procedures;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(b)">(b)</span> Routinely revises policies and procedures based on the results of on-going evaluation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(c)">(c)</span> Identifies and corrects problems;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(d)">(d)</span> Assures accurate, reliable, and prompt reporting of test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(e)">(e)</span> Assures adequate and competent personnel; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(2)(f)">(f)</span> Documents all quality assurance activities; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#A(3)">(3)</span> Establishes and maintains a laboratory safety program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B">B.</span> Standards. A licensee shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(1)">(1)</span> Meets the applicable:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(1)(a)">(a)</span> Quality assurance standards set forth in this chapter and in 42 CFR §§493.1230 — 493.1299; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(1)(b)">(b)</span> Quality testing standards for facility administration set forth in this chapter and in 42 CFR §§493.1100 — 493.1101;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)">(2)</span> Establishes, maintains, and enforces a laboratory safety program that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)">(a)</span> Provides all personnel with access to a safety manual covering the following topics, when applicable:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(i)">(i)</span> General personnel safety;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(ii)">(ii)</span> Fire prevention and control;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(iii)">(iii)</span> Biological hazards;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(iv)">(iv)</span> Chemical hazards;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(v)">(v)</span> Radiological hazards;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(vi)">(vi)</span> Special medical waste disposal; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(a)(vii)">(vii)</span> The reporting of incidents and accidents; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(b)">(b)</span> Complies with the following applicable federal Occupational Safety and Health Administration standards:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(b)(i)">(i)</span> "Occupational Exposure to Hazardous Chemicals in Laboratories", contained in 29 CFR §1910.1450; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(2)(b)(ii)">(ii)</span> "Bloodborne Pathogens," contained in 29 CFR §1910.1030; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(3)">(3)</span> Maintains a collection station:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(3)(a)">(a)</span> As part of and under the direction of the laboratory for which it collects specimens; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.01#B(3)(b)">(b)</span> With equipment and staff appropriate for the collection, preservation, storage, and maintenance of specimens in a manner suitable for later examination.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.02" data-order="|10|10|06|.02|" data-ref-path="10|10|06|.02" class="h__section">.02 Authorization to Request Laboratory Tests.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#A">A.</span> Primary Standard. A laboratory may not perform a laboratory test, except under a health awareness permit or cholesterol permit, without obtaining written or electronic authorization from:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#A(1)">(1)</span> A court of law;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#A(2)">(2)</span> A doctor of medicine, osteopathy, podiatric medicine, or dentistry; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#A(3)">(3)</span> Another person authorized to order laboratory tests under the Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B">B.</span> Other Authorized Persons. Other persons authorized to order laboratory tests include:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(1)">(1)</span> A nurse midwife certified by the Maryland State Board of Nursing under COMAR 10.27.05;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(2)">(2)</span> A nurse practitioner certified by the Maryland State Board of Nursing under COMAR 10.27.07;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(3)">(3)</span> A physician's assistant, as authorized by the physician's assistant's supervising physician;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(4)">(4)</span> A chiropractor requesting a test on blood or urine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(5)">(5)</span> An employer requesting a job-related test for alcohol or controlled dangerous substances;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(6)">(6)</span> Clinical staff who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(6)(a)">(a)</span> Meets the qualifications set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.01.06#D" title="">COMAR 10.47.01.06D</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(6)(b)">(b)</span> Is employed by a substance abuse treatment program that is certified or accredited in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.04.03" title=".03 Certification Required.">COMAR 10.47.04.03</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(6)(c)">(c)</span> Is authorized to order tests to detect the presence of controlled dangerous substances on patients enrolled in the substance abuse treatment program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#B(7)">(7)</span> A pharmacist, for tests that qualify for a letter of exception under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#B" title="">COMAR 10.10.03.02B</a> and for glucose, A1c, lipids (including total cholesterol, HDL, LDL, and triglycerides), AST, and ALT.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.02#C">C.</span> Standards. A licensee shall ensure that the laboratory meets the applicable standards concerning test requisition contained in 42 CFR §493.1241.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.03" data-order="|10|10|06|.03|" data-ref-path="10|10|06|.03" class="h__section">.03 Patient Test Management.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A">A.</span> Primary Standard. A licensee shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(1)">(1)</span> Provides patient manipulation by qualified personnel; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)">(2)</span> Employs and maintains a quality assurance program that provides for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(a)">(a)</span> Proper patient preparation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)">(b)</span> Proper specimen:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)(i)">(i)</span> Collection;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)(ii)">(ii)</span> Identification;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)(iii)">(iii)</span> Preservation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)(iv)">(iv)</span> Transportation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(b)(v)">(v)</span> Processing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(c)">(c)</span> Record maintenance; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#A(2)(d)">(d)</span> Accurate reporting of results.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B">B.</span> Standard — Patient Manipulation and Specimen Collection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)">(1)</span> A person may not manipulate a patient, for example, to collect specimens unless the person is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(a)">(a)</span> A licensed:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(a)(i)">(i)</span> Physician; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(a)(ii)">(ii)</span> Nurse;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(b)">(b)</span> Authorized by law to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(b)(i)">(i)</span> Collect a specimen from an individual for medical laboratory testing; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(b)(ii)">(ii)</span> Manipulate a patient; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(1)(c)">(c)</span> Employed by a licensee under this title.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(2)">(2)</span> A licensee shall ensure that specimens for laboratory testing are collected by individuals who are trained in and have documented experience in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(2)(a)">(a)</span> Preparing patients for specimen collection; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(2)(b)">(b)</span> Collecting the appropriate specimen required for the requested test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)">(3)</span> Qualified personnel authorized by the licensee may collect:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)(a)">(a)</span> Blood specimens, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)(a)(i)">(i)</span> Venipuncture; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)(a)(ii)">(ii)</span> Finger or heel stick whole-blood specimens;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)(b)">(b)</span> Stomach contents; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(3)(c)">(c)</span> Clinical materials for smears and culture, for example, throat and nasopharyngeal swabs, and other specimens required to perform a requested test under the direction or on the written request of a physician or other person authorized by law and identified in <a class="internal-link " href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(4)">(4)</span> An employer may collect a specimen for job-related testing to determine use or abuse of a controlled dangerous substance or alcohol as set forth under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10" title="Chapter 10 Job-Related Alcohol and Controlled Dangerous Substances Testing">COMAR 10.10.10</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(5)">(5)</span> A person collecting specimens for medical laboratory testing or examination shall follow the licensee's policies and procedures contained in the laboratory's quality assurance system as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.06.03#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#B(6)">(6)</span> This section does not apply to the collection of a DNA specimen with a buccal swab used for determining paternity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C">C.</span> Standard — Quality Assurance. A licensee shall ensure that the laboratory's quality assurance system:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C(1)">(1)</span> Provides optimum patient test results by establishing and maintaining mechanisms to preserve specimen integrity and maintain positive specimen identification throughout the entire testing process, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C(1)(a)">(a)</span> Preanalytic phase;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C(1)(b)">(b)</span> Analytic phase; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C(1)(c)">(c)</span> Postanalytic phase; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.03#C(2)">(2)</span> Meets the applicable standards contained in 42 CFR §§493.1230 — 493.1234, 493.1240 — 493.1249, and 493.1281—493.1299.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.04" data-order="|10|10|06|.04|" data-ref-path="10|10|06|.04" class="h__section">.04 Reporting and Releasing Test Results.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#A">A.</span> Primary Standard. A laboratory shall report or release test results, except results of a health awareness test, only to an authorized person.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)">(1)</span> For all test results except those from a health awareness test performed at a temporary laboratory or from a job-related alcohol or controlled dangerous substance test, a licensee shall ensure that the laboratory:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(a)">(a)</span> Reports medical test results only to the physician, dentist, or other authorized person who requested the test, or to another laboratory that requested the test;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(b)">(b)</span> Sends a copy of a test result, other than a result for a health awareness or job-related alcohol or controlled dangerous substances test, directly to the individual tested only after the laboratory:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(b)(i)">(i)</span> Receives a written request from the individual; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(b)(ii)">(ii)</span> Notifies the authorized person who requested the test that the results will be released to the individual tested;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(c)">(c)</span> Meets the applicable standards concerning test reports contained in 42 CFR §§493.1234 and 493.1291; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(1)(d)">(d)</span> Reports a test result on a form that identifies the name and address of the laboratory that performed the test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(2)">(2)</span> For test results stemming from a health awareness test, set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>, and performed at a temporary laboratory, the laboratory may report those results directly to the individual tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(3)">(3)</span> If the results of the tests listed in <a class="internal-link " href="/us/md/exec/comar/10.10.06.02#B(7)" title="">Regulation .02B(7) of this chapter</a> are not within the desired range, the pharmacist shall provide:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(3)(a)">(a)</span> The test results to the patient’s primary care practitioner for evaluation and treatment; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.04#B(3)(b)">(b)</span> The patient with a referral to a licensed independent practitioner for evaluation and treatment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.05" data-order="|10|10|06|.05|" data-ref-path="10|10|06|.05" class="h__section">.05 Quality Control — General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05#A">A.</span> Primary Standard. A licensee operating under a permit shall ensure that the laboratory establishes and follows written quality control procedures for monitoring and evaluating the quality of the analytic phase of the testing process for each testing method and procedure to assure the accuracy and reliability of patient test results and reports.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05#B">B.</span> Standard. A licensee shall ensure that the laboratory meets the applicable quality control standards as set forth in this chapter and in 42 CFR §§493.1200—493.1299.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.05-1" data-order="|10|10|06|.05-1|" data-ref-path="10|10|06|.05-1" class="h__section">.05-1 Quality Control — Quality Control Program.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#A">A.</span> Primary Standard. A licensee shall develop, establish, implement, maintain, and follow quality control policies, procedures, and techniques that ensure accurate and reliable test results and patient test reports.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#B">B.</span> Standard — Quality Control Program. A licensee's quality control program shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#B(1)">(1)</span> Cover all tests and related examinations and procedures performed by the laboratory; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#B(2)">(2)</span> Meet the standards and requirements set forth in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C">C.</span> Standard — Quality Control Practices. A licensee's quality control practices shall include, but are not limited to, the use of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(1)">(1)</span> Analyses of reference materials to ensure that test results are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(1)(a)">(a)</span> Reproducible;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(1)(b)">(b)</span> Accurate; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(1)(c)">(c)</span> Reliable;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(2)">(2)</span> Systems to ensure proper functioning of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(2)(a)">(a)</span> Instruments;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(2)(b)">(b)</span> Equipment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(2)(c)">(c)</span> Reagents;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(3)">(3)</span> Validity, calibration, and systematic procedural checks for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(3)(a)">(a)</span> Reagents;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(3)(b)">(b)</span> Equipment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(3)(c)">(c)</span> Test systems; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)">(4)</span> Systems for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)(a)">(a)</span> Review and reporting of test results that ensure timely error detection and correction; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)(b)">(b)</span> Assessment of laboratory personnel:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)(b)(i)">(i)</span> Performance;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)(b)(ii)">(ii)</span> Proficiency; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#C(4)(b)(iii)">(iii)</span> Competency.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D">D.</span> Standard — Adequacy of Methods and Equipment. A licensee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(1)">(1)</span> Employ methods and equipment that provide accurate and reliable test results and reports;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(2)">(2)</span> Have sufficient and suitable equipment and instruments to perform the type of testing services and volume of tests offered by the laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)">(3)</span> Monitor all test methods, instruments, and test systems for the following performance characteristics, when applicable:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(a)">(a)</span> Detection limits for each:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(a)(i)">(i)</span> Method;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(a)(ii)">(ii)</span> Instrument; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(a)(iii)">(iii)</span> Test system;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(b)">(b)</span> Precision;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(c)">(c)</span> Accuracy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(d)">(d)</span> Specificity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(e)">(e)</span> Sensitivity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(f)">(f)</span> Test interferences; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(3)(g)">(g)</span> Other related test variables that affect test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(4)">(4)</span> Have adequate systems in place to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(4)(a)">(a)</span> Ensure that a statistically valid number of counts or measurement levels are obtained and verified to give accurate and reliable test results for systems each day instruments and equipment such as cell counters, radiation counters, and spectrophotometers are used; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(4)(b)">(b)</span> Report results in an accurate and reliable manner and within the time frames established by the laboratory; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#D(5)">(5)</span> Perform test methods and use instrumentation in a manner that permits the laboratory to provide accurate and reliable test results within the laboratory's stated performance criteria.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#E">E.</span> Standard — Supplies, Reagents, and Materials. A licensee shall ensure that supplies, reagents, and other materials used in the collection, handling, testing, and storing of specimens in the laboratory are stored, labeled, checked for proper reactivity, and used according to §§F — I of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#F">F.</span> Storage. A licensee shall ensure that laboratory materials are stored in the manner stated by the manufacturer.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G">G.</span> Labeling. A licensee shall ensure that laboratory testing materials, including reagents, solutions, culture media, controls, and calibrators are labeled to indicate the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(1)">(1)</span> Identity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(2)">(2)</span> Concentration, strength, or titer;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(3)">(3)</span> Storage requirements;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(4)">(4)</span> Preparation and expiration dates;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(5)">(5)</span> Identity of the preparer; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#G(6)">(6)</span> Other pertinent information that would affect test performance or outcome.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#H">H.</span> Reactivity Checks. A licensee shall ensure that representative samples of each lot of materials used for or in the process of testing specimens are tested on a regularly scheduled basis to determine each material's capacity to perform as required.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I">I.</span> Use of Supplies and Other Materials. A licensee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I(1)">(1)</span> May not use materials that have:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I(1)(a)">(a)</span> Exceeded the material's expiration date;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I(1)(b)">(b)</span> Substandard reactivity; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I(1)(c)">(c)</span> Deteriorated; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.05-1#I(2)">(2)</span> Shall use supplies, reagents, kits, identification systems, and other materials in a manner consistent with the recommendations and instructions provided by the manufacturer.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.06" data-order="|10|10|06|.06|" data-ref-path="10|10|06|.06" class="h__section">.06 Quality Control — Single-Use Test Devices.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#A">A.</span> Primary Standard. This regulation applies to test systems that use single-use test devices as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(1)">(1)</span> General. A licensee shall ensure that the test system is validated on a continuing basis and that the ongoing validation includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(1)(a)">(a)</span> Calibration verification;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(1)(b)">(b)</span> Parallel testing before or, when appropriate, instead of proficiency testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(1)(c)">(c)</span> Proficiency testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(2)">(2)</span> Requirements of the Test System's Manufacturer. In addition to the standards set forth in this regulation, a licensee shall ensure that the laboratory meets the quality control and quality assurance requirements of the test system's manufacturer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)">(3)</span> Test System Validation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(a)">(a)</span> Initial. Before implementing patient testing, a licensee shall ensure that the test system is validated to assure consistency with the test system manufacturer's performance attributes for acceptable accuracy, precision, and functions that affect test reliability and the competency of the testing personnel by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(a)(i)">(i)</span> Performing and documenting at least 20 quality control tests for a period of at least 5 days of test system use in the environment and under the conditions that the test system will be used; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(a)(ii)">(ii)</span> Having all testing personnel participate in the validation process.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(b)">(b)</span> Prior Testing. A test system placed in service for patient testing before the effective date of this chapter does not require an initial validation if a licensee ensures that the laboratory has:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(b)(i)">(i)</span> Maintained documented evidence of an established, comprehensive, and active quality assurance program; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(3)(b)(ii)">(ii)</span> Participated satisfactorily in and continues to participate satisfactorily in an approved proficiency testing program or, when appropriate, periodically has conducted documented, parallel testing with split samples and periodically continues to conduct documented parallel testing with split samples.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(4)">(4)</span> Validity Check. A licensee shall ensure that each time a test is performed the result of the validity check and any corrective action are documented when the result:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(4)(a)">(a)</span> Shows a single-use test device or test system failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(4)(b)">(b)</span> Indicates any substandard performance; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(4)(c)">(c)</span> Requires operator intervention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)">(5)</span> System Check.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(a)">(a)</span> Quantitative Test System. A licensee shall ensure that a system check for a quantitative test system is performed and documented:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(a)(i)">(i)</span> As specified by the manufacturer or at least once each 8 hours of test system use; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(a)(ii)">(ii)</span> After a single-use test device is exposed to an environment or condition that could affect the accuracy or reliability of test results.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(b)">(b)</span> Qualitative Test System. A licensee shall ensure that a system check for a qualitative test system, if available, is performed and documented:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(b)(i)">(i)</span> As required by the manufacturer; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(5)(b)(ii)">(ii)</span> Each day the test system is used.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)">(6)</span> Quality Control Tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(a)">(a)</span> Quantitative Test Systems. A licensee shall ensure that quality control testing for a quantitative test system is performed and documented using at least two levels of control material before patient testing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(a)(i)">(i)</span> On each lot of a single-use test device received in a shipment;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(a)(ii)">(ii)</span> At least weekly for each lot of a single-use test device used for patient testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(a)(iii)">(iii)</span> After the test system undergoes maintenance, repair, adjustment, or an environmental exposure that could affect the accuracy and reliability of test results; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(a)(iv)">(iv)</span> Each day of use during the test system's validation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(b)">(b)</span> Qualitative Test System. A licensee shall ensure that quality control testing for a qualitative test system is performed and documented using known positive and negative control materials before patient testing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(b)(i)">(i)</span> On each lot of a single-use test device received in a shipment;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(b)(ii)">(ii)</span> At least weekly for each lot of a single-use test device used for patient testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(b)(iii)">(iii)</span> After a single-use test device is exposed to an environment or condition that could affect the accuracy or reliability of test results; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(6)(b)(iv)">(iv)</span> Each day of use during test system validation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(7)">(7)</span> Calibration and Verifying Calibration.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(7)(a)">(a)</span> Calibration. A licensee shall ensure that the test system is calibrated as directed by the manufacturer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(7)(b)">(b)</span> Verifying Calibration. A licensee shall ensure that calibration of the test system is verified as directed by the manufacturer or at least every 6 months.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(8)">(8)</span> Quality Assurance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(8)(a)">(a)</span> Activities and Documentation. In addition to following other appropriate quality assurance standards in this chapter, a licensee shall ensure that quality assurance activities and documentation include reviewing, monitoring, and evaluating:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(8)(a)(i)">(i)</span> Single-use test device lot number, expiration, and disposal; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(8)(a)(ii)">(ii)</span> Testing discrepancies, including failed or repeat quality control or patient tests, validity checks, and system checks.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.06#B(8)(b)">(b)</span> Comparison of Test Results. When a facility performs a test using more than one method or test system, has multiple testing sites, or has multiple licensees performing the same test within a facility, the facility's primary or central testing site shall establish and maintain a quality assurance system that twice a year evaluates and defines the relationship of test results using the different methods, test systems, or testing sites.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.07" data-order="|10|10|06|.07|" data-ref-path="10|10|06|.07" class="h__section">.07 Quality Control — Specialty and Subspecialty.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#A">A.</span> Primary Standard. A licensee operating under a permit shall ensure that the laboratory establishes and follows written policies and procedures for a comprehensive quality control program that includes verification and assessment of accuracy, measurement of precision, and detection of error for all analyses and procedures performed by the laboratory.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#B(1)">(1)</span> General. A licensee shall ensure that the laboratory meets the applicable quality control requirements for each specialty and subspecialty under:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#B(1)(a)">(a)</span> 42 CFR §§493.1200—493.1299; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#B(1)(b)">(b)</span> Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.07" title=".07 Quality Control — Specialty and Subspecialty.">.07</a>—.16 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.07#B(2)">(2)</span> Cholesterol. A licensee or approved plan holder of a laboratory that performs cholesterol tests shall ensure that the laboratory obtains and maintains control samples at two levels, near or bracketing the 200 and 240 micrograms/deciliter decision levels.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.08" data-order="|10|10|06|.08|" data-ref-path="10|10|06|.08" class="h__section">.08 Quality Control — Job-Related Alcohol and Drug Testing.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A">A.</span> Primary Standard. A licensee shall ensure that a laboratory has in place a quality assurance program designed to monitor and evaluate all phases of the testing process including but not limited to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(1)">(1)</span> Laboratory certification;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(2)">(2)</span> Specimens, specimen collection, chain of custody, and transport;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(3)">(3)</span> Security and controlled access;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(4)">(4)</span> Storage and specimen retention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(5)">(5)</span> Analytical methods and procedures;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(6)">(6)</span> Accuracy, precision, and reliability;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(7)">(7)</span> Single-use test devices;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(8)">(8)</span> Reporting test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#A(9)">(9)</span> Proficiency testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(1)">(1)</span> Certification. A licensee of a laboratory that offers to perform or performs screening or confirmation tests for alcohol or controlled dangerous substances shall ensure that the laboratory is inspected and certified to perform tests for alcohol or controlled dangerous substances by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(1)(a)">(a)</span> The Secretary;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(1)(b)">(b)</span> The College of American Pathologists;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(1)(c)">(c)</span> The federal Substance Abuse and Mental Health Services Administration (SAMHSA); or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(1)(d)">(d)</span> A government agency, program, or accrediting organization approved by the Secretary as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02.02" title=".02 Accredited Laboratory and Accrediting Organization.">COMAR 10.10.02.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)">(2)</span> Specimens, Specimen Collection, Chain of Custody, and Transport.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)(a)">(a)</span> Permissible Specimens. A licensee shall ensure that job-related tests for alcohol or controlled dangerous substances are only performed using specimens derived from the human body as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.06" title=".06 Permissible Specimens.">COMAR 10.10.10.06</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)(b)">(b)</span> A licensee shall ensure that a specimen is processed, handled, and transported in a manner that protects the identity and physical integrity of the specimen by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)(b)(i)">(i)</span> Accepting a specimen in a sealed container that has a non-resealable closure or an evidentiary tape that assures detection of any tampering; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)(b)(ii)">(ii)</span> Implementing, maintaining, and employing chain of custody procedures, including documentation of specimen handling and access, that cover the life of a specimen from the time of collection through final disposal of the specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(2)(c)">(c)</span> Decontamination Requirement for Hair Specimens. A licensee shall ensure that the laboratory establishes, validates, and uses a procedure to remove possible external contamination from a hair specimen before a test is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)">(3)</span> Security and Controlled Access. A licensee shall ensure that a specimen is collected and processed in a manner that protects the physical integrity of the specimen by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(a)">(a)</span> Collecting and processing a specimen under supervised conditions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(b)">(b)</span> Securing the laboratory or any portion of the laboratory used for job-related alcohol or controlled dangerous substances testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(c)">(c)</span> Using and maintaining secure specimen storage areas that include, when applicable, locked freezers and refrigerators;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(d)">(d)</span> Limiting access to testing and specimen storage facilities to authorized personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(e)">(e)</span> Exercising and maintaining control over a specimen storage area by documenting in an access log the identity, date, time of entry and exit, and the purpose for entry for each individual who enters the storage area; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(f)">(f)</span> Recording, reporting, and maintaining a test result in a manner that prevents alteration and breech of confidentiality by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(f)(i)">(i)</span> Limiting access to a test result to authorized personnel; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(3)(f)(ii)">(ii)</span> Preparing and storing a test result in a secured area.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(4)">(4)</span> Storage and Specimen Retention. A licensee shall ensure that a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(4)(a)">(a)</span> Positive urine or hair specimen is retained in the original collection container for at least 6 months after a final test result is reported;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(4)(b)">(b)</span> Positive urine or blood specimen is stored at less than or equal to -20° Centigrade; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(4)(c)">(c)</span> Negative specimen is retained for at least 5 days at less than or equal to room temperature.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(5)">(5)</span> Analytical Methods and Procedures. A licensee shall ensure that tests are performed using proven and reliable methods and procedures that are approved by the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(5)(a)">(a)</span> Secretary;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(5)(b)">(b)</span> College of American Pathologists (CAP);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(5)(c)">(c)</span> The federal Substance Abuse and Mental Health Services Administration (SAMHSA); or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(5)(d)">(d)</span> United States Food and Drug Administration (FDA).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(6)">(6)</span> Approval of Methods and Procedures. The Secretary shall base approval or acceptability of any analytical method or procedure with questioned validity or reliability on evidence published in a peer-reviewed scientific journal and derived from independent:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(6)(a)">(a)</span> Scientific testing and evaluation; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(6)(b)">(b)</span> Scientifically based clinical trial.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)">(7)</span> Accuracy, Precision, and Reliability. The licensee shall ensure that the laboratory employs quality control mechanisms and practices, including but not limited to those assuring accuracy, precision, and reliability of test results by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(a)">(a)</span> Using a sufficient number of reference standard samples with each batch of test specimens to ensure accuracy of the assay or procedure's linearity over time;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(b)">(b)</span> Using reference standard samples that have values at or near the minimum drug detection levels or concentrations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(c)">(c)</span> Using results obtained from testing reference standard samples to document linearity and calculate test data obtained from test specimens;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(d)">(d)</span> Including in each analytical run quality control samples that are:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(d)(i)">(i)</span> Certified to contain no alcohol or controlled dangerous substance;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(d)(ii)">(ii)</span> Fortified with known reference standards;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(d)(iii)">(iii)</span> Positive with the alcohol or controlled dangerous substance at or near the cutoff or minimum detection level; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(d)(iv)">(iv)</span> Using a total number of quality control samples in an analytical run equal to at least 5 percent of the number of specimens being tested;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(e)">(e)</span> Verifying and documenting at least monthly the linearity and precision of each test method and procedure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(7)(f)">(f)</span> Using methods, procedures, and techniques that prevent samples and specimens from contaminating one another throughout the testing process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)">(8)</span> Cutoff Levels.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(a)">(a)</span> A licensee that offers to perform or performs job-related alcohol or controlled dangerous substances testing shall use the established cutoff levels specified in §B(8)(b) and (c) of this regulation to distinguish a positive from a negative test specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(b)">(b)</span> Urine. A laboratory testing urine shall use the cutoff levels set forth in 49 CFR §40.87.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(c)">(c)</span> Blood, Saliva, and Hair.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(c)(i)">(i)</span> A licensee testing blood, saliva, or hair specimens shall use the cutoff levels established by an agency of the federal government for the purpose of determining whether a specimen is positive or negative for alcohol or a controlled dangerous substance.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(c)(ii)">(ii)</span> If cutoff levels in blood, saliva, or hair have not been established and accepted by an agency of the federal government, a licensee shall establish and use a cutoff level for each screening test and confirmatory test performed to determine whether a specimen is negative for each controlled dangerous substance that the licensee offers to detect by a screening or confirmatory procedure.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(d)">(d)</span> Validation. A licensee shall ensure that the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(d)(i)">(i)</span> Laboratory maintains documented data validating each cutoff level; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(8)(d)(ii)">(ii)</span> Cutoff data is made available for review by the OHCQ.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(9)">(9)</span> Single-Use Test Devices. A laboratory that performs screening tests using single-use test devices, as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>, may meet the quality assurance and quality control standards set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.06.06" title=".06 Quality Control — Single-Use Test Devices.">Regulation .06 of this chapter</a> instead of the standards set forth at <a class="internal-link " href="/us/md/exec/comar/10.10.06.08#B(1)" title="">§B(1) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)">(10)</span> Reporting Test Results. A licensee shall ensure that a job-related laboratory test report includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(a)">(a)</span> A list of all the drug and alcohol tests that were performed on the specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(b)">(b)</span> Positive test results only if the specimen was found positive by a confirmation test that employed a combination of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(b)(i)">(i)</span> Gas chromatography and mass spectrometry (GC/MS);</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(b)(ii)">(ii)</span> Mass spectrometry and mass spectrometry (MS/MS);</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(b)(iii)">(iii)</span> Gas chromatography tandem mass spectrometry (GC/MS/MS); or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(b)(iv)">(iv)</span> Other analytical methods that use mass spectrometry as the primary detection technique;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(c)">(c)</span> The value at the cutoff or detection level of each test, that is, screening test or confirmation test, or both, for alcohol or a controlled dangerous substance performed on the specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(d)">(d)</span> The telephone number of the laboratory that may be used by an employer or individual who was tested to obtain technical assistance for the purpose of interpreting a positive test result; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(e)">(e)</span> Except as provided in Health-General Article, §17-214(i), Annotated Code of Maryland, no information to an employer or prospective employer on:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(e)(i)">(i)</span> The use of a nonprescription drug, excluding alcohol, that is not prohibited under the laws of the State; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(10)(e)(ii)">(ii)</span> The use of a legally prescribed drug, unless the individual tested is unable to establish that the drug was prescribed in accordance with the laws of the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(11)">(11)</span> Proficiency Testing. A licensee shall ensure that the laboratory enrolls and continues to participate satisfactorily in a proficiency testing program that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(11)(a)">(a)</span> Covers each type of job-related alcohol and controlled dangerous substance test specimen analyzed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.08#B(11)(b)">(b)</span> Has the approval of the Secretary as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">COMAR 10.10.05.03</a> of this subtitle.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.09" data-order="|10|10|06|.09|" data-ref-path="10|10|06|.09" class="h__section">.09 Repealed.</h3>
                <h3 id="/us/md/exec/comar/10.10.06.10" data-order="|10|10|06|.10|" data-ref-path="10|10|06|.10" class="h__section">.10 Quality Control — Cytology.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A">A.</span> Primary Standard. A licensee of a laboratory offering to perform or performing tests in the subdiscipline of gynecologic cytology shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(1)">(1)</span> Limits the number of slides an individual may examine as set forth in 42 CFR §493.1274;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(2)">(2)</span> Limits slide examination to the laboratory premises;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(3)">(3)</span> Establishes a quality assurance program and follows written quality control procedures to monitor and evaluate the quality of cytological procedures and testing processes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(4)">(4)</span> Does not pay for the examination of cytology slides on a piecework basis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(5)">(5)</span> Reviews not less than 10 percent of all negative gynecologic slides before reporting results on those slides;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(6)">(6)</span> Employs an individual who qualifies as a supervisory cytotechnologist or a technical supervisor in gynecologic cytology to review negative gynecologic slides;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(7)">(7)</span> Does not allow the evaluation of a slide that shows evidence of unsatisfactory preparation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(8)">(8)</span> Reports as to whether a slide is satisfactory or unsatisfactory for evaluation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(9)">(9)</span> Maintains records for 5 years of slides reported as unsatisfactory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(10)">(10)</span> Maintains and stores for 5 years from the date of examination any slide that was examined;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(11)">(11)</span> Retains cytology reports for at least 10 years;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(12)">(12)</span> Does not send gynecologic cytology slides to a laboratory not holding a State license; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#A(13)">(13)</span> Requires cytotechnologists and pathologists to obtain continuing education.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B(1)">(1)</span> General. A licensee shall ensure that the laboratory complies with the applicable requirements in 42 CFR §493.1221.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B(2)">(2)</span> Continuing Education.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B(2)(a)">(a)</span> A cytotechnologist or pathologist who is employed by a laboratory and who performs primary gynecologic screening shall obtain at least 20 credit hours per calendar year of continuing education in cytology. A credit hour is 1 hour of active participation in the educational activity.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B(2)(b)">(b)</span> An individual may obtain cytological continuing education in a formal or informal educational activity, such as reading journal articles, reviewing case histories, and attending lectures or workshops. This activity provides the individual with increased medical or technical knowledge of cytopathology or exfoliative cytology.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.10#B(2)(c)">(c)</span> A licensee shall ensure that the laboratory annually compiles records of the continuing education for each cytotechnologist and pathologist and retains them for at least 2 years.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.11" data-order="|10|10|06|.11|" data-ref-path="10|10|06|.11" class="h__section">.11 Quality Control — Dermatopathology.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A">A.</span> Primary Standard. In addition to meeting the requirements of other applicable regulations of this subtitle, a licensee of a laboratory performing tests in the subdiscipline of dermatopathology shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A(1)">(1)</span> Retains the services of either a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A(1)(a)">(a)</span> Laboratory director who meets the qualifications in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.04#B(1)" title="">COMAR 10.10.07.04B(1)</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A(1)(b)">(b)</span> Technical supervisor who meets the qualifications in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.05#B(4)" title="">COMAR 10.10.07.05B(4)</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A(2)">(2)</span> Maintains applicable records and reports; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#A(3)">(3)</span> Effectively processes and stores specimens, slides, and tissue.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)">(1)</span> Maintenance of Records, Reports, Tissue, and Slides.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(a)">(a)</span> A licensee shall ensure that the laboratory maintains a system of documentation to monitor the collection, receipt, handling, transport, processing, testing, and reporting of all specimens.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(b)">(b)</span> A system of documentation may include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(b)(i)">(i)</span> A laboratory specimen log book; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(b)(ii)">(ii)</span> Accession sheets or records.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)">(c)</span> A licensee shall ensure that the laboratory generates a written report for each patient specimen that is examined either microscopically or macroscopically. The report shall include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(i)">(i)</span> Patient name, age, and sex;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(ii)">(ii)</span> The dates of specimen collection and processing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(iii)">(iii)</span> The source or anatomic site of a specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(iv)">(iv)</span> A gross description of the specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(v)">(v)</span> A description of the tissue, for example, bisected, submitted in total, number of blocks, or that only representative sections were submitted;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(vi)">(vi)</span> The diagnosis or observed results of the test or examination;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(vii)">(vii)</span> The examining physician's name, signature, and date of report;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(viii)">(viii)</span> If appropriate, the clinical impression or differential diagnosis; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(c)(ix)">(ix)</span> Other pertinent or essential patient history that may affect the accuracy or reliability of the report.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(d)">(d)</span> A licensee shall ensure that a laboratory retains:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(d)(i)">(i)</span> Records and reports for at least 10 years for final reports and 2 years for other laboratory records;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(d)(ii)">(ii)</span> Wet tissue or tissue remnants for 2 weeks after a final report is issued;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(d)(iii)">(iii)</span> A specimen or tissue in a paraffin block for 5 years from the date of examination; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(d)(iv)">(iv)</span> Slides for 10 years from the date of examination.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(e)">(e)</span> A licensee shall ensure that specimens, slides, and tissues are:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(e)(i)">(i)</span> Processed in a facility licensed under this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(e)(ii)">(ii)</span> Appropriately fixed for the tests performed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(e)(iii)">(iii)</span> Properly labeled with at least the patient's name or other cross-referenced identifier, such as a case or accession number; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(1)(e)(iv)">(iv)</span> Adequately stored and effectively filed to allow easy access and retrieval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(2)">(2)</span> Quality Control. When a slide or specimen is processed or stained in the laboratory, the licensee shall ensure that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(2)(a)">(a)</span> A staining container is labeled and covered when not in use;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(2)(b)">(b)</span> A stain and a working solution are changed at appropriate intervals; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.11#B(2)(c)">(c)</span> Routine employee access is provided to flowcharts and other written procedures that accurately reflect the procedures in use.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.12" data-order="|10|10|06|.12|" data-ref-path="10|10|06|.12" class="h__section">.12 Quality Control — Temporary and Mobile Laboratories: General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#A">A.</span> Primary Standard. The licensee shall ensure that a health awareness test or a job-related screening test for alcohol or controlled dangerous substances at a temporary or mobile laboratory is performed:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#A(1)">(1)</span> Under effective supervision, quality control, and safety procedures;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#A(2)">(2)</span> Using a previously evaluated analytical system; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#A(3)">(3)</span> For a job-related screening test for alcohol or controlled dangerous substances, only at the request of an individual authorized in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(1)">(1)</span> Limited Tests. A person may perform at a temporary or mobile laboratory only the health awareness tests defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> and job-related screening tests for alcohol or controlled dangerous substances.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(2)">(2)</span> Health awareness and cholesterol testing may be performed at the request of the examinee. Staff who perform the tests shall have training and experience to perform testing that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(2)(a)">(a)</span> Operation of the analyzers per manufacturer’s recommendations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(2)(b)">(b)</span> Evaluation of the results of the quality controls;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(2)(c)">(c)</span> Interpretation of the test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(2)(d)">(d)</span> Counseling to the individual whose specimen is tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(3)">(3)</span> Supervision. A designated supervisor, knowledgeable in all aspects of the health awareness testing, shall be present at a temporary or mobile laboratory throughout a testing event to oversee testing, including compliance with all applicable requirements set forth in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)">(4)</span> Testing Sites.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(a)">(a)</span> A person may not perform a health awareness test in a restaurant where food or drink is prepared, served, or consumed.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)">(b)</span> A licensee shall ensure that a temporary laboratory:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(i)">(i)</span> Provides space, when applicable, for counseling examinees regarding test results;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(ii)">(ii)</span> Provides space appropriate for the number of staff, analytical systems, and examinees;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(iii)">(iii)</span> Provides work space adequate to minimize problems of transportation, communication, and safety;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(iv)">(iv)</span> Provides electricity of the type and in the amount needed to operate analytical systems properly;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(v)">(v)</span> Includes access to water and disinfectant supplies for routine cleaning and disinfection of the work area, equipment, and personnel;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(vi)">(vi)</span> Contains or is within 1 minute of a telephone with access to emergency assistance by calling 911;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(vii)">(vii)</span> Maintains levels of temperature, humidity, and ventilation to comply with manufacturer's specifications for effective operation of analytical systems;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(viii)">(viii)</span> Is situated a minimum of 12 feet from any produce, meat, or dairy department in a food market;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(ix)">(ix)</span> Maintains partitions, such as ropes, on at least three sides of an area where blood is drawn or processed, to prevent unsupervised access to a blood-drawing or testing area;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(x)">(x)</span> Employs separate receptacles for routine laboratory and special medical wastes within partitioned testing areas;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(xi)">(xi)</span> Provides for the storage of reagents and other testing materials within temperatures recommended by the manufacturer; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(4)(b)(xii)">(xii)</span> Complies with all pertinent State laws and local ordinances.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(5)">(5)</span> Pre-Field Evaluation of Analytical Systems. A licensee may not employ an analytical system in a mobile or temporary laboratory until the laboratory has documented the analytical system's levels of accuracy and precision in a permanent laboratory facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(6)">(6)</span> In-Field Quality Control. A licensee operating a mobile or temporary laboratory shall establish and maintain a continuous quality control program for an analytical system operated in that mobile or temporary laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)">(7)</span> Phlebotomy Quality Control and Safety.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(a)">(a)</span> A licensee employing a phlebotomist at a temporary or mobile laboratory shall ensure that the phlebotomist is trained in proper techniques for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(a)(i)">(i)</span> Specimen collection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(a)(ii)">(ii)</span> Infection control.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(b)">(b)</span> A licensee shall provide appropriate protective clothing and disposable gloves and ensure that they are used appropriately by all personnel involved in drawing or handling blood.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(c)">(c)</span> A phlebotomist shall wear new gloves for each examinee.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(7)(d)">(d)</span> A laboratory employee shall use and clean phlebotomy devices as prescribed by the manufacturer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(8)">(8)</span> Testing Logs. A licensee shall maintain for 2 years a log identifying all:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(8)(a)">(a)</span> Persons tested;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(8)(b)">(b)</span> Test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(8)(c)">(c)</span> Test dates.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)">(9)</span> Results Reporting. The licensee of a temporary or mobile laboratory:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(a)">(a)</span> May give results of a health awareness test immediately following the testing directly to the individual who underwent the test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)">(b)</span> Shall give the test results in writing stating the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)(i)">(i)</span> Name of the individual tested,</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)(ii)">(ii)</span> Name of the laboratory performing the test,</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)(iii)">(iii)</span> Name of the test,</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)(iv)">(iv)</span> Date of the test, and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(9)(b)(v)">(v)</span> Test result with appropriate interpretation or reference range consistent with current nationally recognized standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.12#B(10)">(10)</span> Disposal of Special Medical Waste. A licensee operating a temporary or mobile laboratory shall dispose of special medical waste as required in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.06.06" title="Chapter 06 Communicable Disease Prevention — Handling, Treatment, and Disposal of Special Medical Waste">COMAR 10.06.06</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.13" data-order="|10|10|06|.13|" data-ref-path="10|10|06|.13" class="h__section">.13 Quality Control — Temporary and Mobile Laboratories: Personnel Training.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#A">A.</span> Primary Standard. In addition to meeting other applicable requirements in this chapter, a licensee shall ensure that all laboratory personnel performing a health awareness test at a temporary or mobile laboratory are trained to perform all assigned duties.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(1)">(1)</span> All Personnel. A licensee shall ensure that all personnel are trained to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(1)(a)">(a)</span> Keep examinees' health information confidential;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(1)(b)">(b)</span> Deal with emergency situations such as fainting and anxiety reactions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(1)(c)">(c)</span> Report and document information on testing services and activities; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(1)(d)">(d)</span> Dispose of special medical waste as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.06.06" title="Chapter 06 Communicable Disease Prevention — Handling, Treatment, and Disposal of Special Medical Waste">COMAR 10.06.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(2)">(2)</span> Phlebotomist. A licensee shall ensure that an individual who collects blood specimens is trained in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(2)(a)">(a)</span> Specimen collection methods; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(2)(b)">(b)</span> Infection control and prevention techniques, including CDC recommendations for preventing the transmission of bloodborne pathogens in health care settings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)">(3)</span> Operator of an Analytical System: General. A licensee shall ensure that an operator of an analytical system is trained in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)(a)">(a)</span> Infection control and prevention techniques, including CDC recommendations concerning the transmission of bloodborne pathogens in health care settings; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)(b)">(b)</span> Proper use of the analytical system, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)(b)(i)">(i)</span> Analytical system operation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)(b)(ii)">(ii)</span> System methods used to process the specimen; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(3)(b)(iii)">(iii)</span> Quality control techniques, procedures, and requirements.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(4)">(4)</span> Operator of an Analytical System: Competency.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(4)(a)">(a)</span> Obtaining Personal Competency. Before an individual may operate an analytical system without direct supervision, the individual operator shall demonstrate competency in operating the analytical system by completing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(4)(a)(i)">(i)</span> Pre-field supervised practice that includes performing under direct supervision a minimum of ten tests of each applicable type of health awareness test; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(4)(a)(ii)">(ii)</span> Field testing experience that includes individual performance of directly supervised testing in the field.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.13#B(4)(b)">(b)</span> Documenting Training and Competency. The licensee shall document in writing that each analytical system operator has demonstrated competency as required under this regulation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.14" data-order="|10|10|06|.14|" data-ref-path="10|10|06|.14" class="h__section">.14 Quality Control — Temporary and Mobile Laboratories: Event Registration.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.14#A">A.</span> Primary Standard. In addition to meeting other applicable requirements set forth in this chapter, a licensee intending to perform a health awareness test at a temporary or mobile laboratory shall register the testing event with the Department before the testing event may occur.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.14#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.14#B(1)">(1)</span> A licensee shall inform the OHCQ by phone or in writing of the date, time, location, and on-site supervisor's name for a testing event at least 14 days before the event is to take place.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.14#B(2)">(2)</span> A licensee shall display in a public place at the testing site and throughout the testing event a copy of the laboratory's license.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.06.15" data-order="|10|10|06|.15|" data-ref-path="10|10|06|.15" class="h__section">.15 Quality Control — Temporary and Mobile Laboratories: Cholesterol and Health Awareness.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A">A.</span> Primary Standard. In addition to meeting other applicable requirements in this chapter, a licensee offering to perform or performing cholesterol or health awareness testing at a temporary or mobile laboratory shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A(1)">(1)</span> Develops and maintains a written SOPM;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A(2)">(2)</span> Validates the analyzer initially and utilizes the manufacturer’s reference range for the quality control with each new lot of quality control;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A(3)">(3)</span> Employs and maintains an in-field quality control program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A(4)">(4)</span> Reports test results as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.06.15#B(5)" title="">§B(5) of this regulation</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#A(5)">(5)</span> Informs examinees of test limitations based on current nationally recognized standards for each test performed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(1)">(1)</span> Supervisor. A supervisor knowledgeable in all aspects of health awareness testing shall oversee all cholesterol or health awareness testing conducted at a temporary or mobile laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)">(2)</span> SOPM.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)">(a)</span> A licensee shall develop and maintain a written SOPM covering all current procedures for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(i)">(i)</span> Training personnel;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(ii)">(ii)</span> Analytical system maintenance;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(iii)">(iii)</span> Testing participants and quality control;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(iv)">(iv)</span> Retesting;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(v)">(v)</span> Documenting lot numbers and expiration dates of quality control materials and reagents (cassettes) used for participant testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(vi)">(vi)</span> Evaluation of quality controls on site and documentation of corrective actions when quality control results are unacceptable;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(vii)">(vii)</span> An every 6 month evaluation of all analyzers used in Maryland using the worksheet provided by the Department; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(a)(viii)">(viii)</span> Other aspects of the cholesterol and health awareness testing service's activities.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(b)">(b)</span> The general supervisor or director shall initially approve and when changes are made review, sign, and date the SOPM.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(2)(c)">(c)</span> All personnel shall have routine access to a copy of the SOPM at each testing site throughout each testing event.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(3)">(3)</span> Method Verification and Pre-Field Evaluation of an Analytical System. A licensee shall evaluate each analytical system by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(3)(a)">(a)</span> Performing a method verification to demonstrate that the system produces test results within limits of accuracy and precision, as defined by either the licensee or the system's manufacturer, before the system may be used at a temporary or mobile laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(3)(b)">(b)</span> Analyzing two levels of quality control materials.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(4)">(4)</span> In-field Quality Control. At a temporary or mobile laboratory, a licensee shall maintain a continuous quality control program in which:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(4)(a)">(a)</span> Each person who performs tests at a screening event shall test both levels of quality control samples identified in <a class="internal-link " href="/us/md/exec/comar/10.10.06.15#B(3)(b)" title="">§B(3)(b) of this regulation</a> on one analyzer for each cholesterol and health awareness test performed at the screening event;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(4)(b)">(b)</span> Quality control testing shall be performed on at least one analyzer, if more than one analyzer at a screening event is used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(4)(c)">(c)</span> Each testing person shall test two levels of quality control materials on another analyzer at the beginning of the cholesterol or health awareness event if more than one person is performing tests at an event; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(4)(d)">(d)</span> The laboratory shall complete the comparison worksheet designated by the Department quarterly to ensure that all the analyzers used for reporting test results produce results within 15 percent to 20 percent of the other analyzers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(5)">(5)</span> Examinee results shall be reported above the established reportable range of the instrument, that is, analytic range, as greater than the highest reference point, with the analytic range being determined by pre-field testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)">(6)</span> Reporting and Releasing Test Results.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(a)">(a)</span> A licensee shall release cholesterol or health awareness test results only to the examinee or their physician in writing and in a manner to protect the confidentiality of the test results.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(b)">(b)</span> A licensee shall include the following on its reports:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(b)(i)">(i)</span> The name, address, and phone number of the laboratory performing the test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(b)(ii)">(ii)</span> The date and location of the testing; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(b)(iii)">(iii)</span> The signature, initials, or electronic authentication of a laboratory employee.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.06.15#B(6)(c)">(c)</span> A laboratory shall provide to an examinee a written explanation of all cholesterol and health awareness test results and refer the examinee for medical care when indicated by the results.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.07" data-order="|10|10|07|" data-ref-path="10|10|07" class="h__chapter">Chapter 07 Medical Laboratories — Personnel</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.01#B" title="">Regulation .01B</a> amended effective July 24, 2000 (27:14 Md. R. 1340); June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.03" title=".03 Permitted POL and POCL — Consulting Supervisor Services.">Regulation .03</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.05" title=".05 Permitted Laboratories — Technical Supervisors.">Regulation .05</a> amended effective July 24, 2000 (27:14 Md. R. 1340)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.05#B" title="">Regulation .05B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202, 17-203, 17-206, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.07.01" data-order="|10|10|07|.01|" data-ref-path="10|10|07|.01" class="h__section">.01 Permitted POL and POCL — Director and Associate Director.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#A">A.</span> Primary Standard. The licensee of a permitted POL or POCL shall employ or otherwise engage the services of a qualified director or associate director and a laboratory supervisor or consulting supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)">(1)</span> Qualifications.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(a)">(a)</span> POL. The director of a permitted POL shall be:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(a)(i)">(i)</span> A physician licensed by the Board of Physicians to practice medicine in the State and a member or employee of the practice operating the laboratory; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(a)(ii)">(ii)</span> An employee or contractor of the practice who possesses the training and experience set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.05" title=".05 Permitted Laboratories — Technical Supervisors.">Regulation .05 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(b)">(b)</span> POCL. The director of a permitted POCL shall be:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(b)(i)">(i)</span> A physician of the medical care facility who possesses the applicable training and experience set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.05" title=".05 Permitted Laboratories — Technical Supervisors.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(b)(ii)">(ii)</span> An individual who qualifies as a director under 42 CFR §493.1443, and who possesses the applicable training and experience set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.05" title=".05 Permitted Laboratories — Technical Supervisors.">Regulation .05 of this chapter</a>; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(1)(b)(iii)">(iii)</span> An individual who meets the definition of a technologist as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)">(2)</span> Duties and Responsibilities.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(a)">(a)</span> A director of a permitted POL or POCL shall participate in and actively oversee the planning, organization, direction, and review of all laboratory operations to the extent necessary to ensure compliance with this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)">(b)</span> A director's duties and responsibilities include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(i)">(i)</span> When applicable, employing or otherwise engaging the services of a qualified general supervisor or consulting supervisor;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(ii)">(ii)</span> Ensuring that the general supervisor or consulting supervisor spends sufficient time performing the supervisory duties and responsibilities;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(iii)">(iii)</span> Completing and submitting to the OHCQ forms, supplied by the OHCQ, that document a general or consulting supervisor's education, training, and experience in laboratory practice;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(iv)">(iv)</span> Recruiting qualified and competent technical personnel;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(v)">(v)</span> Obtaining or providing and documenting initial training and continuing education for technical personnel;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(vi)">(vi)</span> Reviewing with the laboratory supervisor or consulting supervisor all laboratory procedures and policies and all evaluative material, including proficiency testing results, pertinent to the operation and performance of the laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(vii)">(vii)</span> Serving as a liaison between the physicians of the practice or medical care facility and the laboratory supervisor or consulting supervisor and other technical personnel to communicate situations such as test interpretations, timeliness of reports, reporting abnormal test results, and new or changing laboratory procedures and policies affecting patient care;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(viii)">(viii)</span> Ensuring that all application forms, documents, and other materials required under this chapter are submitted to the OHCQ within the appropriate time periods; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(2)(b)(ix)">(ix)</span> Designating an associate director, when applicable.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(3)">(3)</span> Associate Director. An associate director shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(3)(a)">(a)</span> Meet the same qualifications as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.01#B(1)" title="">§B(1) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(3)(b)">(b)</span> Act as laboratory director when the laboratory director is away from the laboratory for a period of more than 30 days.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(4)">(4)</span> Supervisory Consultation. A director of a permitted POL or POCL shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(4)(a)">(a)</span> Consult with the laboratory supervisor in person, in writing, or by telephone at least once a month regarding the performance and operation of the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(4)(b)">(b)</span> Conduct an on-site visit to each directed laboratory at least once a month.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(5)">(5)</span> Director Limitation. A POL director may not serve as director or associate director, or both, of more than five medical laboratories at the same time.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(6)">(6)</span> Changes in Employment or Service. A director shall notify the OHCQ within 30 days of any change in the director's service or employment as a laboratory director.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.01#B(7)">(7)</span> Director Disqualification. A director or associate director may be disqualified to direct a permitted POL for failing to comply with the applicable standards and requirements of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.02" data-order="|10|10|07|.02|" data-ref-path="10|10|07|.02" class="h__section">.02 Permitted POL and POCL — General Supervisor and Consulting Supervisor.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#A">A.</span> Primary Standard. A licensee operating a POL or POCL under a permit shall employ or otherwise engage a qualified general supervisor or consulting supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(1)">(1)</span> Requirement. A laboratory shall employ or otherwise engage a qualified general supervisor or consulting supervisor who shall act in concert with the laboratory director to ensure that the laboratory complies with the standards and requirements of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(2)">(2)</span> Qualifications — POL and POCL General Supervisor. To qualify as a laboratory supervisor in a permitted POL or POCL, an individual shall be a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(2)(a)">(a)</span> Physician who is board certified, or eligible to be certified in clinical pathology, and employed to perform or oversee testing on a full-time or part-time basis in the laboratory being supervised;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(2)(b)">(b)</span> Technologist as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> and employed to perform tests at least 1 day a week in the lab being supervised; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(2)(c)">(c)</span> Technician as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> and employed to perform tests on a full-time basis in the lab being supervised.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(3)">(3)</span> Qualifications — Consulting Supervisor. To qualify as a consulting supervisor of a POL or POCL, an individual shall be a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(3)(a)">(a)</span> Technologist as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> who possesses at least 2 years of work experience in a laboratory that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(3)(a)(i)">(i)</span> Operated under a permit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(3)(a)(ii)">(ii)</span> Performed testing services related to those offered by the laboratory to be supervised; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(3)(b)">(b)</span> Physician who is board certified, or eligible to be certified in clinical pathology, and employed to perform or oversee testing on a full-time or part-time basis in the laboratory being supervised.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)">(4)</span> Supervisory Duties and Responsibilities. A general supervisor or consulting supervisor shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(a)">(a)</span> Implement and maintain the applicable laboratory standards and requirements set forth in this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(b)">(b)</span> Ensure proper and reliable test performance, reporting, record keeping, and immediate general and technical supervision of testing personnel and laboratory services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)">(c)</span> Develop, implement, and oversee maintenance of an internal quality assurance program that includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)(i)">(i)</span> A working quality control program or system that determines and documents accuracy and precision of all tests performed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)(ii)">(ii)</span> Selection and use of quality control and standard materials for analysis;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)(iii)">(iii)</span> Recording and documenting quality control data;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)(iv)">(iv)</span> Ongoing analysis of quality control data; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(c)(v)">(v)</span> Implementation and maintenance of a specimen documentation and management system;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(d)">(d)</span> Prepare and maintain a SOPM;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(e)">(e)</span> Ensure full participation in an external proficiency testing program approved by the Secretary as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">COMAR 10.10.05.03</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(f)">(f)</span> Teach proper laboratory techniques, including the importance of quality control, quality assurance, and proficiency testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(g)">(g)</span> Review proficiency testing results, determine sources of error, and work to correct any problems;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(h)">(h)</span> Review proficiency testing results, analytical studies and evaluations, and survey reports with technical personnel to improve test performance and laboratory services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(i)">(i)</span> Maintain, as part of laboratory records, a log or other suitable record documenting monthly consultations with the director and all supervisory activities provided to the laboratory;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(j)">(j)</span> Ensure that laboratory testing personnel:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(j)(i)">(i)</span> Possess the education, training, and experience required to perform and report laboratory test results accurately and promptly;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(j)(ii)">(ii)</span> Are sufficient in number for the scope and complexity of the services provided;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(j)(iii)">(iii)</span> Receive regular in-service training and continuing education appropriate for the scope and complexity of the services provided; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(j)(iv)">(iv)</span> Maintain competency in performing test procedures and reporting test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(k)">(k)</span> Perform other duties and responsibilities as delegated and authorized by the director that may include assisting in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(k)(i)">(i)</span> Developing cost benefit data;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(k)(ii)">(ii)</span> Identifying and recommending adjustments to a laboratory's scope of services; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.02#B(4)(k)(iii)">(iii)</span> Recommending the purchase or replacement of test kits, reagents, and equipment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.03" data-order="|10|10|07|.03|" data-ref-path="10|10|07|.03" class="h__section">.03 Permitted POL and POCL — Consulting Supervisor Services.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A">A.</span> General.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A(1)">(1)</span> A licensee operating a permitted POL or POCL who does not employ or otherwise engage technical personnel who qualify as a general supervisor shall arrange with a qualified consulting supervisor to provide technical and general supervisory consultation services in laboratory practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A(2)">(2)</span> The licensee operating a POL or POCL under a permit shall use a consulting supervisor who:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A(2)(a)">(a)</span> Makes and documents on-site visits to each laboratory facility at least twice each calendar year;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A(2)(b)">(b)</span> Is available by telephone during the laboratory's regular operating hours; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#A(2)(c)">(c)</span> Completes a laboratory inspection checklist, provided by the OHCQ, to be submitted to the OHCQ not more than once every 2 years.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B">B.</span> Additional Visits. The OHCQ may require more than two on-site visits per year by a consulting supervisor when:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(1)">(1)</span> A laboratory exhibits unsatisfactory proficiency testing performance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(2)">(2)</span> An on-site survey by the OHCQ shows that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(2)(a)">(a)</span> A laboratory is not in substantial compliance with the applicable standards and requirements of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(2)(b)">(b)</span> A laboratory's written plan of correction in response to a Department survey does not ensure substantial compliance with the applicable standards and requirements of this chapter; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(2)(c)">(c)</span> A laboratory's testing personnel require additional supervisory consultations to obtain or maintain proficiency in quality assurance, performing or reporting test results, or meeting other applicable standards of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(3)">(3)</span> An inspection checklist submitted by the laboratory shows that the laboratory is operating in a manner that is not in compliance with applicable standards of this chapter; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.03#B(4)">(4)</span> The laboratory's general supervisor or consulting supervisor has been unable to perform the duties and responsibilities set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.02#B(4)" title="">Regulation .02B(4) of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.04" data-order="|10|10|07|.04|" data-ref-path="10|10|07|.04" class="h__section">.04 Permitted Laboratory Other than a POL or POCL — Director.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#A">A.</span> Primary Standard. A licensee operating a permitted laboratory other than a POL or POCL shall employ a director who meets the applicable qualifications, responsibilities, and standards set forth in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(1)">(1)</span> Qualifications. In addition to applicable personnel standards set forth in this chapter, a director shall meet the applicable standards set forth in 42 CFR §493.1443.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(2)">(2)</span> Responsibilities. A director shall carry out the applicable responsibilities set forth in 42 CFR §§493.1407 and 493.1445.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(3)">(3)</span> Associate Director. A director shall designate another individual who qualifies as a director under this chapter to serve as an associate or substitute director when the director:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(3)(a)">(a)</span> Will be away from the laboratory for a period of more than 30 days; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(3)(b)">(b)</span> Is unable to carry out the responsibilities set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.07.04#B(2)" title="">§B(2) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(4)">(4)</span> Communications. A director shall communicate with the laboratory's supervisory personnel in person, in writing, or by telephone at least once a month regarding the performance and operation of the laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(5)">(5)</span> On-site Visits. A director of a laboratory shall conduct an on-site visit of the laboratory at least once a month.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.04#B(6)">(6)</span> Limitation. The director of a permitted laboratory may not serve as director or associate director, or both, of more than five medical laboratories at the same time.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.05" data-order="|10|10|07|.05|" data-ref-path="10|10|07|.05" class="h__section">.05 Permitted Laboratories — Technical Supervisors.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A">A.</span> Primary Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A(1)">(1)</span> A laboratory director certified, or eligible for certification, in anatomic and clinical pathology by the American Board of Pathology qualifies as a technical supervisor in all disciplines and subdisciplines set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>, except:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A(1)(a)">(a)</span> Genetics; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A(1)(b)">(b)</span> Forensic toxicology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A(2)">(2)</span> A licensee who does not employ or otherwise engage a director certified in anatomic and clinical pathology by the American Board of Pathology, or a licensee operating a laboratory that performs testing in the discipline of genetics or forensic toxicology shall employ the services of a technical supervisor for each discipline set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> except the discipline of health awareness testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#A(3)">(3)</span> A technical supervisor shall carry out the applicable responsibilities set forth in 42 CFR §493.1451.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B">B.</span> Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(1)">(1)</span> Requirement. A licensee operating a laboratory that performs testing in one or more disciplines shall employ a director or technical supervisor who meets the qualifications for a technical supervisor in the applicable disciplines or subdisciplines set forth in §B(2)—(13) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(2)">(2)</span> Chemistry. A technical supervisor shall possess a bachelor's or higher degree including significant studies in chemistry and have at least 4 years post-baccalaureate or 2 years post-master's medical laboratory experience in clinical chemistry.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(3)">(3)</span> Gynecologic Cytology. A technical supervisor shall meet the requirements set forth in 42 CFR §493.1449.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)">(4)</span> Dermatopathology. A technical supervisor shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(a)">(a)</span> A physician licensed by the Board of Physicians to practice medicine in the State; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(b)">(b)</span> Either certified or eligible for certification in dermatopathology or anatomic pathology by the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(b)(i)">(i)</span> American Board of Dermatology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(b)(ii)">(ii)</span> American Osteopathic Board of Dermatology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(b)(iii)">(iii)</span> American Board of Pathology; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(4)(b)(iv)">(iv)</span> American Osteopathic Board of Pathology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(5)">(5)</span> Forensic Toxicology — General Qualifications. A technical supervisor shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(5)(a)">(a)</span> Be certified in toxicological chemistry by the American Board of Clinical Chemistry;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(5)(b)">(b)</span> Be certified in forensic toxicology by the American Board of Forensic Toxicology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(5)(c)">(c)</span> Be certified in clinical pathology and chemistry by the American Board of Pathology; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(5)(d)">(d)</span> Possess education and experience in toxicology equivalent to that required by one of these boards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)">(6)</span> Forensic Toxicology — Alternative Qualifications. An individual who does not qualify as a technical supervisor under <a class="internal-link " href="/us/md/exec/comar/10.10.07.05#B(5)" title="">§B(5) of this regulation</a> may qualify as a technical supervisor if the individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(a)">(a)</span> Can document training or experience, or both, in the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(a)(i)">(i)</span> Analysis of biological material for alcohol or controlled dangerous substances, or both; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(a)(ii)">(ii)</span> Forensic applications of analytical toxicology, such as court testimony, use of chain of custody, and specimen security; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(b)">(b)</span> Possesses:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(b)(i)">(i)</span> A degree in medicine or osteopathy acceptable for licensure as a physician by the Maryland State Board of Physicians, with certification in clinical pathology or forensic pathology, and have at least 2 years of laboratory experience in analytical toxicology;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(b)(ii)">(ii)</span> A doctoral degree in a biological, chemical, pharmacological, or toxicological discipline and have at least 2 years of laboratory experience in analytical toxicology; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(6)(b)(iii)">(iii)</span> A master's degree in a biological, chemical, pharmacological, or toxicological discipline with at least 6 years of experience in analytical toxicology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(7)">(7)</span> Genetics. A technical supervisor of biochemical genetics, cytogenetics, or molecular genetics shall possess:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(7)(a)">(a)</span> A degree in medicine or osteopathy acceptable for licensure as a physician by the Maryland State Board of Physicians; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(7)(b)">(b)</span> An earned doctorate in one of the biological or chemical sciences from an accredited institution with:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(7)(b)(i)">(i)</span> 4 years of laboratory experience in genetics; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(7)(b)(ii)">(ii)</span> Eligibility for certification by the American Board of Medical Genetics.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(8)">(8)</span> Hematology. A technical supervisor shall possess a baccalaureate or higher degree including studies in biology or general cytology and have at least 4 years post-baccalaureate or 2 years post-master's medical laboratory experience in hematology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(9)">(9)</span> Immunology. A technical supervisor shall possess a baccalaureate or higher degree including studies in immunology, microbiology, or chemistry and have at least 4 years post-baccalaureate or 2 years post-master's experience in immunology-serology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(10)">(10)</span> Microbiology. A technical supervisor shall possess a baccalaureate or higher degree including studies in microbiology or immunology and have at least 4 years post-baccalaureate or 2 years post-master's medical laboratory experience in clinical microbiology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(11)">(11)</span> Molecular Biology. A technical supervisor shall possess a baccalaureate or higher degree including studies in molecular biology and have at least 4 years post-baccalaureate or 2 years post-master's experience in molecular biology, microbiology, immunology, or clinical chemistry.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(12)">(12)</span> Oral Pathology, Including Oral Cytopathology. A technical supervisor shall be a dentist or physician licensed to practice in Maryland and be certified or eligible for certification by the American Board of Oral Pathology, American Board of Pathology, or the American Osteopathic Board of Pathology.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.05#B(13)">(13)</span> Tissue Pathology. A technical supervisor shall be a physician licensed to practice medicine in Maryland and be certified or eligible for certification in anatomic pathology by the American Board of Pathology or the American Osteopathic Board of Pathology.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.06" data-order="|10|10|07|.06|" data-ref-path="10|10|07|.06" class="h__section">.06 Permitted Laboratory Other than a POL or POCL — Supervisors.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#A">A.</span> Primary Standard. A licensee operating a laboratory other than a POL or POCL shall employ a qualified supervisory technologist or general supervisor, who in the absence of the director or technical supervisor is responsible for the proper performance of laboratory procedures and reporting of laboratory test results.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#B">B.</span> Standards: General Supervisor.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#B(1)">(1)</span> Personnel Qualifications. A general supervisor shall be a technologist who possesses at least 4 years technical experience in a licensed medical laboratory other than a laboratory operating under a letter of exception.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#B(2)">(2)</span> Responsibilities. A general supervisor shall carry out the responsibilities set forth in 42 CFR §493.1463.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#C">C.</span> Standards: Supervisory Cytotechnologist.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#C(1)">(1)</span> Personnel Qualifications. For the specialty of cytology, a laboratory shall employ the services of a supervisory cytotechnologist who meets the qualifications set forth in 42 CFR §493.1469.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#C(2)">(2)</span> Responsibilities. A supervisory cytotechnologist shall carry out the responsibilities set forth in 42 CFR §493.1471.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#D">D.</span> Standards: Supervisor of Blood Gas Analyses. An individual qualifies as a supervisor of blood gas analyses by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#D(1)">(1)</span> Possessing an earned doctoral, master's, or baccalaureate degree in respiratory care or cardiovascular technology; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.06#D(2)">(2)</span> Meeting the personnel qualifications set forth in 42 CFR §493.1449.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.07.07" data-order="|10|10|07|.07|" data-ref-path="10|10|07|.07" class="h__section">.07 Permitted Laboratory Other than POL or POCL — Testing Personnel.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#A">A.</span> Primary Standard. A permitted laboratory other than a POL or POCL shall employ or engage testing personnel, sufficient in number to perform testing for the volume and complexity of testing performed, who meet the qualifications and carry out the responsibilities set forth in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#B">B.</span> Standards — General.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#B(1)">(1)</span> Personnel Qualifications. An individual performing one or more laboratory tests shall meet the applicable qualifications set forth in 42 CFR §493.1489.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#B(2)">(2)</span> Responsibilities. Testing personnel shall carry out the responsibilities set forth in 42 CFR §493.1495.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#C">C.</span> Standards — Cytotechnologist.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#C(1)">(1)</span> Personnel Qualifications. For the specialty of cytology, a licensee shall employ the services of cytotechnologists who meet the qualifications set forth in 42 CFR §§493.1483.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#C(2)">(2)</span> Responsibilities. A cytotechnologist shall carry out the responsibilities set forth in 42 CFR §493.1485.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#D">D.</span> Standards — Blood Gas Analysis—Personnel Qualifications. Personnel performing blood gas analyses shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#D(1)">(1)</span> Meet the standards set forth in 42 CFR §493.1489; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.07.07#D(2)">(2)</span> Complete a 1-year certificate program in respiratory care.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.08" data-order="|10|10|08|" data-ref-path="10|10|08" class="h__chapter">Chapter 08 Medical Laboratories — Sanctions</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.01#B" title="">Regulation .01B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.02#A" title="">Regulation .02A</a>, B amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.04#B" title="">Regulation .04B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.05" title=".05 Departmental Action — Reporting Erroneous or Questionable Patient Test Results.">Regulation .05</a> adopted effective March 27, 2006 (33:6 Md. R. 578)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202, 17-206, 17-210, 17-211, and 17-509, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.08.01" data-order="|10|10|08|.01|" data-ref-path="10|10|08|.01" class="h__section">.01 General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A">A.</span> Authority and Types.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(1)">(1)</span> The Secretary may impose one or more principal or alternative sanctions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(2)">(2)</span> Principal Sanctions. The Secretary may impose the following principal sanctions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(2)(a)">(a)</span> Denial of a license;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(2)(b)">(b)</span> Suspension of a license; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(2)(c)">(c)</span> Revocation of a license.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(3)">(3)</span> Alternative Sanctions. Instead of or in conjunction with lifting a principal sanction, the Secretary may impose one or more of the following alternative sanctions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(3)(a)">(a)</span> A directed plan of correction;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(3)(b)">(b)</span> Limitation on testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#A(3)(c)">(c)</span> Training and technical assistance.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B">B.</span> Reasons for Imposition. A laboratory is subject to the imposition of one or more sanctions when the OHCQ finds:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(1)">(1)</span> A deficiency identified through an on-site survey or a review of materials submitted by a laboratory, such as applications data, personnel qualification materials, and self-inspection checklists;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(2)">(2)</span> Unsuccessful proficiency testing performance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(3)">(3)</span> Demonstrated incompetence, such as showing consistent or repetitive errors in operating equipment or in performing a test or procedure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(4)">(4)</span> False statements made on an application, plan-of-correction, or other form submitted to the OHCQ;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(5)">(5)</span> Misrepresentation in obtaining a permit or letter of exception or in operating a laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(6)">(6)</span> Failure to comply with the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(6)(a)">(a)</span> Cancer reporting requirements of Health-General Article, §18-204, Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(6)(b)">(b)</span> Infectious disease and submission of clinical material requirements of Health-General Article, §18-205, Annotated Code of Maryland, and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.06.01" title="Chapter 01 Communicable Diseases and Related Conditions of Public Health Importance">COMAR 10.06.01</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(7)">(7)</span> Submission of a specimen by a laboratory inside the State to another laboratory that does not possess a license as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03" title="Chapter 03 Medical Laboratories — Licenses">COMAR 10.10.03</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(8)">(8)</span> Conviction by a court of a violation of the laws of the State pertaining to a medical laboratory; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#B(9)">(9)</span> Exceeding the 50 test per year limit when operating under a letter of exception—limited testing for rare diseases as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.05#B" title="">COMAR 10.10.03.05B</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C">C.</span> Factors Affecting Choice of Sanctions. The Secretary shall choose which sanctions to apply to a laboratory based on, but not limited to, the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(1)">(1)</span> Whether a deficiency poses immediate jeopardy to personal or public health or safety;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(2)">(2)</span> The nature, incidence, severity, and duration of the deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(3)">(3)</span> Whether a deficiency has been identified repeatedly;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(4)">(4)</span> The inaccuracy or extent of missing laboratory records, such as missing documentation of remedial action or failure to make records available to the OHCQ;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(5)">(5)</span> The relationship of one deficiency or group of deficiencies to another deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(6)">(6)</span> The overall compliance history of a laboratory, including but not limited to any period of noncompliance that occurred between determinations of compliance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(7)">(7)</span> The corrective and long-term compliance outcomes the Secretary intends to effect through application of the sanction; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#C(8)">(8)</span> The progress a laboratory has made toward regulatory compliance following a reasonable opportunity to correct a deficiency.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#D">D.</span> Mandatory Revocation of a License. The Secretary shall revoke for 1 year the license of a laboratory that intentionally refers a proficiency test sample to another laboratory for analysis.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.01#E">E.</span> Owning and Operating Prohibition Following Revocation. A person who has owned, operated, or directed a laboratory that has had its license revoked may not, within 1 year of the revocation, apply for a license, or own or operate a laboratory for which a license has been issued under this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.08.02" data-order="|10|10|08|.02|" data-ref-path="10|10|08|.02" class="h__section">.02 Departmental Actions — General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A">A.</span> Deficiency Posing Immediate Jeopardy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(1)">(1)</span> If a laboratory's deficiency poses immediate jeopardy to personal or public health or safety, the Secretary shall take one or more of the actions listed in §A(2) and(3) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(2)">(2)</span> Initial Actions. When a deficiency involving immediate jeopardy is first identified, the Secretary shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(2)(a)">(a)</span> Require the laboratory to take immediate action to remove the jeopardy; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(2)(b)">(b)</span> Impose:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(2)(b)(i)">(i)</span> A principal sanction after giving the laboratory at least 24 hours notice; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(2)(b)(ii)">(ii)</span> One or more alternative sanctions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#A(3)">(3)</span> Follow-up Actions. If the OHCQ finds in a follow-up survey of a laboratory under an alternative sanction that the laboratory has not eliminated the immediate jeopardy, the Secretary shall impose a principal sanction after giving the laboratory at least 24 hours notice.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B">B.</span> Deficiency Not Posing Immediate Jeopardy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(1)">(1)</span> If a laboratory's deficiency does not pose immediate jeopardy to personal or public health or safety, the Secretary may take one or more of the actions listed in §B(2)—(4) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(2)">(2)</span> Initial Actions. When a deficiency is first identified, the Secretary may impose one or more alternative sanctions or a principal sanction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(3)">(3)</span> Unsuccessful Proficiency Testing. If a laboratory exhibits unsuccessful proficiency testing, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>, the Secretary may impose the training and technical assistance requirements set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.08.04" title=".04 Enforcement Procedures — Proficiency Testing.">Regulation .04 of this chapter</a> as a directed plan of correction, as well as any other sanction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(4)">(4)</span> Follow-up Actions. If the OHCQ finds in a follow-up survey that a laboratory has not corrected a deficiency within 30 days after it was identified, the Secretary may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(4)(a)">(a)</span> Impose, or continue if already imposed, one or more sanctions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(4)(b)">(b)</span> Conduct one or more on-site visits to evaluate progress in correcting a deficiency; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#B(4)(c)">(c)</span> Conduct an additional follow-up survey to determine whether all corrections have been made.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#C">C.</span> Duration of a Sanction. A sanction shall remain in force until:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#C(1)">(1)</span> A laboratory corrects the deficiency; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#C(2)">(2)</span> A laboratory's license is revoked.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D">D.</span> Lifting of a Sanction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(1)">(1)</span> General Rule. The Secretary may not lift a sanction until regulatory compliance is verified.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(2)">(2)</span> Credible Allegation of Compliance. When a sanctioned laboratory submits a credible allegation of compliance, the Secretary shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(2)(a)">(a)</span> Determine compliance on the basis of the evidence submitted by the laboratory in its allegation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(2)(b)">(b)</span> Conduct a follow-up survey to verify whether the laboratory has achieved compliance; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(2)(c)">(c)</span> Both §D(2)(a) and (b) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.02#D(3)">(3)</span> If a laboratory does not correct all deficiencies within 30 days after imposition of a sanction, the Secretary may initiate action to suspend or revoke the license.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.08.03" data-order="|10|10|08|.03|" data-ref-path="10|10|08|.03" class="h__section">.03 Departmental Actions — Principal Sanctions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#A">A.</span> Hearing Requirement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#A(1)">(1)</span> Except when the Secretary finds that a danger to public health or safety imperatively requires that emergency action be taken to correct a deficiency, the Secretary shall inform the licensee in writing when a suspension or revocation of the licensee's license takes effect, the reason for the suspension or revocation, and that the licensee has an opportunity for a hearing on the matter before the suspension or revocation takes effect, as provided in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-226" title="">State Government Article, §10-226, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#A(2)">(2)</span> When a finding is made that the public health or safety imperatively requires that emergency or immediate action be taken, the Secretary shall inform the licensee in writing of a suspension or revocation of the licensee's license, the reason for the suspension or revocation, and that the licensee has an opportunity for a hearing on the matter, as provided in <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gsg/gsg.pdf" title="">State Government Article, Title 10, Subtitle 2, Annotated Code of Maryland</a>, after the suspension or revocation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B">B.</span> Notice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)">(1)</span> Contents. In cases involving a principal sanction, the Secretary shall give written notice to a licensee of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(a)">(a)</span> Deficiency identified;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(b)">(b)</span> Sanction proposed for imposition;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(c)">(c)</span> Reason for the proposed sanction;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(d)">(d)</span> Projected effective date and duration of the proposed sanction;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(e)">(e)</span> Authority for the proposed sanction; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(1)(f)">(f)</span> Time allowed for a laboratory to respond to the notice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(2)">(2)</span> Opportunity to Respond. During the time allowed and stated in the written notice, a laboratory may submit to the Secretary written evidence or other information against imposition of the proposed sanction or sanctions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(3)">(3)</span> Notice Times.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(3)(a)">(a)</span> If a deficiency is found imperatively to require emergency or immediate action, the Secretary shall provide notice at least 24 hours before the effective date of sanction.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(3)(b)">(b)</span> If a deficiency is found to warrant a principal sanction but does not imperatively require emergency or immediate action, the Secretary shall provide notice at least 10 days before the effective date of sanction.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.03#B(3)(c)">(c)</span> To preserve its right to a hearing, a licensee shall request a hearing within 10 days of its receipt of the notice of the pending sanction.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.08.04" data-order="|10|10|08|.04|" data-ref-path="10|10|08|.04" class="h__section">.04 Enforcement Procedures — Proficiency Testing.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.04#A">A.</span> Application. If a laboratory's performance in proficiency testing is unsuccessful or unsatisfactory, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>, the Secretary may require the laboratory to undertake the directed plan of correction of the training of its personnel or the obtaining of necessary technical assistance, or both, in order to meet the proficiency testing requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.04#B">B.</span> Procedures. A laboratory required to undertake training of personnel or to obtain necessary technical assistance shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.04#B(1)">(1)</span> Document the training or assistance, or both, using forms provided by the OHCQ; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.04#B(2)">(2)</span> Submit the completed forms to the OHCQ.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.08.05" data-order="|10|10|08|.05|" data-ref-path="10|10|08|.05" class="h__section">.05 Departmental Action — Reporting Erroneous or Questionable Patient Test Results.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A">A.</span> If the Department determines that a licensee has reported an erroneous or questionable patient test result that threatens the health or safety of the patient, the Secretary may order the licensee, within a specified period of time, to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(1)">(1)</span> Give prompt notice of the erroneous or questionable patient test result to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(1)(a)">(a)</span> Person who requested that the test be performed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(1)(b)">(b)</span> Physician or other person to whom the laboratory has previously sent a report that contained the erroneous or questionable result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(2)">(2)</span> Provide corrected reports to the persons notified in <a class="internal-link " href="/us/md/exec/comar/10.10.08.05#A(1)" title="">§A(1) of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(3)">(3)</span> Maintain duplicates of both the original report and the corrected report;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(4)">(4)</span> Conduct a quality assessment of all phases of the testing process to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(4)(a)">(a)</span> Determine the cause of the erroneous or questionable test result; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(4)(b)">(b)</span> Take the necessary remedial or corrective action to prevent recurrence of the problem; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)">(5)</span> Take any additional measures necessary to reduce or eliminate the threat to the health and safety of the patient including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(a)">(a)</span> Notifying the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(a)(i)">(i)</span> Patient;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(a)(ii)">(ii)</span> Community at large if the Secretary determines that the licensee's laboratory operation is a threat to patient health and safety; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(a)(iii)">(iii)</span> If the licensee is unable to notify a patient, the Department; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(b)">(b)</span> Retesting:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(b)(i)">(i)</span> The same specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(b)(ii)">(ii)</span> A new specimen; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#A(5)(b)(iii)">(iii)</span> Both the same specimen and a new specimen.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#B">B.</span> Civil Penalty for Failure to Comply with Order.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#B(1)">(1)</span> A laboratory that fails to comply with an order issued by the Secretary under <a class="internal-link " href="/us/md/exec/comar/10.10.08.05#A" title="">§A of this regulation</a> is subject to a civil penalty of up to $1,000 for each day of noncompliance, up to a maximum of $50,000.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#B(2)">(2)</span> The Secretary may impose the civil penalty instead of or in addition to any other sanction imposed under this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C">C.</span> Notice and Hearing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(1)">(1)</span> Notice. Before the Secretary imposes a civil penalty for noncompliance as provided in <a class="internal-link " href="/us/md/exec/comar/10.10.08.05#B" title="">§B of this regulation</a>, the Secretary shall give written notice to the licensee:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(1)(a)">(a)</span> Of the intent to impose a civil money penalty; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(1)(b)">(b)</span> That the licensee has an opportunity for a hearing on the matter before the civil penalty is imposed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)">(2)</span> Content. The Secretary shall give written notice to the licensee of the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)(a)">(a)</span> Reason for the imposition of the civil penalty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)(b)">(b)</span> Amount of the civil penalty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)(c)">(c)</span> Effective date of the imposition of the civil penalty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)(d)">(d)</span> Time allowed for the licensee to respond to the notice; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(2)(e)">(e)</span> Authority for imposing the civil penalty.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(3)">(3)</span> Opportunity to Respond. During the time allowed and stated in the written notice from the Secretary, the licensee may submit to the Secretary written evidence or other information to support the position that the licensee has not violated the requirements of this regulation or Health-General Article, §17-210, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#C(4)">(4)</span> To preserve the right to a hearing, the licensee shall request a hearing within 10 days of receipt of the notice of the Secretary's intent to impose the civil penalty.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D">D.</span> Factors to Be Considered in the Assessment of Penalties. In cases in which the Secretary determines that the imposition of a civil penalty is appropriate, the Secretary shall take into consideration the following factors in determining the amount of the penalty:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(1)">(1)</span> The extent to which the licensee derived any financial benefit from reporting erroneous or questionable patient test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(2)">(2)</span> The willfulness on the part of the licensee;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(3)">(3)</span> The extent of actual or potential public harm caused by reporting erroneous or questionable patient test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(4)">(4)</span> The cost of investigating and prosecuting the case against the licensee;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(5)">(5)</span> The licensee's history of previous failure to meet the standards of this subtitle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#D(6)">(6)</span> The existence of mitigating factors.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#E">E.</span> Payment of Penalties.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#E(1)">(1)</span> At the Secretary's discretion, the Secretary may refer all cases of delinquent payment to the Central Collection Unit of the Department of Budget and Management to institute and maintain proceedings to ensure prompt payment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.08.05#E(2)">(2)</span> All monies collected by the Secretary pursuant to this regulation shall be paid into the General Fund of the State.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.09" data-order="|10|10|09|" data-ref-path="10|10|09" class="h__chapter">Chapter 09 Forensic Laboratories — Personnel Certification and Approval of Laboratory Procedures</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: March 11, 1985 (12:5 Md. R. 483)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.02#A" title="">Regulation .02A</a> amended effective August 6, 1990 (17:15 Md. R. 1859)</p>
                  <p>Regulations .03 and .04 repealed, new Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.03" title=".03 Employment, Employment Certification, and Automatic Decertification.">.03</a>—.06 adopted effective August 6, 1990 (17:15 Md. R. 1859)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.05" title=".05 Report.">Regulation .05</a> recodified as Regulation .07 effective August 6, 1990 (17:15 Md. R. 1859)</p>
                  <p>Regulation .06 amended effective March 1, 1993 (20:4 Md. R. 371)</p>
                  <p>——————</p>
                  <p>——————</p>
                  <p>Chapter revised effective April 10, 1995 (22:7 Md. R. 536)</p>
                  <p>Chapter recodified from <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03" title="Chapter 03 Medical Laboratories — Licenses">COMAR 10.10.03</a> and revised effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.01" title=".01 Qualifications.">Regulation .01</a> amended effective November 23, 2006 (33:23 Md. R. 1795)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.01#A" title="">Regulation .01A</a> amended effective December 23, 2002 (29:25 Md. R. 1982)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.02" title=".02 Approved Training Programs for Chemists, Chemical Analysts, and Analysts.">Regulation .02</a> amended effective December 23, 2002 (29:25 Md. R. 1982)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.02#A" title="">Regulation .02A</a> amended effective November 11, 2013 (40:22 Md. R. 1877)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.03" title=".03 Employment, Employment Certification, and Automatic Decertification.">Regulation .03</a> amended effective December 23, 2002 (29:25 Md. R. 1982); November 23, 2006 (33:23 Md. R. 1795)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.03#A" title="">Regulation .03A</a> amended as an emergency provision effective September 10, 2019 (46:20 Md. R. 842); adopted permanently effective December 30, 2019 (46:26 Md. R. 1165)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">Regulation .04</a> amended effective December 23, 2002 (29:25 Md. R. 1982); November 11, 2013 (40:22 Md. R. 1877)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.09.05" title=".05 Report.">Regulation .05</a> amended effective December 23, 2002 (29:25 Md. R. 1982)</p>
                  <h3>Authority</h3>
                  <p><a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcj&amp;section=10-1001" title="">Courts and Judicial Proceedings Article, §10-1001</a>; Health-General Article, §17-2A-02; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.09.01" data-order="|10|10|09|.01|" data-ref-path="10|10|09|.01" class="h__section">.01 Qualifications.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#A">A.</span> Certified Chemist and Certified Chemical Analyst. An applicant for certified chemist or certified chemical analyst shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#A(1)">(1)</span> Hold a bachelor's degree from an accredited college or university with a major in chemistry, medical technology, biology, physics, pharmacy, pharmacology, or forensic science;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#A(2)">(2)</span> Have completed courses in analytical and organic chemistry; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#A(3)">(3)</span> Have completed a basic training program for certified chemist or certified chemical analyst as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.09.02" title=".02 Approved Training Programs for Chemists, Chemical Analysts, and Analysts.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#B">B.</span> Certified Analyst. An applicant for certified analyst shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#B(1)">(1)</span> Possess a high school diploma or its equivalent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#B(2)">(2)</span> Have completed a basic training program for certified analyst as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.09.02" title=".02 Approved Training Programs for Chemists, Chemical Analysts, and Analysts.">Regulation .02 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.01#B(3)">(3)</span> Identify in the application those specific drug-testing procedures for which certification is being sought and for which training has been received.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.09.02" data-order="|10|10|09|.02|" data-ref-path="10|10|09|.02" class="h__section">.02 Approved Training Programs for Chemists, Chemical Analysts, and Analysts.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#A">A.</span> Certified Chemist.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#A(1)">(1)</span> An applicant for certification as a certified chemist shall have successfully completed:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#A(1)(a)">(a)</span> The basic training program for forensic drug chemists offered by the United States Department of Justice, Drug Enforcement Administration; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#A(1)(b)">(b)</span> A training program in the discipline of controlled dangerous substances provided by a forensic laboratory licensed by the Department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#A(2)">(2)</span> The applicant shall demonstrate completion of the training program referenced in <a class="internal-link " href="/us/md/exec/comar/10.10.09.02#A(1)(b)" title="">§A(1)(b) of this regulation</a> by providing the Department with the forensic laboratory director’s written authorization for that individual to perform casework independently in the discipline of controlled dangerous substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#B">B.</span> Certified Chemical Analyst. An applicant for certification as a certified chemical analyst shall have successfully completed a basic training program approved by the Department that provides training in the identification of marijuana or marijuana products, or both, cocaine base, cocaine hydrochloride, and heroin using procedures approved under <a class="internal-link " href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.02#C">C.</span> Certified Analyst. An applicant for certification as a certified analyst shall have successfully completed a basic training program approved by the Department that provides training in the identification of marijuana or marijuana products, or both, using procedures approved under <a class="internal-link " href="/us/md/exec/comar/10.10.09.04" title=".04 Procedures.">Regulation .04 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.09.03" data-order="|10|10|09|.03|" data-ref-path="10|10|09|.03" class="h__section">.03 Employment, Employment Certification, and Automatic Decertification.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A">A.</span> Employment. An individual applying for certification under this chapter shall be currently employed by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A(1)">(1)</span> The Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A(2)">(2)</span> The Maryland State Police;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A(3)">(3)</span> The Baltimore City Police Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A(4)">(4)</span> The police department or a municipality or county in this State; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#A(5)">(5)</span> A private forensic laboratory licensed by the Maryland Department of Health that has a contract with a Maryland law enforcement agency to provide testing services for controlled dangerous substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#B">B.</span> Employment Certification. An applicant's supervisor shall certify that the applicant is currently employed by an agency listed in <a class="internal-link " href="/us/md/exec/comar/10.10.09.03#A" title="">§A of this regulation</a> by signing the employment certification section of the application.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C">C.</span> Certification and Automatic Decertification.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(1)">(1)</span> Certification under this chapter is only valid when the individual is employed by an agency listed in <a class="internal-link " href="/us/md/exec/comar/10.10.09.03#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(2)">(2)</span> An individual certified under this chapter is automatically decertified when the individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(2)(a)">(a)</span> Is no longer employed by the agency that certified employment;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(2)(b)">(b)</span> Retires from the agency that certified employment; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(2)(c)">(c)</span> Changes employment from one agency listed in <a class="internal-link " href="/us/md/exec/comar/10.10.09.03#A" title="">§A of this regulation</a> to another agency listed in <a class="internal-link " href="/us/md/exec/comar/10.10.09.03#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(3)">(3)</span> An individual shall reapply for certification under this chapter if the individual is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(3)(a)">(a)</span> Rehired by the same agency that previously certified employment; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.09.03#C(3)(b)">(b)</span> Hired by a different agency listed in <a class="internal-link " href="/us/md/exec/comar/10.10.09.03#A" title="">§A of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.09.04" data-order="|10|10|09|.04|" data-ref-path="10|10|09|.04" class="h__section">.04 Procedures.</h3>
                <p>Chemists, chemical analysts, and analysts certified under this chapter are certified only when performing those drug identification procedures:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.04#A">A.</span> Approved by a forensic laboratory licensed by the Department; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.04#B">B.</span> Contained in the "Forensic Chemists and Analysts Training and Procedures Manual" 1992, which is incorporated by reference.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.09.05" data-order="|10|10|09|.05|" data-ref-path="10|10|09|.05" class="h__section">.05 Report.</h3>
                <p>A report prepared pursuant to these regulations shall contain the following information:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#A">A.</span> The signature of the certified chemist, chemical analyst, or analyst performing the drug-identification procedure;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#B">B.</span> The name of the person who delivered the material to be tested to the certified chemist, chemical analyst, or analyst;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#C">C.</span> A statement that the chemist, chemical analyst, or analyst has been certified by the Department to perform the procedures identified in the report;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#D">D.</span> A statement by the certified chemist, chemical analyst, or analyst that the results contained in the report were reached using procedures approved by the Department;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#E">E.</span> A statement by the certified chemist, chemical analyst, or analyst concerning whether the material tested is, or contains, the drug identified in the report; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.09.05#F">F.</span> A statement by the certified chemist, chemical analyst, or analyst that quality control of the drug-identification procedures was performed to ensure the reliability of the procedures performed.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.10" data-order="|10|10|10|" data-ref-path="10|10|10" class="h__chapter">Chapter 10 Job-Related Alcohol and Controlled Dangerous Substances Testing</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: October 5, 1998 (25:20 Md. R. 1529)</p>
                  <p>——————</p>
                  <p>Chapter, <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>, recodified to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10" title="Chapter 10 Job-Related Alcohol and Controlled Dangerous Substances Testing">COMAR 10.10.10</a> effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.03#B" title="">Regulation .03B</a> amended effective February 18, 2002 (29:3 Md. R. 220); December 11, 2003 (30:24 Md. R. 1741)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.04" title=".04 Responsibilities of the Secretary.">Regulation .04</a> repealed and new Regulation .04 adopted effective February 18, 2002 (29:3 Md. R. 220)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.06" title=".06 Permissible Specimens.">Regulation .06</a> amended effective February 18, 2002 (29:3 Md. R. 220); December 11, 2003 (30:24 Md. R. 1741)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.10" title=".10 Preliminary Screening by an Employer or Agent of the Employer.">Regulation .10</a> adopted effective February 18, 2002 (29:3 Md. R. 220)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.10.10#F" title="">Regulation .10F</a> amended effective July 22, 2002 (29:14 Md. R. 1074)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-202 and 17-214, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.10.01" data-order="|10|10|10|.01|" data-ref-path="10|10|10|.01" class="h__section">.01 Purpose.</h3>
                <p>This chapter provides for the protection of employers, employees, and the public by setting fair and effective job-related alcohol and controlled dangerous substances testing standards to ensure accurate and reliable test results and to promote drug-free workplaces.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.02" data-order="|10|10|10|.02|" data-ref-path="10|10|10|.02" class="h__section">.02 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#A">A.</span> This chapter provides the standards and procedures that employers, employees, and the Secretary shall meet when job applicants and employees are required to undergo job-related alcohol and controlled dangerous substances testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B">B.</span> This chapter does not apply to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B(1)">(1)</span> A person who is subject to federal or State commercial motor vehicle statutes or regulations concerning alcohol and controlled dangerous substances testing, to the extent that those statutes or regulations conflict with the requirements of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B(2)">(2)</span> An agency of the federal government;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B(3)">(3)</span> Alcohol or controlled dangerous substances testing of an individual under arrest or held by a law enforcement or correctional agency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B(4)">(4)</span> Alcohol testing conducted by a law enforcement or correctional agency on breath-testing equipment certified by the State toxicologist; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.02#B(5)">(5)</span> Controlled dangerous substances testing by a laboratory facility of a law enforcement or correctional agency that maintains laboratory testing standards comparable to the standards in Health-General Article, §17-214, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.03" data-order="|10|10|10|.03|" data-ref-path="10|10|10|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(1)">(1)</span> "Agent of the employer" means a person other than the employer or a licensed medical laboratory that employs individuals who perform preliminary screening of job applicants for controlled dangerous substances on behalf of the employer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(2)">(2)</span> "Chain-of-custody" means a method of tracking an individual's specimen for the purpose of maintaining control and accountability from initial collection through each stage in handling, testing, storing, reporting test results, and final specimen disposition.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(3)">(3)</span> Confirmation Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(3)(a)">(a)</span> "Confirmation test" means an analytical procedure performed after a preliminary or screening test and intended to verify or positively identify the presence of a controlled dangerous substance in a specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(3)(b)">(b)</span> "Confirmation test" is limited to an analytical procedure that employs a combination of gas chromatography and mass spectrometry (GC/MS or GC/MS/MS) or mass spectrometry and mass spectrometry (MS/MS).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(4)">(4)</span> Controlled Dangerous Substance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(4)(a)">(a)</span> "Controlled dangerous substance" means a drug, substance, or immediate precursor as set forth in Schedules I—V, <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gcr/gcr.pdf" title="">Criminal Law Article, Title 5, Subtitle 4, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(4)(b)">(b)</span> "Controlled dangerous substance" includes new substances controlled under federal law as provided in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=5-202" title="">Criminal Law Article, §5-202, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(5)">(5)</span> Employee.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(5)(a)">(a)</span> "Employee" means an individual who performs work for an employer.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(5)(b)">(b)</span> "Employee" includes a salaried, contractual, full-time, part-time, temporary, hourly, and on-call employee or a volunteer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(6)">(6)</span> "Employer" means a person who employs an individual to perform work.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(7)">(7)</span> "Forensic testing" means testing performed for a nonclinical purpose and under procedures that produce test results that meet rules of evidence required in a court of law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(8)">(8)</span> "Immediate precursor" means a substance as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=5-101" title="">Criminal Law Article, §5-101, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(9)">(9)</span> "Independent test" means a test performed at the request and expense of a job applicant, employee, or contractor to verify a test result obtained on the same specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(10)">(10)</span> "Job applicant" means an individual who has applied for a position with an employer but is not currently employed by the employer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(11)">(11)</span> "Job-related testing" means any alcohol or controlled dangerous substances testing used by an employer for a lawful business purpose.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(12)">(12)</span> Laboratory.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(12)(a)">(a)</span> "Laboratory" means a facility, entity, or site that performs job-related alcohol or controlled dangerous substances testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(12)(b)">(b)</span> "Laboratory" does not include a collection site or other site where an employer or agent of the employer performs preliminary screening of job applicants for a controlled dangerous substance using a single-use test device for forensic testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(13)">(13)</span> "Letter of registration" means the authority in the form of a letter issued by the Secretary granting permission to an employer to perform preliminary screening of job applicants for a controlled dangerous substance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(14)">(14)</span> "License" means the authority in the form of a permit issued by the Secretary granting permission for a laboratory to perform job-related alcohol or controlled dangerous substances testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(15)">(15)</span> "Medical review officer" means a licensed physician with knowledge of drug abuse disorders and drug and alcohol testing who is either employed or under contract to an employer that performs preliminary screening of job applicants for a controlled dangerous substance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(16)">(16)</span> "Non-negative test result" means the result of a preliminary screening for a controlled dangerous substance that is not negative but that has not been confirmed by a licensed laboratory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(17)">(17)</span> "Office of Health Care Quality (OHCQ)" means the Office of Health Care Quality of the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(18)">(18)</span> "Operator" means an individual employed by the employer or agent of the employer who performs a preliminary screening procedure as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.10.03#B(19)" title="">§B(19) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(19)">(19)</span> "Preliminary screening procedure" means a controlled dangerous substance test:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(19)(a)">(a)</span> Using a single-use test device for forensic testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(19)(b)">(b)</span> Performed by an employer or agent of the employer on a job applicant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(20)">(20)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)">(21)</span> "Single-use test device for forensic testing" means the reagent-containing unit of a test system that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)(a)">(a)</span> Is in the form of a sealed container or cartridge possessing a validity check;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)(b)">(b)</span> Possesses a nonresealable closure or an evidentiary tape to ensure detection of tampering;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)(c)">(c)</span> Is self-contained and individually packaged;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)(d)">(d)</span> Is discarded after each test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(21)(e)">(e)</span> Does not allow any test component or constituent of a test system to interact from test to test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(22)">(22)</span> Specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(22)(a)">(a)</span> "Specimen" means material derived from the human body and intended for laboratory testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.03#B(22)(b)">(b)</span> "Specimen" is limited to blood, urine, saliva, and hair.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.04" data-order="|10|10|10|.04|" data-ref-path="10|10|10|.04" class="h__section">.04 Responsibilities of the Secretary.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#A">A.</span> Registration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#A(1)">(1)</span> Requirement. The OHCQ shall register on the Secretary's behalf an employer that conducts a preliminary screening procedure on a job applicant for a controlled dangerous substance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#A(2)">(2)</span> Forms. The OHCQ shall provide to each employer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#A(2)(a)">(a)</span> A registration application form; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#A(2)(b)">(b)</span> A registration renewal form every 2 years after the initial registration.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B">B.</span> Routine Surveys and Complaint Investigation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(1)">(1)</span> Requirement. The Secretary or the OHCQ as the Secretary's designee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(1)(a)">(a)</span> Conduct routine surveys of preliminary screening sites;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(1)(b)">(b)</span> Conduct surveys of preliminary screening sites as part of a complaint investigation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(1)(c)">(c)</span> Investigate written complaints related to compliance with the standards set forth in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)">(2)</span> On-site Surveys. The OHCQ may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(a)">(a)</span> Annually conduct routine on-site surveys of preliminary screening sites;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(b)">(b)</span> Conduct a routine survey any time during a preliminary screening site's normal work hours; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(c)">(c)</span> Include as part of a routine survey or complaint investigation:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(c)(i)">(i)</span> On-site observation and examination of preliminary screening facilities, equipment, screening devices, specimens, and screening procedures;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(c)(ii)">(ii)</span> On-site examination of documents pertinent to employer registration, preliminary screening performed by the employer or agent of the employer, and operator training; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(2)(c)(iii)">(iii)</span> On-site interviews of employers and employees involved in performing, supervising, or managing preliminary screening.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)">(3)</span> Sanctions.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)">(a)</span> Imposition. If the Secretary finds that an employer or agent of an employer is not in compliance with a requirement or standard of this chapter, the Secretary may impose one or more of the following sanctions on the employer, agent of the employer, or both:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)(i)">(i)</span> Suspension of a letter or letters of registration;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)(ii)">(ii)</span> Revocation of a letter or letters of registration;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)(iii)">(iii)</span> A direct plan of correction;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)(iv)">(iv)</span> A limitation on preliminary screening; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(a)(v)">(v)</span> Required training and technical assistance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.04#B(3)(b)">(b)</span> Departmental Actions. The Secretary shall carry out actions related to the imposition or lifting of sanctions involving preliminary screenings in the same manner as those involving a laboratory, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">COMAR 10.10.08</a>, including the providing of notice and hearings.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.05" data-order="|10|10|10|.05|" data-ref-path="10|10|10|.05" class="h__section">.05 Employer Requirements.</h3>
                <p>An employer who for job-related reasons requires an individual to be tested for alcohol or controlled dangerous substances shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.05#A">A.</span> Have the specimen tested by a laboratory that holds a Maryland license in the discipline of job-related alcohol and controlled dangerous substances testing; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.05#B">B.</span> At the time of testing and at the individual's request, inform the person of the name and address of the laboratory that will test the specimen.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.06" data-order="|10|10|10|.06|" data-ref-path="10|10|10|.06" class="h__section">.06 Permissible Specimens.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A">A.</span> General. An employer requiring job-related alcohol or controlled dangerous substances testing shall require that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(1)">(1)</span> A job applicant provide only one or more of the following types of specimen:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(1)(a)">(a)</span> Blood;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(1)(b)">(b)</span> Urine;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(1)(c)">(c)</span> Saliva; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(1)(d)">(d)</span> Hair; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(2)">(2)</span> An employee or contractor provide only one or more of the following types of specimen:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(2)(a)">(a)</span> Blood;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(2)(b)">(b)</span> Saliva; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#A(2)(c)">(c)</span> Urine.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#B">B.</span> Specimen Types. An employer requiring job-related alcohol or controlled dangerous substances testing may not require the testing of any specimen other than:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#B(1)">(1)</span> Blood, urine, saliva, or hair, for a job applicant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#B(2)">(2)</span> Blood, saliva, or urine, for an employee or contractor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#C">C.</span> Hair. An employer may require that a job applicant submit a hair specimen for controlled dangerous substances testing if the hair specimen is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#C(1)">(1)</span> Less than or equal to 1-1/2 inches in length measured from the human body;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#C(2)">(2)</span> Tested only for preemployment purposes; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.06#C(3)">(3)</span> Not used for a purpose other than controlled dangerous substances testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.07" data-order="|10|10|10|.07|" data-ref-path="10|10|10|.07" class="h__section">.07 Specimen Collection and Handling Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A">A.</span> Chain of Custody. A person collecting a specimen shall employ quality assurance and chain-of-custody procedures that include:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A(1)">(1)</span> Collecting a specimen in a sealed container that has a non-resealable closure or an evidentiary tape that assures detection of any tampering;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A(2)">(2)</span> Collecting, handling, storing, and shipping a specimen in a manner that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A(2)(a)">(a)</span> Maintains its identity, confidentiality, and physical integrity; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A(2)(b)">(b)</span> Precludes specimen contamination or adulteration; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#A(3)">(3)</span> Documenting each time a person accesses or transfers the specimen.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.07#B">B.</span> Specimen Quantity. A person collecting a specimen shall collect a quantity sufficient to perform an initial screening test, a confirmation test, and an independent test.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.08" data-order="|10|10|10|.08|" data-ref-path="10|10|10|.08" class="h__section">.08 Protections for Job Applicants, Employees, and Contractors.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A">A.</span> Notice of Positive Test Results.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(1)">(1)</span> An employer who requires a job applicant, employee, or contractor to be tested for job-related reasons for the use or abuse of a controlled dangerous substance or alcohol and who receives notice that a job applicant, employee, or contractor has tested positive for a controlled dangerous substance or alcohol shall provide to the job applicant, employee, or contractor with a confirmed positive test result:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(1)(a)">(a)</span> A copy of the laboratory test indicating the test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(1)(b)">(b)</span> A copy or written summary of the employer's policy covering an employee, contractor, or job applicant with a confirmed positive test result;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(1)(c)">(c)</span> If applicable, written notice of the employer's intent to take disciplinary action, terminate employment, or change the conditions of continued employment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(1)(d)">(d)</span> A statement or copy of the provisions set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.10.08#B" title="">§B of this regulation</a> permitting a job applicant, employee, or contractor to request independent testing of the same sample for verification of the test result.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(2)">(2)</span> The employer shall deliver the information required to be provided under <a class="internal-link " href="/us/md/exec/comar/10.10.10.08#A" title="">§A of this regulation</a> to the job applicant, employee, or contractor:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(2)(a)">(a)</span> Either in person or by certified mail; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#A(2)(b)">(b)</span> Within 7 days from the date confirmed positive test results are received by the employer.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B">B.</span> Right to an Independent Test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B(1)">(1)</span> Challenge. A job applicant, employee, or contractor who is required to submit to job-related alcohol or controlled dangerous substances testing may request that an independent test be performed on the same specimen in a confirmation test by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B(1)(a)">(a)</span> Notifying the employer and the laboratory that performed the confirmation test of the challenge to that test result; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B(1)(b)">(b)</span> Requesting that laboratory to submit a sufficient portion of the original specimen to a different laboratory chosen by the job applicant, employee, or contractor and licensed by the Secretary to perform alcohol or controlled dangerous substances testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B(2)">(2)</span> Testing Sensitivity. The job applicant, employee, or contractor shall employ as an independent testing laboratory one that will perform the independent test using detection levels for alcohol or controlled dangerous substances equal to or lower than those provided by the laboratory that performed the initial confirmation test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.08#B(3)">(3)</span> Costs. The job applicant, employee, or contractor shall pay all costs of independent testing including any costs associated with specimen handling and transport.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.09" data-order="|10|10|10|.09|" data-ref-path="10|10|10|.09" class="h__section">.09 Confidentiality.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.09#A">A.</span> General. Except as otherwise provided in an employer's written drug testing policy, in this regulation, or in Health-General Article, §17-214, Annotated Code of Maryland, all information, interviews, reports, statements, memoranda, and test results received or produced as a result of job-related alcohol or controlled dangerous substances testing are confidential and may be released only under a lawful subpoena, court order, or a release signed by the individual tested, or, in the case of a minor, by the individual's parent or legal guardian.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.09#B">B.</span> Nonprescription and Medically Prescribed Drugs. In the course of obtaining information for, or as a result of, conducting job-related alcohol or controlled dangerous substances testing for an employer, a laboratory, a physician, including a physician retained by the employer, or any other person, may not reveal to the employer information regarding the use of a:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.09#B(1)">(1)</span> Nonprescription drug, excluding alcohol, that is not prohibited under the laws of the State; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.09#B(2)">(2)</span> Medically prescribed drug, unless the individual being tested is unable to establish that the drug was medically prescribed under the laws of the State.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.10.10" data-order="|10|10|10|.10|" data-ref-path="10|10|10|.10" class="h__section">.10 Preliminary Screening by an Employer or Agent of the Employer.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#A">A.</span> In addition to any other applicable requirements in this chapter, an employer or agent of the employer that performs a preliminary preemployment screening procedure for a controlled dangerous substance on a job applicant shall meet the standards set forth in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B">B.</span> Registration Requirement. An employer or agent of the employer shall register the employer initially and every 2 years thereafter with the OHCQ by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B(1)">(1)</span> Submitting to the OHCQ a registration form that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B(1)(a)">(a)</span> Lists the permanent office location of the employer and any agent of the employer in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B(1)(b)">(b)</span> Lists the permanent locations where the employer or agent of the employer performs preliminary screenings; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B(1)(c)">(c)</span> States whether the employer or agent of the employer performs preliminary screenings at temporary sites, uses mobile screening vehicles, or both; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#B(2)">(2)</span> Submitting to the OHCQ a registration fee of $50.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#C">C.</span> Single-Use Test Device. An employer or agent of the employer shall limit screening procedures to those that employ an FDA-cleared or approved single-use test device as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.10.03#B(21)" title="">Regulation .03B(21) of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D">D.</span> Trained Operator. To perform a preliminary screening procedure, an employer or agent of the employer shall employ an operator who has been trained for each type of device to be used, including instruction that includes the operator's:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(1)">(1)</span> Reading the test manufacturer's package insert sheet;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(2)">(2)</span> Observing the test manufacturer's training video or receiving training:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(2)(a)">(a)</span> From the test manufacturer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(2)(b)">(b)</span> From an individual trained by the manufacturer; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(2)(c)">(c)</span> Endorsed by the manufacturer;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(3)">(3)</span> Completing the test manufacturer's self-administered test; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#D(4)">(4)</span> Performing tests, interpreting test results, and reporting results to job applicants under the supervision of a trained operator.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E">E.</span> Training Records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E(1)">(1)</span> Requirement. An employer or agent of the employer shall establish and maintain training records that document the training required to properly perform a screening procedure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E(2)">(2)</span> Documentation. An employer or agent of the employer shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E(2)(a)">(a)</span> Keep a record of the training received by a trainee;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E(2)(b)">(b)</span> Document that a trainee has demonstrated competency in performing the screening procedure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#E(2)(c)">(c)</span> Maintain for at least 2 years documentation that the trainee has been trained as set forth in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F">F.</span> Quality Assurance. An employer or agent of the employer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(1)">(1)</span> Limit screening procedures to those that employ an FDA-cleared or FDA-approved single-use test device for forensic testing, as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.10.03" title=".03 Definitions.">Regulation .03 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(2)">(2)</span> Perform preliminary screening tests in accordance with the quality standards set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.03.02#C(2)" title="">COMAR 10.10.03.02C(2)</a> and (3);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(3)">(3)</span> Collect and handle all specimens and ship non-negative specimens for testing, in a manner that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(3)(a)">(a)</span> Maintains the specimen donor's identity and confidentiality; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(3)(b)">(b)</span> Precludes contamination of and tampering with the specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(4)">(4)</span> Provide a secure area with limited access to store a non-negative specimen before it is shipped to a laboratory and while it is retained pending:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(4)(a)">(a)</span> Confirmatory testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(4)(b)">(b)</span> Notice;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(4)(c)">(c)</span> Any independent testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(4)(d)">(d)</span> Final disposal;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(5)">(5)</span> Submit a non-negative specimen subjected to a preliminary screening procedure to a licensed medical laboratory for confirmatory testing within 24 hours of screening;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(6)">(6)</span> Maintain a written record of the chain-of-custody for a specimen from the time it is collected until it is no longer needed for retesting or confirmatory testing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(7)">(7)</span> Have a medical review officer, as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.10.03#B(15)" title="">Regulation .03B(15) of this chapter</a>, review positive test results resulting from a confirmatory test; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#F(8)">(8)</span> Retain for at least 1 year all records pertaining to preliminary screening.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#G">G.</span> Notice and Independent Testing. An employer or agent of the employer who receives notice that a job applicant has tested positive for a controlled dangerous substance shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#G(1)">(1)</span> Provide to the job applicant the items specified in <a class="internal-link " href="/us/md/exec/comar/10.10.10.08#A" title="">Regulation .08A of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#G(2)">(2)</span> Inform the job applicant of the right to request that an independent test be performed on the same specimen, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.10.08#B" title="">Regulation .08B of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H">H.</span> Voluntary Disclosure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H(1)">(1)</span> For the purposes of facilitating hiring, a job applicant may voluntarily disclose and provide documentation to an operator that the job applicant is using:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H(1)(a)">(a)</span> A nonprescription drug that is not prohibited under the laws of the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H(1)(b)">(b)</span> A medically prescribed drug; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H(1)(c)">(c)</span> Both.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#H(2)">(2)</span> An operator may disclose to the employer information involving the use of medically prescribed and nonprohibited nonprescription drugs voluntarily disclosed and documented to the operator by the job applicant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.10.10#I">I.</span> Surveys and Complaint Investigations. An employer or agent of an employer shall permit the OHCQ to conduct an on-site survey of a preliminary screening site at any time during the screening site's normal hours of operation as part of a complaint investigation or routine inspection to determine compliance with the applicable requirements and standards set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.11" data-order="|10|10|11|" data-ref-path="10|10|11" class="h__chapter">Chapter 11 Biological Agents Registry Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: November 25, 2002 (29:23 Md. R. 1811)</p>
                  <p>——————</p>
                  <p>——————</p>
                  <p>Chapter revised effective July 31, 2006 (33:15 Md. R. 1280)</p>
                  <p>Chapter revised effective January 23, 2012 (39:1 Md. R. 17)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.03#B" title="">Regulation .03B</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.04#B" title="">Regulation .04B</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.07#F" title="">Regulation .07F</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.09#B" title="">Regulation .09B</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.10#E" title="">Regulation .10E</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.11#A" title="">Regulation .11A</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.12#B" title="">Regulation .12B</a>, C amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.13" title=".13 BAR Information Confidentiality and Release of BAR Information.">Regulation .13</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.14" title=".14 Method of Non-Emergency Release of BAR Information.">Regulation .14</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.21" title=".21 BAR Information Security — Physical Safeguards.">Regulation .21</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.11.22" title=".22 BAR Information Security — Technical Security Measures.">Regulation .22</a> amended effective May 18, 2020 (47:10 Md. R. 517)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§17-601—17-605, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.11.01" data-order="|10|10|11|.01|" data-ref-path="10|10|11|.01" class="h__section">.01 Purpose.</h3>
                <p>The purpose of this chapter is to help protect the people of Maryland against the potential threat of biological terrorism by establishing a program to register persons that possess, maintain, transfer, or receive biological agents in the State.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.02" data-order="|10|10|11|.02|" data-ref-path="10|10|11|.02" class="h__section">.02 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.02#A">A.</span> This chapter contains the standards and requirements a person that possesses, maintains, transfers, or receives a biological agent in this State shall meet to comply with the registration of biological agents.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.02#B">B.</span> This chapter does not apply to a biological agent or a certified laboratory or facility that is exempt from the requirements for the interstate shipment of etiologic agents under 42 CFR §§73.5 and 73.6, 9 CFR §§121.5 and 121.6, and 7 CFR §331.5.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.03" data-order="|10|10|11|.03|" data-ref-path="10|10|11|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(1)">(1)</span> “Access” means the ability or the means necessary to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(1)(a)">(a)</span> Read, write, modify, or communicate BAR information; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(1)(b)">(b)</span> Otherwise make use of any system resource related to BAR information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(2)">(2)</span> “Access control” means a method of restricting access to a BAR information resource, allowing only an authorized individual access to the resource.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(3)">(3)</span> “Authentication” means the corroboration that a person is the one claimed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(4)">(4)</span> “BAR” means the Department’s Biological Agents Registry.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)">(5)</span> BAR Information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(a)">(a)</span> “BAR information” means information submitted to the BAR Program by a person required to report a biological agent under this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(b)">(b)</span> “BAR information” identifies:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(b)(i)">(i)</span> A person in this State who possesses, maintains, transfers, or receives a biological agent; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(b)(ii)">(ii)</span> The biological agents possessed, maintained, transferred, and received by a person in this State.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(c)">(c)</span> “BAR information” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(c)(i)">(i)</span> Information contained in any of the documents and records that the BAR Program collects, requests, maintains, processes, or stores;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(c)(ii)">(ii)</span> Information released by the BAR Program, a trusted partner, or a BAR information custodian; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(5)(c)(iii)">(iii)</span> Biological agent incident response plans submitted to a local jurisdiction as required by this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)">(6)</span> BAR Information Custodian.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)(a)">(a)</span> “BAR information custodian” means an individual designated by a trusted partner and authorized by the Department in a trusted partner agreement to receive and maintain BAR information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)(b)">(b)</span> “BAR information custodian” may include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)(b)(i)">(i)</span> A health officer or designee;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)(b)(ii)">(ii)</span> An Emergency Management Director or designee; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(6)(b)(iii)">(iii)</span> Other alternately designated and authorized individuals with a legitimate need to know the BAR information as it relates to the performance of the person's duties.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(7)">(7)</span> “BAR Program” means the Department’s BAR Program within the Laboratories Administration’s Office of Laboratory Emergency Preparedness and Response.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(8)">(8)</span> “Biological agent” means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(8)(a)">(a)</span> A select agent or toxin listed in 42 CFR §§73.3 and 73.4, 7 CFR §331.3, and 9 CFR §§121.3 and 121.4;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(8)(b)">(b)</span> A genetically modified microorganism or genetic element from an organism listed in 42 CFR §§73.3 and 73.4, 7 CFR §331.3, and 9 CFR §§121.3 and 121.4, shown to produce or encode for a factor associated with disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(8)(c)">(c)</span> A genetically modified microorganism or genetic element that contains nucleic acid sequences coding for a toxin listed in 42 CFR §§73.3 and 73.4, and 9 CFR §§121.3 and 121.4, or the toxin's subunits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(9)">(9)</span> Biological Agent Incident.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(9)(a)">(a)</span> “Biological agent incident” means a breach of containment or imminent threat of a breach of containment of a biological agent that poses an immediate threat to an individual's health and safety.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(9)(b)">(b)</span> “Biological agent incident” includes any situation that may cause or potentially cause an exposure to or release of a biological agent, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.11.12#B" title="">Regulation .12B of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(10)">(10)</span> “Biosafety Level (BSL)” means the level of work practices, facility design, and safety equipment to prevent transmission of biologic agents to workers, other individuals, and the environment, as defined in the BMBL.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)">(11)</span> “Biosafety Level-2 (BSL-2)” means the BSL used when:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)(a)">(a)</span> Work is done with biological agents associated with human disease; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)(b)">(b)</span> The route of transmission is by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)(b)(i)">(i)</span> Percutaneous injury;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)(b)(ii)">(ii)</span> Ingestion; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(11)(b)(iii)">(iii)</span> Mucous membrane exposure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(12)">(12)</span> “Biosafety Level-3 (BSL-3)” means the BSL used when:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(12)(a)">(a)</span> Work is done with indigenous or exotic agents associated with a potentially serious or lethal human disease; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(12)(b)">(b)</span> The route of transmission is aerosol inhalation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)">(13)</span> Biosafety Level-4 (BSL-4).</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)(a)">(a)</span> “BSL-4” means the BSL used when work is done with a dangerous and exotic biological agent that poses a high risk of life-threatening or lethal human disease that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)(a)(i)">(i)</span> May be transmitted via the aerosol route;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)(a)(ii)">(ii)</span> Has an unknown mode of transmission; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)(a)(iii)">(iii)</span> Has no available vaccine or therapy.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(13)(b)">(b)</span> “BSL-4” includes the BSL used when the agent has a close or identical antigenic relationship to BSL-4 agents.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(14)">(14)</span> “BMBL” means the “Biosafety in Microbiological and Biomedical Laboratories”, which is incorporated by reference in <a class="internal-link " href="/us/md/exec/comar/10.10.11.04" title=".04 Incorporation by Reference.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(15)">(15)</span> “Centers for Disease Control and Prevention (CDC)” means the federal Centers for Disease Control and Prevention of the federal Department of Health and Human Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(16)">(16)</span> “Compact Disc-Recordable (CD-R)” means a type of write once, read many compact disc format that allows one-time recording of digital information on the disc.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)">(17)</span> Contingency Plan.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)(a)">(a)</span> “Contingency plan” means a plan for responding to an information system emergency.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)(b)">(b)</span> “Contingency plan” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)(b)(i)">(i)</span> Installing system information from backups;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)(b)(ii)">(ii)</span> Preparing critical facilities that can be used to facilitate continuity of operations in the event of an emergency; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(17)(b)(iii)">(iii)</span> Recovering from a disaster.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(18)">(18)</span> “Decryption” means reversing the protective encryption algorithm process to make the previously unintelligible plaintext available for further processing as intelligible plaintext.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(19)">(19)</span> “Deficiency” means a documented lack of compliance with a standard or requirement of the BAR Program set forth in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(20)">(20)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(21)">(21)</span> “Emergency management director” means an individual appointed by the Governor of Maryland, who is directly responsible for the organization, administration, and operation of the local organization for emergency management in the local jurisdiction as set forth in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gps&amp;section=14-109" title="">Public Safety Article, §14-109, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(22)">(22)</span> Encryption.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(22)(a)">(a)</span> “Encryption” means transforming confidential plaintext into ciphertext to protect it so that the data can be securely stored.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(22)(b)">(b)</span> “Encryption” includes encrypting with an algorithm that combines plaintext with other values called keys, or ciphers, so the data becomes unintelligible.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(23)">(23)</span> “Etiologic” means disease causing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(24)">(24)</span> “Exposure” means the condition of being subjected to a biological agent which may have a harmful effect.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(25)">(25)</span> “Facility” means a building or complex of buildings owned by the same person and located at a single mailing address.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(26)">(26)</span> "Genetic element" means a nucleic acid sequence shown to produce or encode for a factor associated with a disease, a toxin, or a toxin's subunits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(27)">(27)</span> "Local jurisdiction" means a county of the State or Baltimore City.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(28)">(28)</span> "Maintaining a biological agent" means manipulating or holding a biological agent to sustain or enhance viability, infectivity, or toxicity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(29)">(29)</span> "Maryland Institute for Emergency Medical Services Systems (MIEMSS)" means the unit established by <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ged&amp;section=13-503" title="">Education Article, §13-503, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(30)">(30)</span> "MDE" means the Maryland Department of the Environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(31)">(31)</span> "MEMA" means the Maryland Emergency Management Agency.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)">(32)</span> Nature of a Biological Agent.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(a)">(a)</span> "Nature of a biological agent" means the term that describes the kind or type of material or organism the agent is.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)">(b)</span> “Nature of a biological agent” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(i)">(i)</span> Toxin;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(ii)">(ii)</span> Bacterium;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(iii)">(iii)</span> Virus;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(iv)">(iv)</span> Rickettsia;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(v)">(v)</span> Fungus;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(vi)">(vi)</span> Allergen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(vii)">(vii)</span> Genetic element; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(b)(viii)">(viii)</span> Any combination of §B(32)(b)(i)—(vii) of this regulation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(32)(c)">(c)</span> "Nature of a biological agent" does not include the name or identity of the biological agent.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(33)">(33)</span> Person.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(33)(a)">(a)</span> "Person" means an individual, receiver, trustee, guardian, personal representative, fiduciary, or representative of any kind and any partnership, firm, association, corporation, or other entity.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(33)(b)">(b)</span> "Person" includes State and federal units of government.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(34)">(34)</span> "Personal identification number (PIN)" means a number or code assigned to an individual and used to provide verification of identity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(35)">(35)</span> “Personal protective equipment (PPE)” means the type of physical barrier equipment necessary to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(35)(a)">(a)</span> Protect an individual from contact with a biological agent; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(35)(b)">(b)</span> Prevent transmission of a biological agent.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(36)">(36)</span> "Possessing a biological agent" means handling, holding, maintaining, owning, or storing a biological agent within the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(37)">(37)</span> Responsible Official.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(37)(a)">(a)</span> "Responsible official" means an individual designated by a person required to report under this chapter to act on the person's behalf.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(37)(b)">(b)</span> "Responsible official" includes an individual designated as an alternate responsible official who acts in the responsible official's absence.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(38)">(38)</span> "Role-based access" means a security mechanism for granting user access to a computer information system containing BAR information, based upon the user's job function.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(39)">(39)</span> “Secretary” means the Secretary of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(40)">(40)</span> "Security incident" means a situation when BAR information is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(40)(a)">(a)</span> Intentionally or unintentionally released to an unauthorized person; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(40)(b)">(b)</span> Otherwise compromised in a way that allows unauthorized access.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)">(41)</span> Security Self-Assessment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(a)">(a)</span> "Security self-assessment" means a person's formal assessment of the sensitivity, vulnerabilities, and security of the person's operations and programs related to the BAR information the person receives, manipulates, stores, or transmits.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(b)">(b)</span> "Security self-assessment" includes the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(b)(i)">(i)</span> Procedures and processes for determining a person's compliance with the BAR information security standards in this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(b)(ii)">(ii)</span> Documentation certifying to the BAR Program that a person meets the BAR information security standards;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(b)(iii)">(iii)</span> Identification and management of security risks; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(41)(b)(iv)">(iv)</span> Security standards self-assessment check list provided by the BAR Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(42)">(42)</span> "Technical security measure" means a process that is put in place to protect information and control individual access to information in order to guard data integrity, confidentiality, and availability.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(43)">(43)</span> "Token" means an electronic device for authenticating user identification and allowing access to a door or computer information system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)">(44)</span> Toxin.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(a)">(a)</span> "Toxin" means a biologically active poisonous substance that is:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(a)(i)">(i)</span> Produced by a living cell or an organism; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(a)(ii)">(ii)</span> Harmful to another organism.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(b)">(b)</span> "Toxin" does not include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(b)(i)">(i)</span> A poisonous substance produced by a living organism for medical purposes, inactivated for use as a vaccine; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(44)(b)(ii)">(ii)</span> A toxin preparation for biomedical research use at a lethal dose of 50 percent (LD50) for vertebrates of more than 100 nanograms per kilogram body weight.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(45)">(45)</span> "Transfer" means the physical relocation of a biological agent from one facility or person to another.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(46)">(46)</span> Trusted Partner.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(46)(a)">(a)</span> "Trusted partner" means a person with whom the Department has a valid trusted partner agreement to receive, possess, maintain, and transfer or share BAR information, as set forth in this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(46)(b)">(b)</span> "Trusted partner" includes only MDE, MEMA, MIEMSS, and a local jurisdiction where a biological agent is located.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(47)">(47)</span> Trusted Partner Agreement.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(47)(a)">(a)</span> "Trusted partner agreement" means a document describing the arrangement between the Department and a trusted partner regarding how, when, and to whom information is released from the BAR.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(47)(b)">(b)</span> "Trusted partner agreement" includes the documentation that describes all the policies, procedures, and mechanisms agreed upon to protect the integrity, confidentiality, and availability of BAR information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.03#B(48)">(48)</span> "User-based access" means a security mechanism used to grant system access to users, based upon the identity of the user.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.04" data-order="|10|10|11|.04|" data-ref-path="10|10|11|.04" class="h__section">.04 Incorporation by Reference.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#A">A.</span> In this chapter, the following documents are incorporated by reference.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B">B.</span> Documents Incorporated.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B(1)">(1)</span> 29 CFR §1910.1450, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B(2)">(2)</span> 42 CFR 73, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B(3)">(3)</span> 9 CFR 121, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B(4)">(4)</span> 7 CFR 331, as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.04#B(5)">(5)</span> CDC/NIH publication, “Biosafety in Microbiological and Biomedical Laboratories”, 5th Edition, December 2009, as amended.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.05" data-order="|10|10|11|.05|" data-ref-path="10|10|11|.05" class="h__section">.05 Registering Under the Biological Agents Registry Program.</h3>
                <p>A person in the State shall participate in and comply with the State's BAR Program by registering with and reporting to the Department, in the manner set forth in this chapter, the information required by the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.06" data-order="|10|10|11|.06|" data-ref-path="10|10|11|.06" class="h__section">.06 Compliance with Federal Standards.</h3>
                <p>A person that possesses, maintains, transfers, or receives a biological agent shall comply with all safeguards contained in 42 CFR 73, 9 CFR 121, and 7 CFR 331 that apply to a person registered to transfer the same agent under federal law and regulation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.07" data-order="|10|10|11|.07|" data-ref-path="10|10|11|.07" class="h__section">.07 Responsibilities of the Department.</h3>
                <p>The Department shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#A">A.</span> Establish and maintain a registry that identifies the biological agents possessed, maintained, transferred, and received by a person in this State;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#B">B.</span> Conduct facility surveys by mail, by on-site visit, or both, initially and periodically after that, to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#B(1)">(1)</span> Ensure compliance with the standards and requirements of the BAR Program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#B(2)">(2)</span> Address any deficiencies or complaints;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#C">C.</span> Provide or approve the forms that a person shall complete and submit to the Department under the BAR Program;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#D">D.</span> Issue notice when a survey of a facility yields findings of deficiencies related to the standards or requirements of the BAR Program;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#E">E.</span> Investigate a complaint that a facility or an employee is not complying with the standards or requirements of the BAR Program; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#F">F.</span> Release BAR information, as provided in this chapter, to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#F(1)">(1)</span> State and federal law enforcement agencies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#F(2)">(2)</span> CDC;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#F(3)">(3)</span> Trusted partners; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.07#F(4)">(4)</span> The Secretary or designee.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.08" data-order="|10|10|11|.08|" data-ref-path="10|10|11|.08" class="h__section">.08 Responsible Official; Alternate Responsible Official.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#A">A.</span> A person required to report to the BAR Program under this chapter shall designate an individual to be the responsible official who:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#A(1)">(1)</span> Is familiar with the requirements of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#A(2)">(2)</span> Has the authority and responsibility to act on the person's behalf related to a biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#A(3)">(3)</span> Shall ensure compliance with the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#B">B.</span> The responsible person shall ensure that the annual inspection and specific reporting requirements and mechanisms are carried out in accordance with 42 CFR §73.9.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#C">C.</span> A person required to report to the BAR Program under this chapter shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#C(1)">(1)</span> Designate one or more individuals to be an alternate responsible official to act in the responsible official's absence; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.08#C(2)">(2)</span> Ensure that the individual designated as an alternate responsible official has the authority required in <a class="internal-link " href="/us/md/exec/comar/10.10.11.08#A" title="">§A of this regulation</a> to ensure compliance with this chapter when acting in the responsible official's absence.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.09" data-order="|10|10|11|.09|" data-ref-path="10|10|11|.09" class="h__section">.09 Reporting Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A">A.</span> What to Report. Using reporting forms provided or approved by the Department, a person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)">(1)</span> Identify all non-exempt biological agents that the person possesses, maintains, transfers, or receives listed under:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(a)">(a)</span> Select agents and toxins in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(a)(i)">(i)</span> 42 CFR §73.3;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(a)(ii)">(ii)</span> 9 CFR §121.3; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(a)(iii)">(iii)</span> 7 CFR §331.3; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(b)">(b)</span> Overlap select agents and toxins in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(b)(i)">(i)</span> 42 CFR §73.4; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(1)(b)(ii)">(ii)</span> 9 CFR §121.4;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)">(2)</span> Indicate as part of the identification if a biological agent is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(a)">(a)</span> Viable or nonviable;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(b)">(b)</span> Purified genomic material;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(c)">(c)</span> Recombinant DNA;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(d)">(d)</span> Used in small or large animal work;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(e)">(e)</span> Used in large-scale production; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(2)(f)">(f)</span> A toxin;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(3)">(3)</span> Identify the physical location of a laboratory and storage area within a facility where a biological agent is contained;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(4)">(4)</span> Identify the biosafety level required for the biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#A(5)">(5)</span> Identify the individual in charge of the biological agent and information needed to contact that individual.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#B">B.</span> When to Report. A person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#B(1)">(1)</span> Complete and submit a report within 30 days of receiving a request to report from the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#B(2)">(2)</span> Submit a report of each transfer and receipt of a biological agent within 24 hours of completing a transfer as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.11.10#D" title="">Regulation .10D of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#B(3)">(3)</span> Respond in writing to a deficiency notice from the Department within 10 work days of receiving the notice; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#B(4)">(4)</span> Respond in writing to notice of a complaint within 10 work days of receiving notice from the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#C">C.</span> Who Submits Reports. A person shall submit a report dated and signed by the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#C(1)">(1)</span> Individual who actually possesses, maintains, transfers, or receives and has charge of a biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#C(2)">(2)</span> Responsible official of the facility where the biological agent is located.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.09#D">D.</span> Where to Report. A person shall return all completed reports and other correspondence to the BAR Program, c/o Laboratories Administration, Maryland Department of Health.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.10" data-order="|10|10|11|.10|" data-ref-path="10|10|11|.10" class="h__section">.10 Additional Requirements Covering Possession, Maintenance, Transfer, or Receipt of a Biological Agent.</h3>
                <p>A person possessing, maintaining, transferring, or receiving a biological agent at a facility located in the State shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#A">A.</span> Possess a laboratory and personnel equipped and capable of handling the biological agents at BSL 2, 3, or 4, depending on the agent and the type of work being performed with the agent, as contained in the BMBL;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#B">B.</span> Meet specific requirements for handling a toxin subject to this chapter as set forth in 29 CFR §1910.1450;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C">C.</span> Allow an official representative of the Department to determine compliance with the standards and requirements of this chapter by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C(1)">(1)</span> Conducting an on-site inspection of the person's facility, including all:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C(1)(a)">(a)</span> Storage areas;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C(1)(b)">(b)</span> Laboratories; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C(1)(c)">(c)</span> Operations; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#C(2)">(2)</span> Examining and reviewing procedures and documentation related to biological agents;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#D">D.</span> Submit a copy of each completed CDC form documenting transfer or receipt of a biological agent, within 24 hours of completing a transfer or receipt, to the BAR Program; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.10#E">E.</span> Inform the Emergency Management Director or designee and health officer or designee in the local jurisdiction where the biological agent is located of the nature and facility location of each reported biological agent that is located in that jurisdiction.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.11" data-order="|10|10|11|.11|" data-ref-path="10|10|11|.11" class="h__section">.11 Reporting of Unauthorized Activities.</h3>
                <p>On learning that there is an unauthorized activity involving a biological agent, including the unauthorized possession, unauthorized attempted possession, unauthorized maintenance, unauthorized transfer, or unauthorized receipt of a biological agent, a person shall immediately alert the Department by:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#A">A.</span> Telephoning the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#A(1)">(1)</span> Laboratories Administration at 443-681-3787 or 410-925-3121 between 8 a.m. and 4:30 p.m. weekdays; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#A(2)">(2)</span> Department's emergency after-hours and weekend telephone line at 410-795-7365 at other times;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#B">B.</span> Asking the individual taking the call to direct the information being reported to the BAR Program or the Director of the Laboratories Administration; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#C">C.</span> Reporting details about the unauthorized activity set forth in this regulation, such as:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#C(1)">(1)</span> The location of a facility and laboratory involved;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#C(2)">(2)</span> The identity of a person possessing or attempting to possess a biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.11#C(3)">(3)</span> Other details pertinent to the report.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.12" data-order="|10|10|11|.12|" data-ref-path="10|10|11|.12" class="h__section">.12 Biological Agent Incident Response Plan.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A">A.</span> Requirement. A person required to report under this chapter shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A(1)">(1)</span> Develop, implement, and maintain a written biological agent incident response plan;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A(2)">(2)</span> Review the plan annually and revise the plan as necessary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A(3)">(3)</span> Submit a copy of the plan and any amendments to the plan to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A(3)(a)">(a)</span> Emergency management director in the local jurisdiction where the biological agent is located; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#A(3)(b)">(b)</span> BAR Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B">B.</span> A person required to submit a biological agent incident response plan shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(1)">(1)</span> Coordinate the biological agent incident response plan with any facility-wide plans;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(2)">(2)</span> Keep the biological agent incident response plan current to reflect actual procedures and practices;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(3)">(3)</span> Locate and maintain the biological agent incident response plan in the workplace;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(4)">(4)</span> Make the biological agent incident response plan available to employees;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)">(5)</span> Ensure that the biological agent incident response plan fully describes the response procedures for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(a)">(a)</span> The theft, loss, or release of a biological agent;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(b)">(b)</span> Inventory discrepancies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(c)">(c)</span> Security breaches, including in computer information systems;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(d)">(d)</span> Severe weather and other natural disasters;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(e)">(e)</span> Workplace violence;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(f)">(f)</span> Bomb threats;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(g)">(g)</span> Suspicious packages;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(h)">(h)</span> Emergencies such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(h)(i)">(i)</span> Fire;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(h)(ii)">(ii)</span> Gas leaks;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(h)(iii)">(iii)</span> Explosions; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(h)(iv)">(iv)</span> Power outages;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(i)">(i)</span> Use of PPE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(j)">(j)</span> Use of onsite emergency equipment to protect both the facility and personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(k)">(k)</span> Employees to follow when performing:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(k)(i)">(i)</span> Rescue or medical duties;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(k)(ii)">(ii)</span> Emergency medical treatment; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(k)(iii)">(iii)</span> First aid;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(l)">(l)</span> Emergency evacuation, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(l)(i)">(i)</span> Type of evacuation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(l)(ii)">(ii)</span> Exit route assignments;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(l)(iii)">(iii)</span> Safe distances; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(l)(iv)">(iv)</span> Places of refuge;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(m)">(m)</span> Decontamination; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(5)(n)">(n)</span> Site security and control;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(6)">(6)</span> Ensure that the plan includes procedures that explain the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(6)(a)">(a)</span> Risks and hazards associated with any biological agent on the premises; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(6)(b)">(b)</span> Actions to contain the biological agent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)">(7)</span> Ensure that the plan contains the following information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(a)">(a)</span> The name and contact information for home, work, and emergencies, for the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(a)(i)">(i)</span> Responsible official; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(a)(ii)">(ii)</span> Alternate responsible official;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(b)">(b)</span> Where applicable, the name and contact information for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(b)(i)">(i)</span> The building owner and manager;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(b)(ii)">(ii)</span> Tenants; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(b)(iii)">(iii)</span> The official in charge of the building's physical security;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(c)">(c)</span> Personnel roles and lines of authority and communication;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(d)">(d)</span> Planning and coordination with local emergency responders; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(7)(e)">(e)</span> A list of the PPE available and where the PPE is located in the facility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(8)">(8)</span> Conduct drills or exercises at least annually to test and evaluate the effectiveness of the plan;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(9)">(9)</span> Notify the Emergency Management Director in the local jurisdiction where the biological agent is located and the BAR Program before a drill or exercise is conducted;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(10)">(10)</span> Notify the Emergency Management Director and the health officer in the local jurisdiction where the biological agent is located and the BAR Program immediately following a biological agent incident involving exposure or potential exposure as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.06.01.03#A" title="">COMAR 10.06.01.03A</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(11)">(11)</span> Prepare a report of the results of a drill, exercise, or biological agent incident;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(12)">(12)</span> Review a report of the results of a drill, exercise, or biological incident to determine if the plan requires revision; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(13)">(13)</span> Within 10 days after a drill, exercise, or biological agent incident, submit a copy of the report to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(13)(a)">(a)</span> Emergency management director in the local jurisdiction where the biological agent is located; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#B(13)(b)">(b)</span> BAR Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.12#C">C.</span> Monitoring Compliance. When a person submits a biological agent incident response plan to the BAR Program, the BAR Program shall verify that the person submitting the plan has provided the information for planning and coordinating with local emergency responders to the Emergency Management Director in the local jurisdiction where the biological agent is located.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.13" data-order="|10|10|11|.13|" data-ref-path="10|10|11|.13" class="h__section">.13 BAR Information Confidentiality and Release of BAR Information.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#A">A.</span> Except as otherwise provided in this chapter, a person shall keep information prepared for or maintained in the BAR, including biological agent incident response plans required by <a class="internal-link " href="/us/md/exec/comar/10.10.11.12" title=".12 Biological Agent Incident Response Plan.">Regulation .12 of this chapter</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#A(1)">(1)</span> Confidential; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#A(2)">(2)</span> Protected from unauthorized access and use.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#B">B.</span> BAR information is not subject to <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gsg/gsg.pdf" title="">State Government Article, Title 10, Subtitle 6, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#C">C.</span> Release or sharing of BAR information as authorized in this chapter does not render the BAR information released or shared a public record.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#D">D.</span> Except as provided in §§G—I of this regulation, a person to whom BAR information has been released may not release the information to another person unless the release is approved by the BAR Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E">E.</span> The BAR Program may release BAR information only to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E(1)">(1)</span> State and federal law enforcement agencies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E(2)">(2)</span> CDC;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E(3)">(3)</span> BAR information custodians of trusted partners;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E(4)">(4)</span> The Secretary or designee; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#E(5)">(5)</span> The health officer of any affected jurisdiction.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#F">F.</span> Before the BAR Program releases BAR information to a person, except State and federal law enforcement agencies, the CDC, and the Department, the person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#F(1)">(1)</span> Enter into and maintain a trusted partner agreement;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#F(2)">(2)</span> Conduct a BAR information security self-assessment; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#F(3)">(3)</span> Submit the results of a BAR information security self-assessment to the BAR Program for approval.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#G">G.</span> Mutual Aid Response. When multiple local jurisdictions respond to an emergency or biological agent incident, the Emergency Management Director of one responding jurisdiction may share BAR information with an Emergency Management Director from another local jurisdiction, and the health officer of one jurisdiction may share BAR information with the health officer of another jurisdiction that is providing mutual aid by assisting with the emergency response.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H">H.</span> Emergency Release Activation Process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(1)">(1)</span> A trusted partner may release on an emergency basis BAR information about the nature and location of a biological agent to another trusted partner or emergency public safety personnel when:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(1)(a)">(a)</span> An on-site alarm goes off at a person's facility where a biological agent is located and an individual at the site is required to place a telephone call to a 9-1-1 center;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(1)(b)">(b)</span> A 9-1-1 center dispatches emergency public safety personnel to a site where a biological agent is known to be located; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(1)(c)">(c)</span> There is a reported breach of containment or imminent threat of a breach of containment of a biological agent that poses an immediate threat to the health and safety of the public or emergency public safety first responders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(2)">(2)</span> MIEMSS may release on an emergency basis the nature and location of a biological agent to a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(2)(a)">(a)</span> Police officer, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gps&amp;section=3-201" title="">Public Safety Article, §3-201(e), Annotated Code of Maryland</a>, who is responding to an emergency; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#H(2)(b)">(b)</span> Fire, rescue, or emergency medical services entity, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gps&amp;section=7-101" title="">Public Safety Article, §7-101, Annotated Code of Maryland</a>, when responding to an emergency.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#I">I.</span> 24/7 Access to BAR Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#I(1)">(1)</span> MDE, MEMA, and MIEMSS may act as a back-up to the BAR Program by maintaining:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#I(1)(a)">(a)</span> 24/7 (24 hours a day, 7 days a week) access to BAR information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#I(1)(b)">(b)</span> Access to BAR information when a trusted partner does not have access to BAR information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#I(2)">(2)</span> MDE, MEMA, or MIEMSS may release BAR information regarding the nature and location of a biological agent to each other or another BAR Program trusted partner if the trusted partner is unable to obtain access to BAR information.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J">J.</span> Emergency Release of Name or Identity of a Biological Agent. MDE, MEMA, or MIEMSS may release by any necessary means of communication the name or identity of the specific biological agent located at the site of an emergency response to protect the health and safety of the public and emergency response personnel if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(1)">(1)</span> There is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(1)(a)">(a)</span> A breach in containment of a biological agent;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(1)(b)">(b)</span> An imminent threat of a breach of containment; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(1)(c)">(c)</span> An exposure or potential exposure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(2)">(2)</span> The breach or imminent threat of a breach, exposure, or potential exposure is confirmed by the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(2)(a)">(a)</span> Responsible official; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(2)(b)">(b)</span> Emergency public safety personnel at the scene of the emergency response;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(2)(c)">(c)</span> Occupational Health; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#J(3)">(3)</span> The release is approved by the Department's physician on-call.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#K">K.</span> Departmental Authorization to Release Name or Identity of Biological Agent.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#K(1)">(1)</span> The Department's physician on-call may release the name or identity of a biological agent as required to mitigate the risk and treat those exposed based on the potential threat to the health and safety of the public.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#K(2)">(2)</span> The Department's physician on-call shall decide when, how, and to whom to release the name or identity of the biological agent.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L">L.</span> Notification Protocol.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)">(1)</span> When there is a breach or imminent threat of a breach in containment of a biological agent, exposure, or potential exposure as described in <a class="internal-link " href="/us/md/exec/comar/10.10.11.13#J" title="">§J of this regulation</a>, the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)(a)">(a)</span> Responsible official or other designated person shall immediately notify the Emergency Management Director and health officer of any affected jurisdiction;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)(b)">(b)</span> Public safety personnel responding to an emergency shall contact the public safety personnel's 9-1-1 center; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)(c)">(c)</span> 9-1-1 center personnel shall notify MIEMSS and each of the following individuals in the jurisdiction where the breach, exposure, or potential exposure occurred:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)(c)(i)">(i)</span> The Emergency Management Director; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(1)(c)(ii)">(ii)</span> The health officer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)">(2)</span> When MIEMSS receives notice of a breach or an imminent threat of a breach of containment of a biological agent, exposure, or potential exposure, MIEMSS shall notify:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(a)">(a)</span> The Department's:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(a)(i)">(i)</span> Physician on-call; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(a)(ii)">(ii)</span> BAR Program within the Office of Laboratory Emergency Preparedness and Response;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(b)">(b)</span> MDE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(c)">(c)</span> MEMA;and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(2)(d)">(d)</span> The health officer of any affected jurisdiction.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(3)">(3)</span> Immediately after the health officer is notified by 9-1-1 center personnel, the health officer shall contact the Department’s physician on-call to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(3)(a)">(a)</span> Verify the BAR information release; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(3)(b)">(b)</span> Confirm a plan of action regarding:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(3)(b)(i)">(i)</span> Release of BAR information; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#L(3)(b)(ii)">(ii)</span> Measures to be taken to protect the health and safety of the public.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#M">M.</span> Using a form provided by the BAR Program, a trusted partner shall notify the BAR Program within 72 hours after the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#M(1)">(1)</span> Trusted partner's BAR information custodian releases or shares BAR information; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.13#M(2)">(2)</span> Trusted partner releases or shares BAR information with another trusted partner.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.14" data-order="|10|10|11|.14|" data-ref-path="10|10|11|.14" class="h__section">.14 Method of Non-Emergency Release of BAR Information.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A">A.</span> A person shall release and transfer BAR information to a trusted partner and a BAR information custodian in a secure manner, which includes the use of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(1)">(1)</span> Read-only optical or electronic media;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(2)">(2)</span> Encryption, decryption, passwords, and firewalls;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(3)">(3)</span> Copy protection to prevent unauthorized copying or duplication.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(4)">(4)</span> A telephone;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(5)">(5)</span> Voice mail;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(6)">(6)</span> An electronic or mechanical recording device; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#A(7)">(7)</span> An internet communication system, such as voice-over-internet-protocol (VoIP).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#B">B.</span> The BAR Program shall release BAR information to a BAR information custodian of a local jurisdiction, MDE, MEMA, and MIEMSS:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#B(1)">(1)</span> When notified by the BAR Program that the BAR information is available for release; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#B(2)">(2)</span> On weekdays between the hours of 8:30 a.m. and 3:30 p.m.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C">C.</span> BAR Program staff shall document the release of all BAR information to trusted partners in a permanent record that contains the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(1)">(1)</span> Name of the BAR information custodian;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(2)">(2)</span> Identity of the trusted partner;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(3)">(3)</span> Means of release of BAR information, including but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(3)(a)">(a)</span> Encrypted email; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(3)(b)">(b)</span> CD-R; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.14#C(4)">(4)</span> Date and time of the release or delivery of the BAR information.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.15" data-order="|10|10|11|.15|" data-ref-path="10|10|11|.15" class="h__section">.15 Release of BAR Information to Law Enforcement Agencies and CDC.</h3>
                <p>The BAR Program may release BAR information to State and federal law enforcement agencies and the CDC without a trusted partner agreement if the release of BAR information is pursuant to:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.15#A">A.</span> A communicable disease investigation commenced or conducted by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.15#A(1)">(1)</span> The Department; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.15#A(2)">(2)</span> A State or federal law enforcement agency having investigative authority; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.15#B">B.</span> An investigation involving a release, theft, or loss of a biological agent.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.16" data-order="|10|10|11|.16|" data-ref-path="10|10|11|.16" class="h__section">.16 Release of BAR Information to Local Jurisdictions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#A">A.</span> The Department shall release to a local jurisdiction the BAR information listed in <a class="internal-link " href="/us/md/exec/comar/10.10.11.16#C" title="">§C of this regulation</a> for each biological agent located within the local jurisdiction, if the local jurisdiction:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#A(1)">(1)</span> Enters into and maintains a trusted partner agreement with the Department; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#A(2)">(2)</span> Limits the number of BAR information custodians in the local jurisdiction to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#A(2)(a)">(a)</span> Health officer or the health officer’s designee; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#A(2)(b)">(b)</span> Emergency management director or the emergency management director’s designee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B">B.</span> The local jurisdiction may use the BAR information for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)">(1)</span> Protecting emergency first-responders, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(a)">(a)</span> Fire fighters;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(b)">(b)</span> Police officers; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(c)">(c)</span> Emergency employees, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(c)(i)">(i)</span> Emergency medical personnel;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(c)(ii)">(ii)</span> Rescue workers; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(1)(c)(iii)">(iii)</span> Public health emergency responders;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(2)">(2)</span> Planning for emergency protection of the public related to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(2)(a)">(a)</span> Release of a biological agent; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(2)(b)">(b)</span> Prevention of a release of a biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#B(3)">(3)</span> Conducting investigations related to biological agents.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C">C.</span> Information Released. The BAR Program shall inform the BAR information custodian in the local jurisdiction of the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C(1)">(1)</span> Location in the local jurisdiction of the biological agent, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C(1)(a)">(a)</span> Facility or entity name; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C(1)(b)">(b)</span> Physical address of the facility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C(2)">(2)</span> Nature of each biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.16#C(3)">(3)</span> The BSL or PPE necessary to protect emergency responders from contact with or transmission of the biological agent.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.17" data-order="|10|10|11|.17|" data-ref-path="10|10|11|.17" class="h__section">.17 Release of BAR Information to MDE, MEMA, and MIEMSS.</h3>
                <p>The Department shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#A">A.</span> Release separately to the BAR information custodians of MDE, MEMA, and MIEMSS the BAR information listed in <a class="internal-link " href="/us/md/exec/comar/10.10.11.17#C" title="">§C of this regulation</a> for each biological agent located within the State, if MDE, MEMA, and MIEMSS each separately becomes a trusted partner by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#A(1)">(1)</span> Entering and maintaining a trusted partner agreement with the Department; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#A(2)">(2)</span> Authorizing and identifying the individual who is the designated BAR information custodian in the trusted partner agreement;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B">B.</span> Make BAR information available to MDE, MEMA, and MIEMSS for the purpose of planning for the protection of the public related to the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(1)">(1)</span> Release of a biological agent, such as a breach in containment;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(2)">(2)</span> Prevention of a release of a biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(3)">(3)</span> Mitigation and planning for the protection of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(3)(a)">(a)</span> Critical infrastructure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(3)(b)">(b)</span> Key assets; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#B(3)(c)">(c)</span> Emergency public safety personnel; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C">C.</span> Provide the following BAR information of each biological agent in the State that is registered under this chapter to the BAR information custodian of MDE, MEMA, and MIEMSS, including for the entity that possesses, maintains, transfers, or receives a biological agent:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(1)">(1)</span> Name and contact information of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(1)(a)">(a)</span> The responsible official;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(1)(b)">(b)</span> The alternate responsible official; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(1)(c)">(c)</span> Other personnel or staff listed by the facility who are responsible for a biological agent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(2)">(2)</span> Location of the biological agent, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(2)(a)">(a)</span> Facility or entity name; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(2)(b)">(b)</span> Physical address of the facility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(3)">(3)</span> Name or identity of each biological agent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(4)">(4)</span> Nature of each biological agent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(5)">(5)</span> BSL necessary to handle safely and contain the biological agent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.17#C(6)">(6)</span> PPE necessary to protect emergency responders from contact with or transmission of the biological agent.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.18" data-order="|10|10|11|.18|" data-ref-path="10|10|11|.18" class="h__section">.18 BAR Information Updates.</h3>
                <p>The Department shall provide updated BAR information to the BAR information custodians of all trusted partners authorized under this chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A">A.</span> Within 30 days when there is an:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A(1)">(1)</span> Upward change in the BSL at a listed person's facility, for example from BSL-3 to BSL-4; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A(2)">(2)</span> Addition to the BAR, including a new:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A(2)(a)">(a)</span> Person possessing or maintaining a biological agent;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A(2)(b)">(b)</span> Facility where a biological agent is located; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#A(2)(c)">(c)</span> Biological agent; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.18#B">B.</span> At least once each year.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.19" data-order="|10|10|11|.19|" data-ref-path="10|10|11|.19" class="h__section">.19 BAR Information Security Standards — General.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#A">A.</span> A trusted partner shall protect and maintain BAR information in a secure manner by limiting access only to a BAR information custodian who is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#A(1)">(1)</span> An individual designated by the trusted partner; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#A(2)">(2)</span> Authorized by the Department in a trusted partner agreement.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B">B.</span> Before the Department shares BAR information with a trusted partner, the trusted partner shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(1)">(1)</span> Develop, implement, and maintain administrative, physical, and technical security measures and practices to protect and safeguard the integrity, confidentiality, and availability of BAR information by managing and supervising the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(1)(a)">(a)</span> Selection, execution, and use of security measures to protect BAR information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(1)(b)">(b)</span> Conduct of personnel in relation to the protection of BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(2)">(2)</span> Assess potential risks and vulnerabilities to the BAR information in its possession using a BAR information security self-assessment checklist provided by the BAR Program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(3)">(3)</span> Submit a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(3)(a)">(a)</span> Completed BAR information security self-assessment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#B(3)(b)">(b)</span> Document verifying that the trusted partner's BAR information custodian has successfully undergone a security risk assessment as described in 42 CFR §73.7.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#C">C.</span> If a BAR information custodian believes that the security of BAR information has been or is suspected to have been misused, mishandled, lost, stolen, or otherwise compromised, the BAR information custodian shall immediately notify the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#C(1)">(1)</span> BAR Program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.19#C(2)">(2)</span> Individuals who signed the BAR information custodian's trusted partner agreement.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.20" data-order="|10|10|11|.20|" data-ref-path="10|10|11|.20" class="h__section">.20 BAR Information Security Standards — Administrative Procedures.</h3>
                <p>A trusted partner shall establish and maintain administrative procedures to protect BAR information integrity, confidentiality, and availability, which include:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#A">A.</span> Entering and maintaining with the Department a trusted partner agreement that certifies that the trusted partner shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#A(1)">(1)</span> Establish and implement the policies and procedures to carry out the requirements of this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#A(2)">(2)</span> Designate a BAR information custodian;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B">B.</span> Establishing and implementing a contingency plan for protecting confidentiality of and access to BAR information when responding to a disaster or computer information system emergency, which includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(1)">(1)</span> Preparing critical facilities that can be used to facilitate continuing protection of BAR information in the event of an emergency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(2)">(2)</span> Disaster recovery procedures to follow in the event of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(2)(a)">(a)</span> Fire;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(2)(b)">(b)</span> Vandalism;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(2)(c)">(c)</span> Natural disaster; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(2)(d)">(d)</span> Computer information system failure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(3)">(3)</span> An emergency mode operation plan that includes procedures for assuring continuing protection of BAR information when the trusted partner continues to operate in the event of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(3)(a)">(a)</span> Fire;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(3)(b)">(b)</span> Vandalism;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(3)(c)">(c)</span> Natural disaster; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(3)(d)">(d)</span> Computer information system failure; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(4)">(4)</span> Testing and revising procedures that document the process of periodically testing the written contingency plan procedures to determine:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(4)(a)">(a)</span> Weaknesses; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#B(4)(b)">(b)</span> The subsequent process of revising the procedures, if necessary;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#C">C.</span> A mechanism for the receipt, viewing, manipulation, storage, release, dissemination, and disposal of BAR information;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#D">D.</span> Information-use policies that ensure that BAR information is used only as specified in this chapter;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E">E.</span> Internal audit procedures for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(1)">(1)</span> Maintaining records of computer information system activity including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(1)(a)">(a)</span> Logons;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(1)(b)">(b)</span> File accesses; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(1)(c)">(c)</span> Security incidents; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(2)">(2)</span> Reviewing the records of computer information system activity for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(2)(a)">(a)</span> Breaches in security; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#E(2)(b)">(b)</span> Unauthorized access;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F">F.</span> Personnel security procedures that ensure that only personnel who have the required authorizations and agency clearances have access to BAR information by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(1)">(1)</span> Providing oversight of unauthorized personnel when the personnel are performing their duties near BAR information, which includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(1)(a)">(a)</span> Supervision of maintenance personnel by an authorized and knowledgeable individual; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(1)(b)">(b)</span> Assuring that unauthorized or unsupervised operating and maintenance personnel do not have and cannot acquire access to BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(2)">(2)</span> Maintaining and reviewing a record of access authorizations that documents the levels of access granted to an individual accessing BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(3)">(3)</span> Establishing personnel clearance procedures as a protective measure applied to determine that an individual's access to BAR information is permissible; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#F(4)">(4)</span> Ensuring that BAR information computer information system users, including maintenance personnel, receive security awareness training;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G">G.</span> Employee termination procedures for ending an employee's employment or a user's access to BAR information, which includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(1)">(1)</span> Changing locks, lock combinations, or keypad codes when personnel knowledgeable of locks, lock combinations, or keypad codes no longer need to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(1)(a)">(a)</span> Know the information; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(1)(b)">(b)</span> Access BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(2)">(2)</span> Removal from access lists, including physical eradication of an individual's access privileges;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(3)">(3)</span> Termination or deletion of an individual's access privileges to BAR information for which the individual currently has authorization and need-to-know access when the authorization and need-to-know access no longer exists; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(4)">(4)</span> Returning to the trusted partner any access devices, such as:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(4)(a)">(a)</span> Keys;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(4)(b)">(b)</span> Tokens;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(4)(c)">(c)</span> Badges; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#G(4)(d)">(d)</span> Cards; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H">H.</span> Training for all personnel concerning the vulnerabilities of the BAR information and ways to ensure the protection of BAR information, which include:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(1)">(1)</span> Awareness training including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(1)(a)">(a)</span> Password maintenance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(1)(b)">(b)</span> Security incident reporting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(1)(c)">(c)</span> Viruses and other forms of malicious software;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(2)">(2)</span> Periodic security reminders of security concerns; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)">(3)</span> User education in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(a)">(a)</span> What to do if a virus is detected;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(b)">(b)</span> Monitoring logon success or failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(c)">(c)</span> How to report discrepancies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(d)">(d)</span> Password management, including the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(d)(i)">(i)</span> Rules to be followed in creating and changing passwords; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.20#H(3)(d)(ii)">(ii)</span> Need to keep passwords confidential.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.21" data-order="|10|10|11|.21|" data-ref-path="10|10|11|.21" class="h__section">.21 BAR Information Security — Physical Safeguards.</h3>
                <p>A trusted partner shall establish physical safeguards to guard BAR information integrity, confidentiality, and availability, which include:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#A">A.</span> Physical protection of the personal computer system used for viewing BAR information and related buildings and equipment from:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#A(1)">(1)</span> Fire;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#A(2)">(2)</span> Natural and environmental hazards;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#A(3)">(3)</span> Disasters; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#A(4)">(4)</span> Intrusion;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B">B.</span> A secure work station location with physical safeguards to eliminate or minimize the possibility of unauthorized access to BAR information, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(1)">(1)</span> Locating a personal computer used to access and view BAR information in a locked room;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(2)">(2)</span> Restricting access to the locked room to authorized personnel by using:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(2)(a)">(a)</span> Electronic keypads;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(2)(b)">(b)</span> Electronic access badges; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(2)(c)">(c)</span> Door locks;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(3)">(3)</span> Placing the computer monitor in a way that screen contents are not viewable by an unauthorized person;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(4)">(4)</span> Locking file cabinets, desks, and desk drawers that contain BAR information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(4)(a)">(a)</span> During nonworking hours; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(4)(b)">(b)</span> When the BAR information custodian is not present in the immediate area; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#B(5)">(5)</span> Making BAR information nonviewable or unobtainable before admitting an unauthorized person into the workspace;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C">C.</span> BAR information media control procedures that govern the receipt, removal, and disposal of BAR information CD-R discs or thumb drives into or out of the facility, which include:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(1)">(1)</span> Access control so that only the BAR information custodian can receive the BAR information media;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(2)">(2)</span> Accountability procedures that trace the receipt, removal, and disposal of BAR information media;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(3)">(3)</span> BAR information storage; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(4)">(4)</span> Tracking the disposal process and the final disposition of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(4)(a)">(a)</span> Electronic BAR information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#C(4)(b)">(b)</span> BAR information hardware on which electronic BAR information is stored;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#D">D.</span> Emergency mode operation access controls that enable continuing protection to BAR information in the event of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#D(1)">(1)</span> Fire;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#D(2)">(2)</span> Vandalism;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#D(3)">(3)</span> Natural disaster; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#D(4)">(4)</span> BAR information computer information system failure;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#E">E.</span> A facility security plan to safeguard BAR information on the premises from unauthorized physical access, tampering, and theft;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#F">F.</span> Verifying access authorizations before granting physical access;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#G">G.</span> Maintaining documentation of repairs and modifications to the physical components of the facility including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#G(1)">(1)</span> Hardware;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#G(2)">(2)</span> Walls;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#G(3)">(3)</span> Doors; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#G(4)">(4)</span> Locks; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#H">H.</span> Procedures governing the reception and hosting of visitors, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#H(1)">(1)</span> Sign-in logs for visitors; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.21#H(2)">(2)</span> Providing escorts for visitors, if appropriate.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.22" data-order="|10|10|11|.22|" data-ref-path="10|10|11|.22" class="h__section">.22 BAR Information Security — Technical Security Measures.</h3>
                <p>A trusted partner shall establish a system of technical security measures to protect BAR information integrity, confidentiality, and availability, which include:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A">A.</span> A BAR information security assessment to determine the sensitivity, vulnerabilities, and security of the trusted partner's programs and operations related to the BAR information the trusted partner:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A(1)">(1)</span> Receives;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A(2)">(2)</span> Views;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A(3)">(3)</span> Manipulates;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A(4)">(4)</span> Stores; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#A(5)">(5)</span> Transmits;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#B">B.</span> An information system certification based on a technical evaluation as part of and in support of the security process, which establishes the extent to which the trusted partner's computer system used for BAR information meets the security requirements of this chapter;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C">C.</span> Establishing and utilizing procedures and processes to guard against unauthorized access to BAR information by using:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(1)">(1)</span> Access controls that include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(1)(a)">(a)</span> Emergency role-based access of BAR information that documents the instructions for obtaining BAR information during a crisis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(1)(b)">(b)</span> User-based access; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(1)(c)">(c)</span> The use of encryption and decryption;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(2)">(2)</span> An alarm that can sense an unauthorized access within the computer system and produce a signaled response such as a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(2)(a)">(a)</span> System closure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(2)(b)">(b)</span> Time-phased automatic shutdown and restart cycle; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(2)(c)">(c)</span> Screen indicating a multiple password failure lockout;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(3)">(3)</span> Audit controls that record and examine system activity;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(4)">(4)</span> Audit trails of the use of and access to BAR information collected and used to facilitate a security audit; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#C(5)">(5)</span> Event reporting that shows a screen message indicating an unauthorized request for BAR information access.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D">D.</span> Establishing procedures and processes for computer system authorization control for an individual to obtain access for the use and disclosure of BAR information, which include:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(1)">(1)</span> Role-based access;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(2)">(2)</span> User-based access;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(3)">(3)</span> BAR information authentication that corroborates that BAR information has not been altered or destroyed in an unauthorized manner by using a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(3)(a)">(a)</span> Message authentication code; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(3)(b)">(b)</span> Digital signature;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(4)">(4)</span> BAR information custodian authentication that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(4)(a)">(a)</span> Automatic logoff that causes an electronic session to terminate after a predetermined time of inactivity; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(4)(b)">(b)</span> A unique user identifier:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(4)(b)(i)">(i)</span> Made up of a combination alpha and numeric characters; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(4)(b)(ii)">(ii)</span> Maintained in security procedures for identifying and tracking individual user identity; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(5)">(5)</span> A logon mechanism using a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(5)(a)">(a)</span> Password;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(5)(b)">(b)</span> Personal identification number (PIN);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(5)(c)">(c)</span> Token; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#D(5)(d)">(d)</span> Any combination of §D(5)(a)—(c) of this regulation;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E">E.</span> A security configuration management plan that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(1)">(1)</span> A written security plan documenting the rules, procedures, and instructions concerning all components related to BAR information security;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(2)">(2)</span> Hardware and software installation and maintenance reviews;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(3)">(3)</span> Security testing to ensure that the selected security features are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(3)(a)">(a)</span> Implemented as designed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(3)(b)">(b)</span> Adequate for the operational environment; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#E(4)">(4)</span> Virus checking on a routine and regular basis;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#F">F.</span> Security incident procedures that describe how to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#F(1)">(1)</span> Report security incidents and breaches; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#F(2)">(2)</span> Respond to and take action as a result of the receipt of a security incident report; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.22#G">G.</span> Sanction policies and procedures describing the disciplinary actions and notice of possible civil or criminal penalties an individual may be subject to for misuse or misappropriation of BAR information.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.23" data-order="|10|10|11|.23|" data-ref-path="10|10|11|.23" class="h__section">.23 Trusted Partner Agreement.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#A">A.</span> Requirement. The Department may not share BAR information with a person until the person becomes a trusted partner by entering into a trusted partner agreement, using the form developed by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B">B.</span> The Department shall develop and use a trusted partner form that contains, as applicable, separate clauses that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(1)">(1)</span> Establish the length of time that the trusted partner agreement is in effect;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)">(2)</span> Address that confidentiality will survive the termination, expiration, or cancellation of the trusted partner agreement and state that the trusted partner:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(a)">(a)</span> May not use BAR information in a way that is detrimental to the Department;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(b)">(b)</span> Shall keep BAR information confidential;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(c)">(c)</span> Shall limit disclosure of BAR information only:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(c)(i)">(i)</span> To individuals with a legitimate need in performance of the individuals' duties; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(c)(ii)">(ii)</span> On a need-to-know basis as prescribed by this chapter; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(d)">(d)</span> Shall employ security policies that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(d)(i)">(i)</span> Protect the confidentiality of BAR information; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(2)(d)(ii)">(ii)</span> Prevent improper disclosures or access to BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(3)">(3)</span> Require the trusted partner to notify the Department whenever the trusted partner discloses BAR information as allowed by this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(4)">(4)</span> Warrant and represent that the trusted partner is in compliance with all applicable State and federal laws and regulations regarding BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(5)">(5)</span> Require the trusted partner to execute a trusted partner agreement that upholds the standards and requirements in the trusted partner agreement that the trusted partner has with the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)">(6)</span> Require the trusted partner to notify the Department when there is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(a)">(a)</span> An improper or unauthorized:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(a)(i)">(i)</span> Disclosure of BAR information; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(a)(ii)">(ii)</span> Access to BAR information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(b)">(b)</span> A misuse of BAR information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(c)">(c)</span> A computer information system compromise that affects BAR information; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(6)(d)">(d)</span> An authorized release of BAR information as set forth in this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(7)">(7)</span> Address corrective action by stating:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(7)(a)">(a)</span> The steps necessary to prevent any further unauthorized disclosure and misuse of BAR information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(7)(b)">(b)</span> That the trusted partner shall maintain an incident log of all unauthorized disclosures and misuse of BAR information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(7)(c)">(c)</span> That the trusted partner shall send a copy of incident log entries to the BAR Program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(8)">(8)</span> Require the trusted partner to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(8)(a)">(a)</span> Return the BAR information that was provided to the trusted partner; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(8)(b)">(b)</span> Exercise due diligence to destroy all material based on BAR information in a manner that renders nonidentifiable all documents, memoranda, notes, or other writings created or prepared by or for the trusted partner or BAR information custodian;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(9)">(9)</span> Require the trusted partner to make available on demand to the Department all policies and procedures relevant to safeguarding BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(10)">(10)</span> Address the authority of the individuals signing the trusted partner agreement that state that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(10)(a)">(a)</span> The individuals signing the trusted partner agreement have the right and authority to execute the agreement on behalf of their respective entity; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(10)(b)">(b)</span> No further approvals are necessary to make the trusted partner agreement binding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(11)">(11)</span> State that the trusted partner agreement is the entire agreement between the Department and the trusted partner;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(12)">(12)</span> State that the trusted partner agreement may not be amended, except as agreed to by the Department in writing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(13)">(13)</span> State that no provision or clause in the trusted partner agreement may be waived unless approved in writing by the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(14)">(14)</span> Identify the individual designated by the trusted partner and authorized by the Department to receive, maintain, and if provided by this chapter, release BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(15)">(15)</span> Attest that the BAR information custodian has the trusted partner's agency clearance to receive BAR information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(16)">(16)</span> Address a trusted partner's security policy that states the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(16)(a)">(a)</span> Value of BAR information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(16)(b)">(b)</span> Protection responsibilities; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(16)(c)">(c)</span> Organizational commitment for a system to protect the integrity, confidentiality, and availability of BAR information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.11.23#B(17)">(17)</span> State that if a provision, section, subsection, sentence, clause, or phrase of the trusted partner agreement is held invalid, the remaining portions of the trusted partner agreement remain valid.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.11.24" data-order="|10|10|11|.24|" data-ref-path="10|10|11|.24" class="h__section">.24 Penalties.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.24#A">A.</span> Fine. A person who violates a provision of Health-General Article, Title 17, Subtitle 6, Annotated Code of Maryland, or this chapter is guilty of a misdemeanor and on conviction is subject to a fine not exceeding $100 for the first offense and not exceeding $500 for each subsequent conviction for a violation of the same provision.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.11.24#B">B.</span> Subsequent Offense. Each day a violation is continued after the first conviction is a subsequent offense.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.12" data-order="|10|10|12|" data-ref-path="10|10|12" class="h__chapter">Chapter 12 Medical Laboratories — Public Health HIV Testing Programs</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.01" title=".01 Scope.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.10" title=".10 Confirmatory Test.">.10</a> adopted as an emergency provision effective January 19, 2005 (32:3 Md. R. 287); adopted permanently effective March 14, 2005 (32:5 Md. R. 580)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.01#A" title="">Regulation .01A</a>, B amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.02#B" title="">Regulation .02B</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.03" title=".03 Incorporation by Reference.">Regulation .03</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.04" title=".04 Public Health Testing License for Rapid HIV Antibody Testing and HCV Testing.">Regulation .04</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.04#E" title="">Regulation .04E</a> amended effective August 29, 2016 (43:17 Md. R. 953)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.06#D" title="">Regulation .06D</a>, E amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.07#B" title="">Regulation .07B</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.09" title=".09 Manufacturer's Requirements.">Regulation .09</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.12.10" title=".10 Confirmatory Test.">Regulation .10</a> amended effective April 1, 2013 (40:6 Md. R. 473)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, Annotated Code of Maryland</p>
                </section>
                <div class="table_wrap">
                  <table>
                    <tbody>
                      <tr>
                        <td data-vertical-align="middle">Regulation</td>
                        <td data-vertical-align="middle">Sections</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.01 Scope</td>
                        <td data-vertical-align="middle">17-202</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.02 Definitions</td>
                        <td data-vertical-align="middle">17-202</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.03 Incorporation by Reference</td>
                        <td data-vertical-align="middle">17-201, 17-202</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.04 Public Health Testing License, for Rapid<br/>      HIV Antibody Testing</td>
                        <td data-vertical-align="middle">17-202, 17-204, 17-205, 17-206, <br/>17-207, 17-208, 17-209, 17-210</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.05 Quality Assessment Plan and Quality <br/>      Control Requirements</td>
                        <td data-vertical-align="middle">17-202, 17-206</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.06 Personnel Training and Competency</td>
                        <td data-vertical-align="middle">17-202, 17-206</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.07 Standard Operating Procedures Manual</td>
                        <td data-vertical-align="middle">17-202</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.08 Public Health Testing Program Director</td>
                        <td data-vertical-align="middle">17-203, 17-206</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.09 Manufacturer's Requirements</td>
                        <td data-vertical-align="middle">17-202</td>
                      </tr>
                      <tr>
                        <td data-vertical-align="middle">.10 Confirmatory Test</td>
                        <td data-vertical-align="middle">17-202</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <h3 id="/us/md/exec/comar/10.10.12.01" data-order="|10|10|12|.01|" data-ref-path="10|10|12|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#A">A.</span> This chapter sets the standards and requirements for a person to obtain and maintain a public health testing license to operate a public health testing program to perform rapid HIV antibody testing and rapid hepatitis C virus testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#B">B.</span> This chapter applies to public health testing programs approved by the Secretary to conduct rapid HIV antibody testing and rapid hepatitis C virus testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#C">C.</span> This chapter does not apply to any other type of laboratory testing entity such as a:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#C(1)">(1)</span> Point-of-care laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#C(2)">(2)</span> Commercial reference laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#C(3)">(3)</span> Hospital; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.01#C(4)">(4)</span> Physician office laboratory.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.02" data-order="|10|10|12|.02|" data-ref-path="10|10|12|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(1)">(1)</span> "CDC" means the federal Centers for Disease Control and Prevention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(2)">(2)</span> "CLIA" means the federal Clinical Laboratory Improvement Amendments of 1988.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(3)">(3)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(4)">(4)</span> "Primary standard" means a general comprehensive standard or set of standards as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(5)">(5)</span> "Public health testing program" means a medical laboratory as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> that is affiliated or collaborating with the Department for the purpose of offering or performing rapid HIV antibody testing or rapid hepatitis C virus testing approved by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(6)">(6)</span> "Public health testing license" means a license as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> issued by the Secretary authorizing the director of a public health HIV or hepatitis C (HCV) testing program to offer or perform rapid HIV tests or rapid hepatitis C virus tests.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)">(7)</span> Quality Assessment Plan.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)(a)">(a)</span> "Quality assessment plan" means a planned system of step-by-step activities to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)(a)(i)">(i)</span> Testing is being carried out according to the manufacturer's instructions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)(a)(ii)">(ii)</span> Results are accurate and reliable; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)(a)(iii)">(iii)</span> Problems and mistakes are found and corrected to avoid adverse outcomes.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(7)(b)">(b)</span> "Quality assessment plan" includes the ongoing activities that monitor, review, evaluate, and improve the overall quality of the procedures and processes before, during, and after a test is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8)">(8)</span> Quality Control.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8)(a)">(a)</span> "Quality control" means the policies and procedures defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a> that monitor and evaluate the analytical or test performance phase of the testing process.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8)(b)">(b)</span> "Quality control" includes the operational techniques, tasks, or activities used to find and correct problems that might occur in the test system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8-1)">(8-1)</span> “Rapid hepatitis C virus test” means a public health hepatitis test that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8-1)(a)">(a)</span> Is a single-use test device as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8-1)(b)">(b)</span> Uses whole blood as the specimen to detect hepatitis C antibodies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8-1)(c)">(c)</span> Is waived under the CLIA program; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(8-1)(d)">(d)</span> Provides a test result while the individual being tested is waiting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(9)">(9)</span> "Rapid HIV antibody test" means a public health HIV test that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(9)(a)">(a)</span> Is a single-use test device as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(9)(b)">(b)</span> Uses whole blood or oral fluid as the specimen to detect HIV antibodies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(9)(c)">(c)</span> Is waived under the CLIA program; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(9)(d)">(d)</span> Provides a test result while the individual being tested is waiting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.02#B(10)">(10)</span> "Secretary" means the Secretary of Health.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.03" data-order="|10|10|12|.03|" data-ref-path="10|10|12|.03" class="h__section">.03 Incorporation by Reference.</h3>
                <p>In this chapter, the CDC “Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988 (2007)” is incorporated by reference.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.04" data-order="|10|10|12|.04|" data-ref-path="10|10|12|.04" class="h__section">.04 Public Health Testing License for Rapid HIV Antibody Testing and HCV Testing.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#A">A.</span> A person shall obtain a public health testing license before offering or performing rapid HIV antibody testing or rapid hepatitis C virus testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#B">B.</span> A person may not:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#B(1)">(1)</span> Offer or perform rapid HIV antibody testing or hepatitis C virus testing without obtaining a public health testing license issued under this chapter; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#B(2)">(2)</span> Transfer the public health testing license to another person.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#C">C.</span> The Secretary may issue a public health testing license under this chapter if the Secretary determines that the public health testing program meets the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D">D.</span> The Department shall issue a public health testing license that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(1)">(1)</span> Is valid for a period of not more than 2 years;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(2)">(2)</span> States that the license is limited to the performance of rapid HIV antibody testing and rapid hepatitis C virus testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(3)">(3)</span> Lists the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(3)(a)">(a)</span> Name of the director;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(3)(b)">(b)</span> Name of the public health testing program; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#D(3)(c)">(c)</span> Address of the public health testing program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E">E.</span> To obtain, maintain, or renew a public health testing license, a person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(1)">(1)</span> Make records and reports available to the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(2)">(2)</span> Possess a valid CLIA Certificate of Waiver from the U.S. Health and Human Services' Centers for Medicare and Medicaid Services;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(3)">(3)</span> Submit to the Department:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(3)(a)">(a)</span> When seeking an initial license or license renewal, a quality assessment plan that describes the testing activities;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(3)(b)">(b)</span> The location of all testing sites; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(3)(c)">(c)</span> The name and address of the laboratory that will perform confirmatory tests for the person operating the public health testing program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#E(4)">(4)</span> Submit amendments or changes to the public health testing program's quality assessment plan to the Department and obtain the Department's approval prior to implementation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F">F.</span> The Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F(1)">(1)</span> Review each submitted quality assessment plan to determine compliance with the requirements of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F(2)">(2)</span> Conduct on-site surveys of public health testing programs:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F(2)(a)">(a)</span> To investigate a complaint; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F(2)(b)">(b)</span> Periodically to determine compliance with this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#F(3)">(3)</span> Approve the plan for implementation by the public health testing program if the plan is in compliance with the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.04#G">G.</span> The Secretary may impose one or more sanctions as provided in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.01" title=".01 General.">COMAR 10.10.08.01</a>—.03 if the Secretary determines that the public health testing program does not meet the standards of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.05" data-order="|10|10|12|.05|" data-ref-path="10|10|12|.05" class="h__section">.05 Quality Assessment Plan and Quality Control Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#A">A.</span> Primary Standard. A person seeking or holding a public health testing license shall establish and maintain a quality assessment plan with written policies and procedures for monitoring and evaluating the operations and activities of the program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B">B.</span> Quality Assessment Plan Components. A person seeking or holding a public health testing license shall ensure that the quality assessment plan addresses the operations and activities that occur before, during, and after testing and include the following components:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)">(1)</span> Verifying, before performing a test; that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(a)">(a)</span> The testing process works as set forth in the manufacturer's test specifications and instructions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(b)">(b)</span> Personnel are trained and competent to perform assigned tasks;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(c)">(c)</span> Procedures and logistics are in place for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(c)(i)">(i)</span> Performing a confirmatory test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(c)(ii)">(ii)</span> Collecting a specimen for referral to a laboratory to perform a confirmatory test; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(c)(iii)">(iii)</span> Referring an individual to a health care provider to have a confirmatory test performed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(1)(d)">(d)</span> Biohazardous waste handling procedures are in place;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)">(2)</span> Troubleshooting procedures that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(a)">(a)</span> Detect and resolve a problem that occurs during the testing process;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(b)">(b)</span> Require communication of a problem immediately to the director or appropriate supervisory personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(c)">(c)</span> State when to discontinue testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(d)">(d)</span> Identify how to take corrective action in response to a problem; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(e)">(e)</span> State how to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(e)(i)">(i)</span> Document a problem and the actions taken; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(2)(e)(ii)">(ii)</span> Verify that a corrective action taken has addressed the problem;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)">(3)</span> Procedures and mechanisms to maintain records that document:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(a)">(a)</span> Personnel training and competency;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(b)">(b)</span> Specimen referral and transfer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(c)">(c)</span> Daily temperatures of the areas that will affect testing results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)">(d)</span> Quality control test results that include the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)(i)">(i)</span> Results of the quality control test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)(ii)">(ii)</span> Date and time the control testing was performed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)(iii)">(iii)</span> Lot number and expiration of the test kit;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)(iv)">(iv)</span> Lot number and expiration date of the quality controls; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(d)(v)">(v)</span> Corrective actions taken if control results are invalid; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)">(e)</span> Test result records for the individuals who are tested that include the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(i)">(i)</span> Test result;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(ii)">(ii)</span> Date and time testing was performed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(iii)">(iii)</span> Unique laboratory code for the individual being tested;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(iv)">(iv)</span> Test kit lot number and expiration date;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(v)">(v)</span> Results of internal validity checks;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(vi)">(vi)</span> Action taken if a result is invalid;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(vii)">(vii)</span> Documentation of required confirmatory testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(viii)">(viii)</span> Documentation when a specimen is sent for confirmation or the individual is referred for a confirmatory test;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(ix)">(ix)</span> Confirmatory test results, when available; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.12.05#B(3)(e)(x)">(x)</span> Identity of the individual who performed the test.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.06" data-order="|10|10|12|.06|" data-ref-path="10|10|12|.06" class="h__section">.06 Personnel Training and Competency.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#A">A.</span> Primary Standard. A person seeking or holding a public health testing license shall ensure that the personnel of the public health testing program are trained in how to perform assigned tasks and responsibilities.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#B">B.</span> Personnel Training Components. A person seeking or holding a public health testing license shall ensure that personnel training includes the following components:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#B(1)">(1)</span> How to perform the test, including procedures performed before, during, and after testing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#B(2)">(2)</span> How the testing is integrated into the overall counseling and testing program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#B(3)">(3)</span> The components of the public health testing program's quality assessment plan; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#B(4)">(4)</span> The use of bloodborne pathogen precautions and biohazard safety.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C">C.</span> Training Method. A person seeking or holding a public health testing license shall ensure that the public health testing program personnel training includes the following activities:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C(1)">(1)</span> Reading the manufacturer's instructions for performing the test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C(2)">(2)</span> Observing a trained individual performing the test or viewing a video of a trained individual performing the test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C(3)">(3)</span> Practicing the performance of the test with positive and negative controls;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C(4)">(4)</span> Practicing the specimen collection procedure; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#C(5)">(5)</span> Reviewing the procedures and forms on how to document the testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#D">D.</span> Personnel Competency. A supervisor or qualified trainer shall assess and document the competency of the public health testing program personnel for each task for which the individual is responsible:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#D(1)">(1)</span> Before the individual is permitted to perform testing without assistance for the first time;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#D(2)">(2)</span> Annually; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#D(3)">(3)</span> When procedures or test systems are changed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.06#E">E.</span> A person seeking or holding a public health testing license shall have available and ensure that personnel follow the CDC “Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988” (2007).</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.07" data-order="|10|10|12|.07|" data-ref-path="10|10|12|.07" class="h__section">.07 Standard Operating Procedures Manual.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#A">A.</span> Primary Standard. A person seeking or holding a public health testing license shall develop and maintain a standard operating procedures manual (SOPM) that is available to and followed by the public health testing program personnel.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B">B.</span> A person seeking or holding a public health testing license shall ensure that the SOPM includes the step-by-step instructions for the operations, tasks, and techniques occurring before, during, and after testing, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(1)">(1)</span> How to set up the testing site;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(2)">(2)</span> Use of quality assessment plan components, policies, and procedures;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(3)">(3)</span> The test manufacturer's product inserts and instructions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(4)">(4)</span> Standard precautions for bloodborne pathogens;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(5)">(5)</span> Use of gloves and other personal protective equipment;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(6)">(6)</span> Handling and disposal of biohazardous waste;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(7)">(7)</span> How to provide testing information to an individual before the individual is tested;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(8)">(8)</span> How to counsel an individual receiving screening test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.07#B(9)">(9)</span> How to refer an individual who has been tested for HIV antibodies or hepatitis C antibodies, or both, for services as prescribed in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.10#C" title="">COMAR 10.18.08.10C</a> and 10.18.09.07.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.08" data-order="|10|10|12|.08|" data-ref-path="10|10|12|.08" class="h__section">.08 Public Health Testing Program Director.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#A">A.</span> Primary Standard. A person seeking or holding a public health testing license shall employ or otherwise engage the services of a director to oversee and manage the public health testing program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B">B.</span> The director of a public health testing program shall oversee the planning, organization, direction, operation, and review of the program's operations, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(1)">(1)</span> Recruiting competent personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(2)">(2)</span> Providing and documenting initial training and continuing education of program personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(3)">(3)</span> Communicating and consulting with program personnel on a regular basis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(4)">(4)</span> Conducting and documenting periodic on-site visits at the testing sites;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(5)">(5)</span> Maintaining the quality assessment plan; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.08#B(6)">(6)</span> Ensuring that the program, testing site, and personnel meet applicable federal requirements and all standards and requirements set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.09" data-order="|10|10|12|.09|" data-ref-path="10|10|12|.09" class="h__section">.09 Manufacturer's Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.09#A">A.</span> Primary Standard. In addition to meeting the quality assessment plan requirements set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.12.05" title=".05 Quality Assessment Plan and Quality Control Requirements.">Regulation .05 of this chapter</a>, a person seeking or holding a public health testing license shall ensure that public health testing program personnel meet the requirements and follow the manufacturer's test specifications and instructions for the rapid HIV test or rapid hepatitis virus C test being used.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.09#B">B.</span> A person seeking or holding a public health testing license shall ensure that public health testing program personnel pay attention to the precautions and warnings set forth in the manufacturer's testing specifications and instructions for the rapid HIV test or rapid hepatitis virus C test being used for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.09#B(1)">(1)</span> Product usage;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.09#B(2)">(2)</span> Test system and kit controls; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.12.09#B(3)">(3)</span> The step-by-step instructions for performing the rapid HIV antibody test or rapid hepatitis C virus test.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.12.10" data-order="|10|10|12|.10|" data-ref-path="10|10|12|.10" class="h__section">.10 Confirmatory Test.</h3>
                <p>When an individual has a positive test result with the rapid HIV antibody test or rapid hepatitis C virus test, a person seeking or holding a public health testing license to offer or perform testing shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.10#A">A.</span> Offer to perform a confirmatory test;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.10#B">B.</span> Collect a specimen to refer to a laboratory to perform a confirmatory test; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.12.10#C">C.</span> Refer that individual to a health care provider to have a confirmatory test performed.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.13" data-order="|10|10|13|" data-ref-path="10|10|13" class="h__chapter">Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.01" title=".01 Purpose.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.27" title=".27 Sanctions.">.27</a> adopted as an emergency provision effective January 1, 2009 (36:2 Md. R. 97); adopted permanently effective March 23, 2009 (36:6 Md. R. 490)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.02#A" title="">Regulation .02A</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.03#B" title="">Regulation .03B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.04#B" title="">Regulation .04B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.06#B" title="">Regulation .06B</a> amended as an emergency provision effective July 1, 2012 (39:15 Md. R. 962); amended permanently effective August 20, 2012 (39:16 Md. R. 1080)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.06#B" title="">Regulation .06B</a> amended effective April 27, 2015 (42:8 Md. R. 608); April 14, 2025 (52:7 Md. R. 321)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.12" title=".12 First-Tier, Supplemental, and Second-Tier Tests.">Regulation .12</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C</a> amended effective August 23, 2021 (48:17 Md. R. 669); April 14, 2025 (52:7 Md. R. 321)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.13" title=".13 Screening Test Blood-Spot Specimens — Collection and Test Requisition.">Regulation .13</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.14" title=".14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.">Regulation .14</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.15" title=".15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.">Regulation .15</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.16" title=".16 Test Records — Retention.">Regulation .16</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.17" title=".17 Testing — First-Tier.">Regulation .17</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.18#B" title="">Regulation .18B</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.20#A" title="">Regulation .20A</a>, C amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.21" title=".21 Quality Assessment and Quality Assurance.">Regulation .21</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.23" title=".23 Reporting Test Results.">Regulation .23</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.24#A" title="">Regulation .24A</a>, D amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.25" title=".25 Reporting System and Communication Software.">Regulation .25</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.26#A" title="">Regulation .26A</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.27#C" title="">Regulation .27C</a> amended effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§13-101—13-103, 13-108—13-112, 13-601—13-605, 17-201—17-206, 17-210,<br/>17-211, 17-215, and 17-216, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.10.13.01" data-order="|10|10|13|.01|" data-ref-path="10|10|13|.01" class="h__section">.01 Purpose.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#A">A.</span> This chapter, together with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>, establishes a coordinated Statewide system for the screening of newborn infants in the State for certain hereditary and congenital disorders associated with severe problems of health or development.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B">B.</span> This chapter also protects the public health by ensuring that accurate and reliable newborn screening and diagnostic test results are provided to a newborn infant's health care providers by requiring a medical laboratory performing screening tests, diagnostic tests, or both, on newborn infants for hereditary disorders, congenital disorders, or both, to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(1)">(1)</span> Operate under reliable procedures and test methods;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(2)">(2)</span> Employ qualified personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(3)">(3)</span> Establish and maintain reliable quality control and quality assurance programs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.01#B(4)">(4)</span> Interact effectively with components of the Department's coordinated Statewide Newborn Screening Program to identify newborn infants who may be at risk for a hereditary or congenital disorder.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.02" data-order="|10|10|13|.02|" data-ref-path="10|10|13|.02" class="h__section">.02 Scope.</h3>
                <p>This chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#A">A.</span> Identifies standards and requirements for a medical laboratory performing screening tests, diagnostic tests, or both, for hereditary and congenital disorders on blood-spot specimens from newborn infants; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B">B.</span> Addresses the following newborn screening and diagnostic tests:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)">(1)</span> Screening tests, which are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)(a)">(a)</span> First-tier tests; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(1)(b)">(b)</span> Supplemental tests; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)">(2)</span> Diagnostic tests, which are:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)(a)">(a)</span> Second-tier tests; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.02#B(2)(b)">(b)</span> Supplemental tests.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.03" data-order="|10|10|13|.03|" data-ref-path="10|10|13|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)">(1)</span> "Abnormal test result" means a first-tier, supplemental, or second-tier test result that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)(a)">(a)</span> Falls outside the normal range for the analyte measured; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(1)(b)">(b)</span> Triggers a request for additional testing or is diagnostic for a disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)">(2)</span> Allele.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)(a)">(a)</span> "Allele" means any one of a series of two or more different forms of a gene or DNA sequence that can exist at a single locus on a chromosome.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(2)(b)">(b)</span> "Allele" includes the gene or DNA sequence for hemoglobin traits and disease states, such as hemoglobin S (HbS) for sickle cell disease.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(3)">(3)</span> "Analyte" means the substance or chemical constituent in blood being measured in a screening test used to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)">(4)</span> Birthing Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(a)">(a)</span> "Birthing facility" means a facility that provides the antepartum, intrapartum, and postpartum management and care of women and their newborn infants.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)">(b)</span> "Birthing facility" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)(i)">(i)</span> Birthing service that is licensed or accredited as a unit of a hospital; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(4)(b)(ii)">(ii)</span> Freestanding birthing center as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.05.02.01#B" title="">COMAR 10.05.02.01B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)">(5)</span> Blood-Spot Specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(a)">(a)</span> “Blood-spot specimen” means a whole-blood specimen collected from a newborn infant’s heel and applied to the designated area on a blood-spot collection test requisition card for the purpose of performing screening tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)">(b)</span> “Blood-spot specimen” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(i)">(i)</span> The first screening blood-spot specimen collected from a newborn infant, usually in the birthing facility or other place where the newborn infant was born, within 48 hours after the newborn infant’s birth;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(ii)">(ii)</span> The second screening blood-spot specimen collected from a newborn infant, usually collected when the newborn infant is between 10 and 14 days of age; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(5)(b)(iii)">(iii)</span> A blood-spot specimen collected subsequent to a blood-spot specimen specified in §B(5)(b)(i) and (ii) of this regulation as required to meet the medical needs and condition of the newborn infant and any additional specific screening blood-spot specimen collection and screening test requirements of this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(6)">(6)</span> "Borderline result" means a screening test result that is at or near the established cut-off level for a particular analyte.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(7)">(7)</span> "CLIA" means the federal Clinical Laboratory Improvement Amendments of 1988.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)">(8)</span> Congenital Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(a)">(a)</span> "Congenital disorder" means a significant structural or functional abnormality of the body that is present at birth.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)">(b)</span> "Congenital disorder" does not include a condition that results from:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)(i)">(i)</span> An intrauterine infection; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(8)(b)(ii)">(ii)</span> A birth injury.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(9)">(9)</span> "Council" means the State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(10)">(10)</span> “Courier” means an entity employed by a person to convey a blood-spot specimen from the site of blood-spot specimen collection to the laboratory where the blood-spot specimen will be tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(11)">(11)</span> "Cut-off level" means a pre-determined, measurable value established for an analyte detected by a screening test, where that value is used to determine when a newborn infant's test result is normal, borderline, or abnormal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(12)">(12)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)">(13)</span> "Diagnostic test" means a test that is used to establish or confirm the presence of a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)(a)">(a)</span> Specific disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(13)(b)">(b)</span> Hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(14)">(14)</span> “First screening” means a screening performed on the first blood-spot specimen collected from a newborn infant after birth.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)">(15)</span> “First–tier test” means a blood test performed on a newborn infant’s blood-spot specimen that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)(a)">(a)</span> Indicates the probable presence or absence of a hereditary or congenital disorder; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(15)(b)">(b)</span> Identifies a newborn infant who is at increased risk for a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(16)">(16)</span> “Follow-Up Unit” means the follow-up component and staff of the Department’s Newborn Screening Program, which carries out the duties set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">COMAR 10.52.12.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)">(17)</span> Hereditary Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)">(a)</span> "Hereditary disorder" means a disorder that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)(i)">(i)</span> Is transmissible through the genetic material deoxyribonucleic acid (DNA); or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(a)(ii)">(ii)</span> Arises through the improper processing of information in the genetic material.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)">(b)</span> "Hereditary disorder" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(i)">(i)</span> Hemoglobin disorders;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(ii)">(ii)</span> Metabolic disorders; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(17)(b)(iii)">(iii)</span> Endocrine disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(18)">(18)</span> “Home birth” means the birth of an infant which occurs intentionally outside of a birthing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(19)">(19)</span> “Home birth attendant” means a physician who is licensed to practice under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 14, Annotated Code of Maryland</a>, a nurse midwife who is licensed and certified under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Annotated Code of Maryland</a>, or a direct-entry midwife who is licensed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Subtitle 6C, Annotated Code of Maryland</a>, who is caring for the mother and infant at delivery during a home birth as defined in <a class="internal-link " href="/us/md/exec/comar/10.10.13.03#B(18)" title="">§B(18) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)">(20)</span> "Metabolic Disorder" means a disorder caused by a genetic alteration that results in a defect in the function of a specific enzyme, hormone, or protein, which can be detected by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)(a)">(a)</span> Direct analysis of the enzyme, hormone, or protein; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(20)(b)">(b)</span> Testing for a substance whose metabolism is altered as a result of the defect.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)">(21)</span> "Newborn" or "newborn infant" means an infant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(a)">(a)</span> Born in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(b)">(b)</span> Born on federal property within Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(c)">(c)</span> Born outside of Maryland to parents whose residence is in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(d)">(d)</span> From whom a blood-spot specimen was collected and submitted to the Department’s public health laboratory for newborn screening by a birthing facility or other health care provider located in Maryland, regardless of the infant’s place of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)">(e)</span> Who has a screening test requested by the Follow-Up Unit:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(i)">(i)</span> For first-tier screening follow-up;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(ii)">(ii)</span> For confirmation of a previous screening test result; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(e)(iii)">(iii)</span> To assist with a newborn infant's diagnosis, therapy, or follow-up care; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(21)(f)">(f)</span> Who is in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)">(22)</span> Newborn Screening or Screening.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(a)">(a)</span> "Newborn screening" or "screening" means one or more first-tier tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)">(b)</span> "Newborn screening" or "screening" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)(i)">(i)</span> First-tier testing on a first, second, or subsequent blood-spot specimen; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(22)(b)(ii)">(ii)</span> Supplemental first-tier testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)">(23)</span> Newborn Screening Program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)">(a)</span> "Newborn Screening Program" means the Department's screening program for hereditary and congenital disorders, which performs operations and activities necessary to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(i)">(i)</span> Newborn infants are given the opportunity to be tested;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(ii)">(ii)</span> At risk newborn infants who are tested are identified and located;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(iii)">(iii)</span> Newborn infants are given access to necessary follow-up testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(iv)">(iv)</span> Diagnostic tests are available and the diagnosis is made or ruled out; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(a)(v)">(v)</span> Newborn infants diagnosed with a hereditary or congenital disorder are given access to treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)">(b)</span> "Newborn Screening Program" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(i)">(i)</span> The Department's public health laboratory as the sole screening laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(ii)">(ii)</span> Another state's public health laboratory or a commercial laboratory that may serve the State as a screening laboratory during an emergency under a Departmental mutual aid agreement;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(iii)">(iii)</span> Supplemental and second-tier testing performed by a state public health laboratory or by a permitted commercial or research laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(iv)">(iv)</span> The Follow-Up Unit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(23)(b)(v)">(v)</span> The State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(24)">(24)</span> "Normal limit" means a measurable, numerical value or range that is considered not to indicate or establish the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(25)">(25)</span> "Permittee" means a person issued a permit by the Secretary to operate a medical laboratory as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01.03#B" title="">COMAR 10.10.01.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)">(26)</span> "Public health laboratory" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)(a)">(a)</span> The Department's public health laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(26)(b)">(b)</span> Another state's public health laboratory or a commercial laboratory permitted in Maryland that is approved under a Departmental emergency mutual aid agreement to perform newborn screening tests on Maryland newborns.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)">(27)</span> Quality Assessment Plan.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)">(a)</span> "Quality assessment plan" means a planned system of step-by-step activities to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(i)">(i)</span> Testing is carried out according to the manufacturer's instructions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(ii)">(ii)</span> Testing results are accurate and reliable;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(iii)">(iii)</span> Testing problems and errors are found and corrected to avoid adverse health outcomes for newborn infants; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(a)(iv)">(iv)</span> Testing results are reported and communicated in a timely manner as required by this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(27)(b)">(b)</span> "Quality assessment plan" includes the ongoing activities that monitor, review, evaluate, and improve the overall quality of the procedures and processes before, during, and after a test is performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(28)">(28)</span> "Quality control" has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.03#B" title="">COMAR 10.10.06.03B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)">(29)</span> Screening Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(a)">(a)</span> "Screening test" means a first-tier test used to detect a hereditary or congenital disorder listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12" title=".12 First-Tier, Supplemental, and Second-Tier Tests.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)">(b)</span> “Screening test” includes a test performed on a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(i)">(i)</span> First screening blood-spot specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(ii)">(ii)</span> Second screening blood-spot specimen; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(b)(iii)">(iii)</span> Subsequent screening blood-spot specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)">(c)</span> "Screening test" does not include a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)(i)">(i)</span> Diagnostic test; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(29)(c)(ii)">(ii)</span> Second-tier test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(30)">(30)</span> “Second screening” means a test performed on a routine second blood-spot specimen collected when the newborn infant is between 10 and 14 days old even though the test results from the newborn’s first blood-spot specimen were normal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)">(31)</span> Second-Tier Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(a)">(a)</span> “Second-tier test” means a test performed on a newborn screening blood-spot specimen when a first-tier test provides an abnormal screening test result or a borderline abnormal screening test result.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)">(b)</span> "Second-tier test" includes a test that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(i)">(i)</span> Establishes or confirms a newborn infant's risk for a hereditary or congenital disorder;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(ii)">(ii)</span> Separates a newborn infant into a lower or higher risk category for a hereditary or congenital disorder; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(31)(b)(iii)">(iii)</span> Is diagnostic because it confirms the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(32)">(32)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)">(33)</span> “Supplemental test” means a test performed on a blood-spot specimen collected from a newborn infant that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)(a)">(a)</span> Used to detect a hereditary or congenital disorder not specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(33)(b)">(b)</span> Not required to be performed by the Department's public health laboratory under this chapter or <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.03#B(34)">(34)</span> “Unsatisfactory blood-spot specimen” means a blood-spot specimen that may produce an inaccurate or unreliable test result because the blood-spot specimen exhibits one of the problems of collection as specified in Regulation .21B and C of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.04" data-order="|10|10|13|.04|" data-ref-path="10|10|13|.04" class="h__section">.04 Permit.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A">A.</span> Eligibility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(1)">(1)</span> Except as set forth in a Departmental mutual aid agreement, the Department's public health laboratory is the sole laboratory that may hold a State permit to perform and that may perform a first-tier newborn screening test on a newborn infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)">(2)</span> A medical laboratory other than the State's public health laboratory may obtain a permit to perform:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(a)">(a)</span> A supplemental test;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(b)">(b)</span> A second-tier test; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#A(2)(c)">(c)</span> Supplemental and second-tier tests.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B">B.</span> Requirements. Before offering to perform or performing a first-tier, supplemental, or second-tier test on a blood-spot specimen collected from a newborn infant, a person shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)">(1)</span> Obtain and maintain a valid:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)(a)">(a)</span> Permit issued by the Secretary to operate a medical laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(1)(b)">(b)</span> CLIA Certificate from the U.S. Health and Human Services' Centers for Medicare and Medicaid Services; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)">(2)</span> Meet applicable standards and requirements for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)(a)">(a)</span> A medical laboratory, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>—.08; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.04#B(2)(b)">(b)</span> Testing for hereditary or congenital disorders in a newborn infant as set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.05" data-order="|10|10|13|.05|" data-ref-path="10|10|13|.05" class="h__section">.05 Inspection Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#A">A.</span> Inspection Authority. The Department may conduct on-site inspections of a permittee or applicant for a permit to perform supplemental or second-tier tests to screen for or diagnose congenital and hereditary disorders in newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B">B.</span> Inspection Types. The Department may conduct the following types of inspections to assess compliance with the requirements of this subtitle and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(1)">(1)</span> An initial inspection before issuing a permit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(2)">(2)</span> A routine inspection during the permit period; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.05#B(3)">(3)</span> An inspection subsequent to a complaint.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.06" data-order="|10|10|13|.06|" data-ref-path="10|10|13|.06" class="h__section">.06 Fees.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#A">A.</span> Permit Fees. A permittee or applicant for a permit that is not exempt under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04.01#C" title="">COMAR 10.10.04.01C</a>, or that is not another state's public health laboratory approved to provide newborn screening tests under a Departmental mutual aid agreement, shall pay to the Department the applicable fees as required by <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.04" title="Chapter 04 Medical Laboratories">COMAR 10.10.04</a> and this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#B">B.</span> Screening and Follow-up Fee Requirement. A birthing center or person responsible for having newborn screening carried out for a newborn infant born outside a birthing facility shall pay a fee of $163.74 per newborn infant to the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C">C.</span> Screening and Follow-Up Fee Payment. A birthing center or person responsible for having newborn screening carried out for a newborn infant born outside a birthing facility shall pay to the Department the total fees owed:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C(1)">(1)</span> On a quarterly basis; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.06#C(2)">(2)</span> Within 30 days of receiving an invoice from the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.07" data-order="|10|10|13|.07|" data-ref-path="10|10|13|.07" class="h__section">.07 Director Requirement, Qualifications, and Responsibilities.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#A">A.</span> Director Requirement. A permittee that offers to perform or performs a first-tier, supplemental, or second-tier test shall employ a director.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B">B.</span> Director Qualifications. The director shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(1)">(1)</span> Meet the qualifications for a medical laboratory director set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.04" title=".04 Permitted Laboratory Other than a POL or POCL — Director.">COMAR 10.10.07.04</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)">(2)</span> Possess a current license as a laboratory director issued by the state in which the laboratory is located if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)(a)">(a)</span> The laboratory is not located in Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#B(2)(b)">(b)</span> Licensing is required by the state in which the laboratory is located.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C">C.</span> Director Responsibilities. The director is responsible for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(1)">(1)</span> The overall operation and administration of the laboratory, including the employment of a sufficient number of competent personnel;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(2)">(2)</span> Ensuring that each first-tier, supplemental, or second-tier test conducted is performed accurately and reliably in all aspects of the testing process, including the preanalytic, analytic, and post-analytic phases of the total testing process; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)">(3)</span> Ensuring compliance with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(a)">(a)</span> This chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(b)">(b)</span> The applicable parts of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>— <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">10.10.08</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.07#C(3)(c)">(c)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.08" data-order="|10|10|13|.08|" data-ref-path="10|10|13|.08" class="h__section">.08 Technical Supervisor Requirement, Qualifications, and Responsibilities.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#A">A.</span> Technical Supervisor Requirement. A permittee that offers to perform or performs a first-tier, supplemental, or second-tier test shall employ a technical supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#B">B.</span> Director as Technical Supervisor. The director may function as the technical supervisor if the director meets the technical supervisor qualifications specified in this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#C">C.</span> Technical Supervisor Qualifications. The technical supervisor shall meet the qualifications for a technical supervisor set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.05#A(1)" title="">COMAR 10.10.07.05A(1)</a> and B(7).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D">D.</span> Technical Supervisor Responsibilities. A technical supervisor shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)">(1)</span> Responsible for the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)(a)">(a)</span> Technical and scientific methods used in the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(1)(b)">(b)</span> Oversight of the laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(2)">(2)</span> Available to the laboratory personnel on an as-needed basis to provide supervision as specified in this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.08#D(3)">(3)</span> Accessible to the laboratory to provide on-site, telephonic, or electronic consultation to laboratory personnel and clients.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.09" data-order="|10|10|13|.09|" data-ref-path="10|10|13|.09" class="h__section">.09 Clinical Consultant Requirement, Qualifications, and Responsibilities.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#A">A.</span> Clinical Consultant Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ a clinical consultant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#B">B.</span> Director as Clinical Consultant. The director may function as the clinical consultant if the director meets the qualifications set forth under <a class="internal-link " href="/us/md/exec/comar/10.10.13.09#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C">C.</span> Clinical Consultant Qualifications. The clinical consultant shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(1)">(1)</span> A doctor of medicine or a doctor of osteopathy licensed to practice medicine or osteopathy; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)">(2)</span> Board certified by the American Board of Medical Genetics as a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(a)">(a)</span> Clinical geneticist;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(b)">(b)</span> Medical geneticist; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#C(2)(c)">(c)</span> Biochemical geneticist.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D">D.</span> Clinical Consultant Responsibilities. A clinical consultant shall provide clinical consultation related to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(1)">(1)</span> Inquiries concerning specific newborn screening tests;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(2)">(2)</span> Interpretation of specific test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(3)">(3)</span> Possible diagnostic or supplemental testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.09#D(4)">(4)</span> Assistance in ensuring that appropriate tests are ordered to meet clinical expectations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.10" data-order="|10|10|13|.10|" data-ref-path="10|10|13|.10" class="h__section">.10 General Supervisor Requirement, Qualifications, and Responsibilities.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#A">A.</span> General Supervisor Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ a general supervisor.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B">B.</span> General Supervisor Qualifications. The general supervisor shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(1)">(1)</span> Meet the qualifications for a general supervisor set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.06#B(1)" title="">COMAR 10.10.07.06B(1)</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)">(2)</span> Have at least 6 months experience supervising the operation of applicable test systems, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(a)">(a)</span> Tandem mass spectrophotometry (MS/MS);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(b)">(b)</span> Time-resolved immunofluorometry;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(c)">(c)</span> Enzyme-linked immunosorbent assay (ELISA) systems; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#B(2)(d)">(d)</span> Isoelectric focusing and high-performance liquid chromatography.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C">C.</span> General Supervisor Responsibilities. A general supervisor shall carry out the responsibilities set forth in 42 CFR §493.1463, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)">(1)</span> Supervising the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)(a)">(a)</span> Day-to-day operation of the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(1)(b)">(b)</span> Personnel performing tests and reporting test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.10#C(2)">(2)</span> Being accessible to testing personnel at all times testing is performed to provide on-site, telephonic, or electronic consultation and resolve technical problems in accordance with policies and procedures established and approved by the director and technical supervisor.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.11" data-order="|10|10|13|.11|" data-ref-path="10|10|13|.11" class="h__section">.11 Testing Personnel Requirement and Qualifications.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.11#A">A.</span> Requirement. A permittee that offers to perform or performs first-tier, supplemental, or second-tier tests shall employ sufficient laboratory testing personnel to perform testing in accordance with the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.11#B">B.</span> Qualifications. Testing personnel shall meet the qualifications set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.07.07" title=".07 Permitted Laboratory Other than POL or POCL — Testing Personnel.">COMAR 10.10.07.07</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.12" data-order="|10|10|13|.12|" data-ref-path="10|10|13|.12" class="h__section">.12 First-Tier, Supplemental, and Second-Tier Tests.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#A">A.</span> First-Tier Tests; Requirement. The Department’s public health laboratory shall perform first-tier tests on all screening blood-spot specimens collected from a newborn infant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B">B.</span> First-Tier Tests; Testing Limitations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B(1)">(1)</span> Only the Department's public health laboratory may screen for the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">§C of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#B(2)">(2)</span> A permittee may perform a supplemental or a second-tier test only when the test is requested by an individual authorized to request a medical laboratory test as provided in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C">C.</span> First-Tier Tests. The Department’s public health laboratory shall perform a first-tier test on a newborn infant to screen for the following hereditary and congenital disorders, which are approved for screening by the Council and the Secretary:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(1)">(1)</span> Biotinidase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(2)">(2)</span> Congenital adrenal hyperplasia (CAH);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(3)">(3)</span> Hypothyroidism;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(4)">(4)</span> Galactosemia, galactose-1-phosphate uridyl transferase deficiency (GALT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(5)">(5)</span> Epimerase Galactosemia, uridine diphosphate-galactose-4-epimerase deficiency (GALE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(6)">(6)</span> Galactokinase Galactosemia, galactokinase deficiency (GALK1);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(7)">(7)</span> Sickle cell disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(8)">(8)</span> Sickle cell disease: S beta-thalessemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(9)">(9)</span> Sickle C disease: SC disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(10)">(10)</span> Other hemoglobin variants;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(11)">(11)</span> Phenylketonuria (PKU);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(12)">(12)</span> Hyperphenylalaninemia (Hyper-PHE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(13)">(13)</span> Biopterin cofactor biosynthesis defects (BIOPT-BS);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(14)">(14)</span> Biopterin cofactor regeneration defects (BIOPT-REG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(15)">(15)</span> Tyrosinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(16)">(16)</span> Tyrosinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(17)">(17)</span> Tyrosinemia, type III;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(18)">(18)</span> Homocystinuria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(19)">(19)</span> Hypermethioninemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(20)">(20)</span> Branched chain ketoaciduria (BCK), also called maple syrup urine disease (MSUD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(21)">(21)</span> Citrullinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(22)">(22)</span> Citrullinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(23)">(23)</span> Arginosuccinic aciduria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(24)">(24)</span> Argininemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(25)">(25)</span> Methylmalonic acidemia, mutase deficiency (MMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(26)">(26)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects A and B (Cbl A, B);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(27)">(27)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects C and D (Cbl C, D);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(28)">(28)</span> Propionic acidemia (PA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(29)">(29)</span> Isovaleric acidemia (IVA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(30)">(30)</span> Glutaric aciduria type I (GA I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(31)">(31)</span> 3-Hydroxy-3-methylglutaryl-CoA (HMG) lysase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(32)">(32)</span> Isobutryl-CoA dehydrogenase (IBCD) deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(33)">(33)</span> 2-Methylbutyryl-CoA dehydrogenase deficiency (2MBG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(34)">(34)</span> 3-Methlycrotonyl-CoA carboxylase deficiency (3MCC);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(35)">(35)</span> 3-Methlyglutaconyl-CoA hydratase deficiency (3MGA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(36)">(36)</span> 2-Methyl-3-hydroxybutyrl-CoA dehydrogenase deficiency (2M3HBA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(37)">(37)</span> Mitochondrial acetoacetyl-CoA thiolase (3-ketothiolase) deficiency (BKT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(38)">(38)</span> Multiple carboxylase deficiency (MCD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(39)">(39)</span> Malonic acidemia (MAL);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(40)">(40)</span> Medium chain acyl-CoA dehydrogenase deficiency (MCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(41)">(41)</span> Medium chain ketoacyl-CoA thiolase deficiency (MCKAT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(42)">(42)</span> Short chain acyl-CoA dehydrogenase deficiency (SCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(43)">(43)</span> Short chain 3-hydroxy acyl Co-A dehydrogenase deficiency (SCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(44)">(44)</span> Very long chain acyl-CoA dehydrogenase deficiency (VLCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(45)">(45)</span> 3-hydroxy long chain acyl-CoA dehydrogenase deficiency (LCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(46)">(46)</span> Multiple acyl-CoA dehydrogenase (MAD) or glutaric acidemia type II deficiency (GA II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(47)">(47)</span> Carnitine/acylcarnitine translocase deficiency (translocase deficiency);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(48)">(48)</span> Carnitine palmitoyl transferase type I deficiency (CPT I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(49)">(49)</span> Carnitine palmitoyl transferase type II deficiency (CPT II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(50)">(50)</span> Carnitine uptake disorder;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(51)">(51)</span> Trifunctional protein deficiency (TFP);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(52)">(52)</span> 2,4-dienoyl-CoA reductase deficiency (DE RED);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(53)">(53)</span> Cystic fibrosis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(54)">(54)</span> Severe combined immunodeficiency (SCID);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(55)">(55)</span> Pompe disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(56)">(56)</span> Fabry disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(57)">(57)</span> Spinal muscular atrophy (SMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(58)">(58)</span> Mucopolysaccharidosis type I (MPS I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(59)">(59)</span> Mucopolysaccharidosis type II (MPS II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(60)">(60)</span> X-linked Adrenoleukodystrophy (X-ALD); and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#C(61)">(61)</span> Guanidinoacetate Methyltransferase Deficiency (GAMT).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D">D.</span> Approved Methods:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)">(1)</span> A permittee shall use:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(a)">(a)</span> A colorimetric method for testing for a biotinidase deficiency, which is the disorder listed at <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(1)" title="">§C(1) of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(b)">(b)</span> A fluorometric method when testing for galactosemia, which is the disorder listed at §C(4)—(6) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(c)">(c)</span> A fluorescent-linked immunoassay method when testing for the hereditary or congenital disorders listed in §C(2) and (3) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(d)">(d)</span> Isoelectric focusing followed by high-performance liquid chromatography when testing for sickle cell disease, which is the disorder listed at §C(7)—(10) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(e)">(e)</span> Tandem mass-spectrometry when testing for the metabolic disorders listed in §C(11)—(52) of this regulation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(f)">(f)</span> IRT/IRT (immunoreactive trypsinogen/immuno-reactive trypsinogen) when testing for cystic fibrosis, which is the disorder listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(53)" title="">§C(53) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(1)(g)">(g)</span> Real time polymerase chain reaction method when testing for severe combined immunodeficiency, which is listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">§C(54) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.12#D(2)">(2)</span> A permittee shall have 60 days from the amendment's effective date to comply with any amendment made by the Secretary to <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#D" title="">§D of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.13" data-order="|10|10|13|.13|" data-ref-path="10|10|13|.13" class="h__section">.13 Screening Test Blood-Spot Specimens — Collection and Test Requisition.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A">A.</span> Blood-Spot Specimen Collection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(1)">(1)</span> A person shall collect a newborn infant’s blood-spot specimen for testing under this chapter by using only the special blood-spot specimen collection test requisition card provided by the Department.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)">(2)</span> The Department shall provide the special blood-spot specimen collection test requisition card to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)(a)">(a)</span> Individual in charge of a birthing facility or the individual’s designated representative; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(2)(b)">(b)</span> Home birth attendant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)">(3)</span> The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall collect a blood-spot specimen consisting of heel-stick whole blood obtained:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(a)">(a)</span> When a newborn infant is 24 to 48 hours old;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(b)">(b)</span> On a blood-spot specimen collection test requisition card provided by the Department; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#A(3)(c)">(c)</span> As set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.13.14" title=".14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.">Regulation .14 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B">B.</span> Blood-Spot Specimen Collection Test Requisition Card Information. An individual shall record the following information as specified on the Department-supplied blood-spot specimen collection test requisition card:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)">(1)</span> Newborn infant information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(b)">(b)</span> Date of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(c)">(c)</span> Time of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(d)">(d)</span> Current weight;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(e)">(e)</span> Gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(f)">(f)</span> Race;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(g)">(g)</span> Gestational age;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)">(h)</span> Birthing facility identification, including the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(i)">(i)</span> Facility name;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(ii)">(ii)</span> Facility street address, city, state, and zip code; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(h)(iii)">(iii)</span> Newborn infant's medical record or chart number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(i)">(i)</span> Date and time of first feeding;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)">(j)</span> Type of feeding, such as:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(i)">(i)</span> Breast;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(ii)">(ii)</span> Lactose-containing formula; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(j)(iii)">(iii)</span> Formula containing no lactose;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(k)">(k)</span> Transfusion history, including transfusion date and time;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(l)">(l)</span> General health status of the newborn infant; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(1)(m)">(m)</span> The total protein and calorie intake for any newborn infant in a neonatal intensive care setting;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)">(2)</span> Blood-spot specimen information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(a)">(a)</span> Date of collection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(b)">(b)</span> Time of collection; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(2)(c)">(c)</span> Initials or other identifier of the individual who collected the blood-spot specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)">(3)</span> Mother or guardian information, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(b)">(b)</span> Street address, city, state, and zip code; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(3)(c)">(c)</span> Telephone number where the mother or guardian may be reached;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)">(4)</span> Information on the pediatrician or attending physician who will be following the newborn infant, including the physician's:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(a)">(a)</span> Name;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(b)">(b)</span> Street address, city, state, and zip code; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(4)(c)">(c)</span> Telephone number; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)">(5)</span> Other information that can affect the test results or the interpretation of the test results when applicable, such as that antibiotics were administered to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)(a)">(a)</span> Mother; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.13#B(5)(b)">(b)</span> Newborn infant.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.14" data-order="|10|10|13|.14|" data-ref-path="10|10|13|.14" class="h__section">.14 Screening Test Blood-Spot Specimens — Procedures, Submission, and Delivery Requirements.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A">A.</span> Standard Operating Procedure. The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall maintain written standard operating procedures for the collection, handling, storage, and transport of newborn infant blood-spot specimen collection test requisition cards, including instructions for staff to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(1)">(1)</span> Ensure and maintain blood-spot specimen integrity, quality, and acceptability;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)">(2)</span> Ensure proper:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(a)">(a)</span> Site preparation and cleaning;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(b)">(b)</span> Performance of the heel stick puncture; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(2)(c)">(c)</span> Application of whole blood to the collection test requisition card;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)">(3)</span> Identify precautions against:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(a)">(a)</span> Milking or squeezing the blood-spot specimen collection site;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(b)">(b)</span> Layering successive drops of blood on the same circle on the blood-spot specimen collection test requisition card;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(c)">(c)</span> Filling the circles on both sides of the filter paper;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(d)">(d)</span> Touching or smearing a blood-spot specimen before it is fully air-dried;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(e)">(e)</span> Scratching or abrading the blood-spot specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(f)">(f)</span> Not allowing a blood-spot specimen to dry thoroughly before sending the blood-spot specimen collection test requisition card to a laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(3)(g)">(g)</span> Damaging, stretching, or wrinkling the filter paper before, during or after blood-spot specimen collection;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(4)">(4)</span> Recognize unsatisfactory blood-spot specimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)">(5)</span> Handle and temporarily store a blood-spot specimen collection test requisition card, including the procedures and techniques for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(a)">(a)</span> Drying blood-spot specimens;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(b)">(b)</span> Stacking of blood-spot specimen collection test requisition cards; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#A(5)(c)">(c)</span> Temporarily storing blood-spot specimen collection test requisition cards.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B">B.</span> Submission and Delivery Requirements. The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall transport and deliver to the Department’s public health laboratory a newborn infant blood-spot specimen collection test requisition card using:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(1)">(1)</span> An employee or private courier;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)">(2)</span> A commercial carrier providing:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)(a)">(a)</span> Overnight express delivery; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(2)(b)">(b)</span> Priority delivery;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(3)">(3)</span> A county or State operated courier system, where that service is available; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.14#B(4)">(4)</span> A combination of §B(1)—(3) of this regulation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.15" data-order="|10|10|13|.15|" data-ref-path="10|10|13|.15" class="h__section">.15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#A">A.</span> Use. A permittee may use a newborn infant blood-spot specimen from a newborn infant to test for only the conditions listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B">B.</span> Research. A researcher may not use a Maryland newborn infant’s blood spot specimen or test results for research purposes unless the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)">(1)</span> Research is approved in writing by the Department's:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)(a)">(a)</span> Newborn Screening Program; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(1)(b)">(b)</span> Institutional Review Board; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#B(2)">(2)</span> Researcher acknowledges in writing that the researcher will return all untested blood-spot specimens to the Department’s public health laboratory within 6 months of completing the approved research.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#C">C.</span> Storage. A permittee or researcher shall store a newborn infant blood-spot specimen in a sealed, moisture-proof container at between 2ºC and 6ºC.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D">D.</span> Retention.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)">(1)</span> A permittee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)(a)">(a)</span> Retain a newborn infant’s gel, produced when testing for hemoglobin disorders, for at least 90 days after testing is complete; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(1)(b)">(b)</span> Return to the State’s public health laboratory all untested blood-spot specimens received from the Department’s public health laboratory for supplemental or diagnostic testing within 90 days after testing is completed by the permittee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.15#D(2)">(2)</span> The Department’s public health laboratory shall retain and maintain for 25 years a newborn infant’s blood-spot specimen after the blood-spot specimen is received for screening, supplemental testing, or diagnostic testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.16" data-order="|10|10|13|.16|" data-ref-path="10|10|13|.16" class="h__section">.16 Test Records — Retention.</h3>
                <p>The Department’s public health laboratory shall retain and maintain electronically or as a hard copy for 25 years the:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#A">A.</span> Top copy of the requisition portion of the blood-spot specimen collection test requisition card;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#B">B.</span> All test results and reports;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#C">C.</span> Electronic data bases; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D">D.</span> Supporting documents that show how a reported test result was obtained and verified, including but not limited to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(1)">(1)</span> Quality control records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(2)">(2)</span> Instrument maintenance and repair records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(3)">(3)</span> Test reagent records; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.16#D(4)">(4)</span> Instrument and test system data.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.17" data-order="|10|10|13|.17|" data-ref-path="10|10|13|.17" class="h__section">.17 Testing — First-Tier.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#A">A.</span> The Department’s public health laboratory shall test, using first-tier tests, appropriately timed and collected blood-spot specimen of a newborn infant’s blood for the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B">B.</span> Full-Term Healthy Newborn Infants.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)">(1)</span> If a newborn infant is born at term and is healthy, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)(a)">(a)</span> First screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> on a blood-spot specimen collected when the full-term healthy newborn infant is between 24 and 48 hours old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(1)(b)">(b)</span> Second screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 10 and 14 days old.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)">(2)</span> If the first blood-spot specimen is collected when a full term healthy newborn infant is younger than 24 hours old, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)(a)">(a)</span> Second screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> on a blood-spot specimen collected when the newborn infant is between 24 hours and 7 days old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#B(2)(b)">(b)</span> Third screening using first-tier tests on a blood-spot specimen collected when the full-term healthy infant is between 1 and 4 weeks old.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C">C.</span> Premature or Ill Newborn Infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)">(1)</span> If a newborn infant who is born prematurely or expected to be ill for more than 14 days was younger than 24 hours old when the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(a)">(a)</span> Second screening using first-tier tests to detect the disorders listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C" title="">Regulation .12C of this chapter</a> when the newborn infant is between 24 hours and 3 days old; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)">(b)</span> Third screening using first-tier tests when the newborn infant is between 7 days and 14 days old to screen for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(i)">(i)</span> Amino acid disorders as specified in Regulation .12C(11)—(24) of this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(ii)">(ii)</span> Acylcarnitine disorders as specified in Regulation .12C(25)—(52) of this chapter;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(iii)">(iii)</span> Congenital hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(1)(b)(iv)">(iv)</span> Severe combined immunodeficiency, as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">Regulation .12C(54) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)">(2)</span> If a newborn infant who is born prematurely or expected to be ill for more than 14 days was 24 hours old or older at the time the newborn infant’s blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall perform a second screening to screen for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(a)">(a)</span> Amino acid disorders as specified in Regulation .12C(11)—(24) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(b)">(b)</span> Acylcarnitine disorders as specified in Regulation .12C(25)—(52) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(c)">(c)</span> Congenital hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(2)(d)">(d)</span> Severe combined immunodeficiency, as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(54)" title="">Regulation .12C(54) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)">(3)</span> If a newborn infant was transfused before the blood-spot specimen was collected for a first screening, the Department’s public health laboratory shall conduct, in addition to any other screenings specified in §B(1) and (2) of this regulation, a fourth screening using first-tier tests on a blood-spot specimen collected 4 months after a newborn infant’s last transfusion to screen for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(a)">(a)</span> Hemoglobin as specified in Regulation .12C(7)—(10) of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(b)">(b)</span> Biotinidase as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(1)" title="">Regulation .12C(1) of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.17#C(3)(c)">(c)</span> Galactose-1-P-uridyl-1-transferase as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(3)" title="">Regulation .12C(3) of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.18" data-order="|10|10|13|.18|" data-ref-path="10|10|13|.18" class="h__section">.18 Testing — Second-Tier and Supplemental.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A">A.</span> When a test request is made by an individual authorized to request a laboratory test, as set out in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.02" title=".02 Authorization to Request Laboratory Tests.">COMAR 10.10.06.02</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A(1)">(1)</span> A permittee other than the Department's public health laboratory may perform a second-tier or supplemental test; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#A(2)">(2)</span> The Department's public health laboratory may perform a second-tier test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B">B.</span> A permittee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(1)">(1)</span> May not contract out, subcontract, or otherwise transfer supplemental or second-tier testing to another laboratory that does not hold a Maryland permit in the discipline of diagnostic and supplemental testing for hereditary and congenital disorders in newborns;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(2)">(2)</span> Shall complete a second-tier or supplemental test on a blood-spot specimen within 3 working days after the blood-spot specimen arrives at the laboratory; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.18#B(3)">(3)</span> Shall report the results of a second-tier or supplemental screening test as required in Regulations .23 and .24 of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.19" data-order="|10|10|13|.19|" data-ref-path="10|10|13|.19" class="h__section">.19 Proficiency and Competency Testing for Newborn Screening Tests.</h3>
                <p>A permittee shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#A">A.</span> Meet all requirements set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#B">B.</span> Successfully participate in one or more approved proficiency testing programs that cover all first-tier, second-tier, and supplementary tests offered or performed;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#C">C.</span> Evaluate and document performance, semiannually during the first year of testing and annually thereafter, of all individuals responsible for testing; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.19#D">D.</span> In addition to the proficiency testing requirement in <a class="internal-link " href="/us/md/exec/comar/10.10.13.19#A" title="">§A of this regulation</a>, participate in the Centers for Disease Control and Prevention's Newborn Screening Quality Assurance Program.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.20" data-order="|10|10|13|.20|" data-ref-path="10|10|13|.20" class="h__section">.20 Quality Control.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A">A.</span> Quality Control Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(1)">(1)</span> A permittee shall develop, establish, implement, maintain and follow written quality control policies, procedures, and techniques that provide and ensure accurate, reliable, and valid test results and reports.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)">(2)</span> A permittee's quality control program shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)(a)">(a)</span> Cover all tests, methods, and procedures performed by the laboratory; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(2)(b)">(b)</span> Meet the standards and requirements set forth in this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)">(3)</span> A permittee's quality control procedures and practices shall include, but are not limited to, the use of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(a)">(a)</span> Analyses of reference materials to ensure the reproducibility and accuracy of test results;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(b)">(b)</span> Systems to ensure proper functioning of instruments, equipment, reagents, and performance of laboratory personnel;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(c)">(c)</span> Valid reagents, equipment, calibration, and systematic procedural checks;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(d)">(d)</span> A system that ensures timely and pertinent error detection and correction for the review and reporting of test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#A(3)(e)">(e)</span> Quality control materials from the Centers for Disease Control and Prevention's Newborn Screening Quality Assurance Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B">B.</span> Adequacy of Methods and Equipment. To ensure the adequacy of test methods, test systems, and equipment, a permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(1)">(1)</span> Employ methods, test systems, and equipment that provide accurate and reliable test results and reports;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(2)">(2)</span> Have sufficient and suitable equipment and instruments to perform the type and volume of tests offered and performed by the laboratory;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(3)">(3)</span> Perform tests in a manner that provides accurate and reliable test results;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)">(4)</span> Monitor test methods, instruments, and testing systems, where applicable, for the following performance characteristics:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(a)">(a)</span> Method, instrument, and test system detection limits and cutoff levels;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(b)">(b)</span> Precision;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(c)">(c)</span> Accuracy;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(d)">(d)</span> Specificity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(e)">(e)</span> Sensitivity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(f)">(f)</span> Interferences; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(4)(g)">(g)</span> Other related test variables that affect test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)">(5)</span> Have adequate quality control systems and procedures in place to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(a)">(a)</span> Obtain and verify a statistically valid number of counts or measurement levels to give accurate and reliable test results for an analytical instrument, each day an instrument is used for testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)">(b)</span> Report results:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(i)">(i)</span> As set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06.04" title=".04 Reporting and Releasing Test Results.">COMAR 10.10.06.04</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(ii)">(ii)</span> As set forth in 42 CFR §493.1291; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#B(5)(b)(iii)">(iii)</span> Within the time frames required by this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C">C.</span> Supplies, Reagents, and Materials.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(1)">(1)</span> A permittee shall ensure that supplies, reagents, and other materials used in the collected, handling, testing, and storing of newborn blood-spot specimens are stored, labeled, checked for proper reactivity, and used according to the provisions of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)">(2)</span> A permittee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)">(a)</span> Label laboratory supplies and materials used in the testing process, including reagents, solutions, controls, and calibrators to indicate the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(i)">(i)</span> Identity of reagents, solutions, controls, and calibrators;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(ii)">(ii)</span> Strength or concentration;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(iii)">(iii)</span> Storage requirements;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(iv)">(iv)</span> Preparation and expiration date;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(v)">(v)</span> Identity of the preparer; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(a)(vi)">(vi)</span> Other pertinent information that affects test performance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(b)">(b)</span> Store laboratory materials in the manner recommended by the manufacturer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(c)">(c)</span> Test representative samples of each lot of materials used for or in the process of testing blood-spot specimens on a regularly scheduled basis to determine that each lot of test material is capable of performing as required; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(2)(d)">(d)</span> Use supplies, reagents, kits, test systems, and other materials in a manner consistent with the recommendations and instructions provided by the manufacturer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)">(3)</span> A permittee may not use supplies, reagents, kits, test systems, or other materials in the testing process that have:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(a)">(a)</span> Exceeded the materials' established expiration dates;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(b)">(b)</span> Substandard reactivity; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.20#C(3)(c)">(c)</span> Deteriorated.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.21" data-order="|10|10|13|.21|" data-ref-path="10|10|13|.21" class="h__section">.21 Quality Assessment and Quality Assurance.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A">A.</span> A permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(1)">(1)</span> Establish and follow a written quality assessment plan that covers all phases of the testing process;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(2)">(2)</span> Meet the applicable quality assurance requirements of <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.06" title="Chapter 06 Medical Laboratories — Quality Assurance">COMAR 10.10.06</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)">(3)</span> Have an accessioning mechanism or system that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)(a)">(a)</span> Tracks blood-spot specimens and allows first and subsequent blood-spot specimens and test results from the same newborn infant to be linked for testing and analysis; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#A(3)(b)">(b)</span> Identifies a specific analyte that requires retesting when a newborn infant's prior screening test results for that analyte are abnormal or border-line abnormal.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B">B.</span> A permittee may not test a blood-spot specimen exhibiting:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(1)">(1)</span> Blood that did not saturate the filter paper;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(2)">(2)</span> A circle containing no blood;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(3)">(3)</span> A blood clot or tissue on the surface of the blood;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(4)">(4)</span> A circle over-saturated with blood showing dark areas in the circle or at the perimeter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(5)">(5)</span> Blood that appears layered or clotted; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#B(6)">(6)</span> Serum rings or blood that appears diluted, discolored, or contaminated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C">C.</span> A permittee may not test a blood-spot specimen:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(1)">(1)</span> Collected more than 10 days before the screening test is to be started;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)">(2)</span> That is unaccompanied by information necessary for the testing to be meaningful, including the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(a)">(a)</span> Age of the newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(b)">(b)</span> Identification of the newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(c)">(c)</span> Date and time of blood-spot specimen collection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(d)">(d)</span> Date and time of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(e)">(e)</span> Newborn infant's weight; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(2)(f)">(f)</span> Date and time of a newborn infant's first feeding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(3)">(3)</span> If an infant was transfused before the first screening and the repeat blood-spot specimen collected to test for hemoglobin was drawn earlier than 4 months after the last transfusion; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)">(4)</span> If the newborn infant was younger than 24 hours old or the newborn's age was unknown at the time of collection and the requested screening test is for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)(a)">(a)</span> Congenital adrenal hyperplasia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(2)" title="">Regulation .12C(2) of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#C(4)(b)">(b)</span> Thyroxine or thyroid stimulating hormone as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D">D.</span> Within 24 hours of receipt of an unsatisfactory blood-spot specimen, the permittee shall notify the submitter of the unsatisfactory blood-spot specimen by telephone, facsimile, or electronic mail:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D(1)">(1)</span> That the blood-spot specimen cannot be tested; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#D(2)">(2)</span> To submit another blood-spot specimen as soon as possible.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E">E.</span> If a permittee reports a test result on a newborn infant and later discovers that the test result was erroneous or questionable, the permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)">(1)</span> Give prompt notice of the erroneous or questionable patient test result to the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(a)">(a)</span> Person who requested that the test be performed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(b)">(b)</span> Physician or other person to whom the laboratory has previously sent a report that contained the erroneous or questionable result; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(1)(c)">(c)</span> Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(2)">(2)</span> Provide corrected reports to the persons notified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.21#E" title="">§E of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(3)">(3)</span> Maintain duplicates of both the original report and the corrected report;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(4)">(4)</span> Conduct a quality assessment of all phases of the testing process to determine the cause of the erroneous or questionable test result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(5)">(5)</span> Take the necessary remedial or corrective action to prevent recurrence of the problem; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)">(6)</span> Take any additional measures necessary to reduce or eliminate the threat to the health and safety of the patient including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(a)">(a)</span> Notifying a parent or guardian of the newborn infant of the erroneous or questionable result;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(b)">(b)</span> Retesting the same blood-spot specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(c)">(c)</span> Testing a new blood-spot specimen; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.21#E(6)(d)">(d)</span> Retesting the same blood-spot specimen and testing a new blood-spot specimen.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.22" data-order="|10|10|13|.22|" data-ref-path="10|10|13|.22" class="h__section">.22 Quality Assurance — Continuity of Operations and Disaster Recovery Plan.</h3>
                <p>A permittee shall develop, implement, and maintain written continuity of operations and disaster recovery plans that ensure the continuous performance of essential functions and operations:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.22#A">A.</span> During an emergency; or</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.22#B">B.</span> When the laboratory temporarily can no longer meet the requirements and standards set forth in this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.23" data-order="|10|10|13|.23|" data-ref-path="10|10|13|.23" class="h__section">.23 Reporting Test Results.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A">A.</span> All Test Results. For a newborn infant, a permittee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)">(1)</span> Report all first-tier, supplemental, and second-tier results to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(a)">(a)</span> The person who requested the test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)">(b)</span> An individual who will use the test results in identifying, tracking, caring for, and treating the newborn infant, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)(i)">(i)</span> A physician specialist; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(1)(b)(ii)">(ii)</span> Personnel in the Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(2)">(2)</span> Report to the persons listed in <a class="internal-link " href="/us/md/exec/comar/10.10.13.23#A(1)" title="">§A(1) of this regulation</a> within 3 working days after the laboratory obtains the blood-spot specimen, all test results that are within normal limits;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(3)">(3)</span> Report to a person requesting a second or subsequent screening the test results from the newborn infant's prior screening if not previously reported to the person;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)">(4)</span> Include with each report the following information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(a)">(a)</span> Date the blood-spot specimen was received in the laboratory;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(b)">(b)</span> Date of the report; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(4)(c)">(c)</span> Cut-off level for each reported analyte; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#A(5)">(5)</span> Report all abnormal test results to the Follow-Up Unit on the same day that a test result is obtained and reviewed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B">B.</span> Specific Test results. A permittee may not report a test result as being within normal limits for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)">(1)</span> Amino acid levels for disorders specified in Regulation .12C(11)—(24) of this chapter and for a total galactose level for galactosemia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(3)" title="">Regulation .12C(3) of this chapter</a> if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)(a)">(a)</span> A newborn infant was not on milk or formula feeding at least 24 hours before the blood-spot specimen was collected; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(1)(b)">(b)</span> The time of milk or formula feeding is unknown; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)">(2)</span> 17-hydroxy progesterone results for congenital adrenal hyperplasia as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(2)" title="">Regulation .12C(2) of this chapter</a> and thyroxine and thyroid stimulating hormone for hypothyroidism as specified in <a class="internal-link " href="/us/md/exec/comar/10.10.13.12#C(4)" title="">Regulation .12C(4) of this chapter</a> if the blood-spot specimen was collected when the newborn infant was:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)(a)">(a)</span> Younger than 24 hours old; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.23#B(2)(b)">(b)</span> Of unknown age.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.24" data-order="|10|10|13|.24|" data-ref-path="10|10|13|.24" class="h__section">.24 Reporting Abnormal Test Results to the Follow-Up Unit.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A">A.</span> Reporting Requirements. A permittee shall immediately report an abnormal or diagnostic test result to the Follow-Up Unit by:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(1)">(1)</span> Telephoning and personally speaking to an individual in the Follow-Up Unit;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(2)">(2)</span> Telephoning and personally speaking to a back-up individual representing the Follow-Up Unit, if an attempt to make in-person contact with an employee of the Follow-Up Unit fails; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#A(3)">(3)</span> Following up a telephonic report within 24 hours with a report by facsimile or electronic mail to the Follow-Up Unit.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#B">B.</span> Verification Requirement. A permittee shall contact the Follow-Up Unit by telephone at least once every 6 months to ensure that the permittee is able to meet the requirements in <a class="internal-link " href="/us/md/exec/comar/10.10.13.24#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C">C.</span> Reporting Requirements; General. A permittee shall provide with each abnormal result, where applicable, the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(1)">(1)</span> Identity or name of each analyte measured;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)">(2)</span> Measured numerical concentration or range of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)(a)">(a)</span> Each analyte measured; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(2)(b)">(b)</span> All related analytes measured;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(3)">(3)</span> Value of any relevant ratios used to determine abnormality;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(4)">(4)</span> Postnatal age of the newborn infant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(5)">(5)</span> Appropriate gestational age/birth weight control range;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(6)">(6)</span> Cut-off level for the analyte of a hereditary or congenital disorder; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#C(7)">(7)</span> Measure of the degree of abnormality of the test result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D">D.</span> Reporting Requirements; Sickle Cell Disease Hemoglobin. A permittee shall report results for hemoglobin disorders as specified in Regulation .12C(7)—(10) of this chapter for sickle cell disease in terminology that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(1)">(1)</span> The alleles present in decreasing quantitative order; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)">(2)</span> Specifying trait states and possible disease states for at least the following alleles:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(a)">(a)</span> Hemoglobin C;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(b)">(b)</span> Hemoglobin D;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(c)">(c)</span> Hemoglobin E;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(d)">(d)</span> Hemoglobin G;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(e)">(e)</span> Hemoglobin O; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.24#D(2)(f)">(f)</span> Hemoglobin S.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.25" data-order="|10|10|13|.25|" data-ref-path="10|10|13|.25" class="h__section">.25 Reporting System and Communication Software.</h3>
                <p>A permittee shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#A">A.</span> Have available and use a reliable and accurate electronic information system that is capable of collecting, compiling, transferring, and communicating all normal and abnormal test results to the Follow-Up Unit; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B">B.</span> Provide the Follow-Up Unit, where applicable, with:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(1)">(1)</span> The necessary information system and electronic communications software or interface to be used by the Follow-Up Unit to receive from the permittee the newborn screening test results and reports required in this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)">(2)</span> Software programming assistance to ensure that the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)(a)">(a)</span> Permittee's data transmitted to the Follow-Up Unit is accurate and timely; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.25#B(2)(b)">(b)</span> The Follow-Up Unit's information system maintains compatibility with the permittee's information system.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.26" data-order="|10|10|13|.26|" data-ref-path="10|10|13|.26" class="h__section">.26 Availability of Statistical and Scientific Data.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A">A.</span> Statistical Reports. The State’s public health laboratory, the Follow-Up Unit, or both, on request, shall provide Newborn Screening Program statistical data for official State and national reports to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(1)">(1)</span> The Council;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(2)">(2)</span> The Department's Office of Genetics and Children with Special Healthcare Needs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#A(3)">(3)</span> State and federal agencies that use test results and statistics for the care and treatment of newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.26#B">B.</span> Research Investigations. The Laboratories Administration, the Follow-Up Unit, or both, may participate in research investigations approved by the Department's Institutional Review Board.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.10.13.27" data-order="|10|10|13|.27|" data-ref-path="10|10|13|.27" class="h__section">.27 Sanctions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A">A.</span> Due to the life-threatening nature and effect of errors in newborn screening testing, the Secretary may order summarily the suspension of a permit if the Secretary finds that the public health, safety, or welfare imperatively requires emergency action, including but not limited to, if a permittee has:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(1)">(1)</span> Failed to report a newborn infant's abnormal test result as required in this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)">(2)</span> Falsified a document submitted to the Department, including but not limited to a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)(a)">(a)</span> Newborn infant screening test report; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(2)(b)">(b)</span> Quality control or quality assurance report; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#A(3)">(3)</span> Failed to provide a corrected or amended test report if the permittee has reported an erroneous or questionable test result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B">B.</span> If the Secretary summarily suspends a permit as provided in <a class="internal-link " href="/us/md/exec/comar/10.10.13.27#A" title="">§A of this regulation</a>, the Secretary shall promptly give the permittee:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B(1)">(1)</span> Written notice of the suspension, the finding, and the reasons that support the finding; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#B(2)">(2)</span> An opportunity to be heard.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C">C.</span> The Secretary may impose a directed plan of correction, limit testing, deny a permit renewal, or suspend or revoke a current permit if a permittee has:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)">(1)</span> Failed to meet the applicable standards and requirements set forth in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)(a)">(a)</span> Health-General Article, Title 17, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(1)(b)">(b)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.01" title="Chapter 01 General">COMAR 10.10.01</a>—.08 and this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(2)">(2)</span> Conducted research on newborn infant blood-spot specimens within the Newborn Screening Program’s approval as required in <a class="internal-link " href="/us/md/exec/comar/10.10.13.15" title=".15 Test Blood-Spot Specimens — Use, Research, Storage, and Retention.">Regulation .15 of this chapter</a>; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#C(3)">(3)</span> Failed to pay the Department any fee required under this subtitle.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D">D.</span> In addition to sanctions provided in §§A and C of this regulation, the Secretary may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D(1)">(1)</span> Impose any sanction provided in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08" title="Chapter 08 Medical Laboratories — Sanctions">COMAR 10.10.08</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#D(2)">(2)</span> Refer a person for criminal prosecution, as provided at Health-General Article, §17-216, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#E">E.</span> A person may have a hearing on the imposition of a sanction and an opportunity to respond to a sanction imposed by the Secretary under this regulation as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.08.03" title=".03 Departmental Actions — Principal Sanctions.">COMAR 10.10.08.03</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.13.27#F">F.</span> Except as provided in §§A and B of this regulation, before the Secretary denies, suspends, or revokes a permit, the Secretary shall give the applicant or permittee notice of the action and an opportunity to be heard.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.08" aria-label="Subtitle 08 HEALTH FACILITIES GRANTS">
                <div class="h__ui">Previous</div>
                <span>Subtitle 08 HEALTH FACILITIES GRANTS</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.11" aria-label="Subtitle 11 MATERNAL AND CHILD HEALTH">
                <div class="h__ui">Next</div>
                <span>Subtitle 11 MATERNAL AND CHILD HEALTH</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
            <p>The codes and laws on this website are in the public domain.</p>
            <p>
      Please do not scrape. Instead, bulk download the <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a>.
    </p>
            <p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p>
          </div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
